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 Abstract 
The minichromosome maintenance complex (MCM2-7) is the putative DNA 
helicase in eukaryotes, and is essential for DNA replication. Mis-regulation of its 
assembly and function can lead to genomic instability, replication stress and 
genome re-replication, which are powerful drivers toward the acquisition of 
mutations and the formation of cancer.  
I have produced and purified recombinant human MCM2-7 (hMCM) 
in Escherichia coli (E. coli). Recombinant hMCM has ATP hydrolysis and helicase 
activity, when assayed in the absence of post-translational modifications or 
accessory proteins. Using electron microscopy asymmetric single particle 
reconstruction, I have produced 23 Å resolution structures. The structures reveal 
that recombinant hMCM forms an asymmetric complex that changes 
conformation in the presence of a forked DNA substrate. 
By applying serial extractions to mammalian cells synchronised by release from 
quiescence, I have revealed dynamic changes in the sub-nuclear 
compartmentalisation of MCM2 as cells pass through late G1 and early S phase, 
identifying a brief window when MCM2 becomes transiently attached to the 
nuclear matrix. This suggests that functional MCM2-7 loading takes place at the 
nuclear matrix. Using this information I have developed a system to study the 
regulated assembly of recombinant hMCM, to support molecular dissection of 
the loading process. Using cellular extracts, I show regulated binding of 
recombinant hMCM, which translates into initiation of DNA replication and is 
stimulated by cyclin E/CDK2. Furthermore, I have demonstrated that both cyclin 
A/CDK2 and Dbf4/Drf1-dependant kinase (DDK) are required for inducing a 
conformational change in hMCM that is associated with S phase of the cell cycle. 
Understanding of the assembly of hMCM will serve as a foundation for analysis 
of corruption of the process, its effect on genome instability and gene expression, 
and how these events lead to the ‘birth’ of cancer cells. Very early events in the 
development of cancer cells are most likely to yield new and effective 
opportunities for detection and treatment of a broad range of cancers.  
2
 Table of Contents 
Abstract ......................................................................................................................... .2 
Table	  of	  Contents	  .................................................................................................................	  3	  
List	  of	  Figures	  ........................................................................................................................	  9	  
List	  of	  Tables	  .......................................................................................................................	  12	  
Acknowledgements	  ..........................................................................................................	  13	  
Declaration	  ..........................................................................................................................	  14	  
1	   Introduction .............................................................................................................. 16	  
1.1	   Cell	  cycle	  ....................................................................................................................	  16	  1.1.1	   Quiescence	  .........................................................................................................................	  18	  
1.2	   Cell	  cycle	  control	  ....................................................................................................	  18	  1.2.1	   Cyclin	  dependent	  kinase	  (CDK)	  ................................................................................	  19	  1.2.2	   Cyclin	  A/CDK2	  .................................................................................................................	  20	  1.2.3	   Cyclin	  E/CDK2	  .................................................................................................................	  20	  1.2.4	   DDK	  .......................................................................................................................................	  21	  
1.3	   DNA	  replication	  ......................................................................................................	  22	  
1.4	   Minichromosome	  maintenance	  (MCM2-­‐7)	  complex	  ..................................	  22	  1.4.1	   Localisation	  of	  MCM	  proteins	  ...................................................................................	  25	  1.4.2	   MCM	  complexes	  hydrolyse	  ATP	  ...............................................................................	  26	  1.4.3	   MCM	  as	  a	  helicase	  ...........................................................................................................	  27	  
1.5	   MCM2-­‐7	  loading	  ......................................................................................................	  28	  1.5.1	   Origins	  .................................................................................................................................	  31	  1.5.2	   ORC	  .......................................................................................................................................	  31	  1.5.3	   Cdc6	  ......................................................................................................................................	  32	  1.5.4	   Cdt1	  ......................................................................................................................................	  33	  1.5.5	   MCM2-­‐7	  ..............................................................................................................................	  34	  1.5.6	   Metazoan	  specific	  proteins	  involved	  in	  MCM2-­‐7	  loading	  .............................	  36	  
1.6	   MCM2-­‐7	  activation	  .................................................................................................	  37	  1.6.1	   Pre-­‐IC	  ...................................................................................................................................	  38	  1.6.2	   Pre-­‐LC	  ..................................................................................................................................	  38	  1.6.3	   Cdc45	  ...................................................................................................................................	  41	  1.6.4	   GINS	  ......................................................................................................................................	  41	  1.6.5	   MCM10	  ................................................................................................................................	  42	  
3
 1.6.6	   Ctf4	  ........................................................................................................................................	  42	  1.6.7	   Metazoan	  specific	  initiation	  proteins	  ....................................................................	  42	  1.6.8	   CMG	  activation	  .................................................................................................................	  43	  
1.7	   Phosphorylation	  of	  MCM	  proteins	  ....................................................................	  44	  1.7.1	   Phosphorylation	  by	  DDK	  .............................................................................................	  44	  1.7.2	   MCM4	  phosphorylation	  ...............................................................................................	  45	  1.7.3	   MCM2	  phosphorylation	  ...............................................................................................	  46	  1.7.4	   Order	  of	  CDK	  and	  DDK	  kinase	  activity	  ..................................................................	  47	  
1.8	   Structure	  of	  MCM2-­‐7	  complexes	  .......................................................................	  48	  
1.9	   Nuclear	  matrix	  ........................................................................................................	  49	  
1.10	   Aims	  .........................................................................................................................	  52	  
2	   Material and methods ............................................................................................. 55	  
2.1	   E.	  coli	  cell	  culture	  ....................................................................................................	  55	  2.1.1	   Growth	  media	  ..................................................................................................................	  55	  2.1.2	   Antibiotics	  .........................................................................................................................	  55	  2.1.3	   Preparation	  of	  heat	  shock	  competent	  E.	  coli	  cells	  with	  rubidium	  chloride……………………	  .................................................................................................................	  55	  2.1.4	   E.	  coli	  transformation	  ...................................................................................................	  56	  
2.2	   Mammalian	  cell	  culture	  .......................................................................................	  56	  2.2.1	   Growth	  media	  and	  conditions	  ...................................................................................	  56	  2.2.2	   Cell	  synchrony	  .................................................................................................................	  57	  2.2.2.1	   G1	  phase	  synchrony	  .............................................................................................................	  57	  2.2.2.2	   S	  phase	  synchrony	  ................................................................................................................	  57	  
2.3	   Protein	  analysis	  ......................................................................................................	  58	  2.3.1	   SDS	  PAGE	  ...........................................................................................................................	  58	  2.3.1.1	   Preparation	  and	  running	  of	  gels	  .....................................................................................	  58	  2.3.1.2	   Sample	  preparation	  .............................................................................................................	  59	  2.3.2	   Native	  PAGE	  ......................................................................................................................	  59	  2.3.2.1	   Preparation	  and	  running	  of	  gels	  .....................................................................................	  59	  2.3.2.2	   Sample	  preparation	  .............................................................................................................	  59	  2.3.3	   Coomassie	  blue	  staining	  ..............................................................................................	  59	  2.3.4	   Western	  blotting	  .............................................................................................................	  60	  2.3.4.1	   Transfer	  .....................................................................................................................................	  60	  2.3.4.2	   Antibody	  detection	  ...............................................................................................................	  60	  2.3.5	   Immunofluorescence	  (IF)	  ...........................................................................................	  61	  
4
 2.3.5.1	   Mounting	  coverslips	  ............................................................................................................	  61	  2.3.5.2	   Image	  analysis	  ........................................................................................................................	  62	  2.3.6	   Determining	  protein	  concentration	  .......................................................................	  64	  
2.4	   hMCM	  production	  and	  purification	  ..................................................................	  64	  2.4.1	   Expression	  of	  hMCM	  .....................................................................................................	  64	  2.4.2	   hMCM	  purification	  .........................................................................................................	  65	  
2.5	   ATP	  hydrolysis	  assay	  ............................................................................................	  66	  
2.6	   DNA	  helicase	  assay	  ................................................................................................	  67	  2.6.1	   Substrate	  preparation	  ..................................................................................................	  67	  2.6.1.1	   Oligonucleotide	  labelling	  ...................................................................................................	  67	  2.6.1.2	   Oligonucleotide	  annealing	  ................................................................................................	  67	  2.6.1.3	   Substrate	  purification	  .........................................................................................................	  68	  2.6.1.4	   Substrate	  quantification	  ....................................................................................................	  68	  2.6.2	   Assay	  conditions	  .............................................................................................................	  69	  
2.7	   Electron	  microscopy	  (EM)	  ...................................................................................	  69	  2.7.1	   Binding	  of	  duplex	  DNA	  to	  hMCM	  for	  EM	  ..............................................................	  69	  2.7.2	   Negative	  stain	  EM	  ...........................................................................................................	  70	  2.7.3	   Image	  processing	  ............................................................................................................	  70	  2.7.4	   Domain	  fitting	  ..................................................................................................................	  71	  
2.8	   Mammalian	  cell	  analysis	  .....................................................................................	  72	  2.8.1	   Assay	  for	  DNA	  synthesis	  ..............................................................................................	  72	  2.8.2	   Protein	  extraction	  for	  western	  blot	  ........................................................................	  72	  2.8.3	   Protein	  extraction	  for	  immunofluorescence	  ......................................................	  75	  2.8.3.1	   Cross-­‐linking	  ...........................................................................................................................	  77	  
2.9	   Cell	  free	  system	  .......................................................................................................	  77	  2.9.1	   Harvesting	  of	  nuclei	  and	  cytoplasmic	  extracts	  ..................................................	  77	  2.9.2	   DNA	  initiation	  assays	  ....................................................................................................	  78	  2.9.2.1	   Two-­‐step	  assays	  ....................................................................................................................	  78	  2.9.2.2	   Analysis	  by	  fluorescence	  ...................................................................................................	  79	  2.9.2.3	   Analysis	  by	  western	  blotting	  ...........................................................................................	  79	  2.9.3	   in	  vitro	  phosphorylation	  assays	  ...............................................................................	  80	  2.9.3.1	   Phosphatase	  assays	  ..............................................................................................................	  80	  2.9.3.2	   Inhibitors	  ..................................................................................................................................	  80	  
2.10	   Statistical	  analysis	  ...............................................................................................	  80	  
3	   Production and purification of recombinant hMCM ....................................... 83	  
5
 3.1	   Introduction	  .............................................................................................................	  83	  
3.2	   Aims	  ............................................................................................................................	  84	  
3.3	   Experimental	  design	  .............................................................................................	  84	  
3.4	   Results	  and	  discussion	  .........................................................................................	  84	  3.4.1	   Production	  and	  Purification	  of	  Recombinant	  hMCM	  ......................................	  84	  3.4.2	   Production	  and	  purification	  of	  mutant	  hMCM	  ...................................................	  93	  3.4.3	   ATP	  hydrolysis	  activity	  of	  hMCM	  ............................................................................	  93	  3.4.4	   ATP-­‐dependent	  DNA	  unwinding	  by	  hMCM	  ......................................................	  100	  3.4.5	   Structural	  analysis	  ......................................................................................................	  102	  
3.5	   Conclusion	  .............................................................................................................	  109	  
4	   Expression and localisation of endogenous mammalian MCM proteins .. 111	  
4.1	   Introduction	  ..........................................................................................................	  111	  
4.2	   Aims	  .........................................................................................................................	  112	  
4.3	   Experimental	  design	  ..........................................................................................	  112	  
4.4	   Results	  ....................................................................................................................	  112	  4.4.1	   Cells	  released	  from	  quiescence	  enter	  G1	  in	  a	  highly	  regulated	  manner……………………	  ...............................................................................................................	  112	  4.4.2	   MCM	  protein	  expression	  peaks	  at	  the	  initiation	  of	  DNA	  replication	  ....	  113	  4.4.3	   Sub-­‐cellular	  localisation	  of	  MCM2	  ........................................................................	  116	  4.4.4	   MCM2	  is	  transiently	  bound	  to	  the	  nuclear	  matrix	  ........................................	  116	  4.4.5	   MCM2	  is	  tightly	  associated	  with	  chromatin	  after	  initiation	  .....................	  120	  
4.5	   Discussion	  ..............................................................................................................	  122	  
4.6	   Conclusions	  ...........................................................................................................	  123	  
5	   Functional assembly of recombinant hMCM .................................................. 127	  
5.1	   Introduction	  ..........................................................................................................	  127	  
5.2	   Aims	  .........................................................................................................................	  128	  
5.3	   Experimental	  design	  ..........................................................................................	  128	  
5.4	   Results	  and	  discussion	  ......................................................................................	  128	  5.4.1	   Cell	  free	  characterisation	  .........................................................................................	  128	  5.4.2	   Regulated	  binding	  of	  hMCM	  in	  isolated	  nuclei	  ...............................................	  130	  5.4.3	   Recombinant	  cyclin	  A/CDK2	  and	  cyclin	  E/CDK2	  improve	  hMCM	  loading	  in	  isolated	  nuclei	  .........................................................................................................................	  133	  5.4.4	   hMCM	  is	  functionally	  loaded	  onto	  chromatin	  in	  vitro	  .................................	  133	  5.4.5	   Effect	  of	  DDK	  on	  hMCM	  loading	  ............................................................................	  136	  
6
 5.4.6	   MCM2	  mobility	  shift	  is	  dependent	  on	  both	  DDK	  and	  cyclin	  A/CDK2	  ...	  136	  5.4.7	   Mobility	  shift	  of	  MCM	  proteins	  is	  a	  reversible	  phosphorylation	  ............	  140	  5.4.8	   Cyclin	  A/CDK2	  is	  required	  before	  DDK	  to	  induce	  increased	  mobility	  of	  MCM2	   ……………………………………………………………………………………………………...140	  
5.5	   Conclusions	  ...........................................................................................................	  147	  
6	   Discussion and future work ................................................................................ 149	  
6.1	   Recombinant	  hMCM	  is	  active	  ..........................................................................	  149	  6.1.1	   hMCM	  stoichiometry	  ..................................................................................................	  150	  6.1.2	   Essential	  residues	  in	  hMCM	  ....................................................................................	  151	  
6.2	   Recombinant	  hMCM	  undergoes	  a	  conformational	  change	  when	  bound	  
to	  DNA	  ................................................................................................................................	  151	  6.2.1	   Subunit	  arrangement	  and	  orientation	  ...............................................................	  152	  6.2.2	   Which	  MCM2-­‐7	  subunit	  preferentially	  binds	  DNA?	  .....................................	  152	  6.2.3	   X-­‐ray	  crystal	  structure	  of	  hMCM	  ...........................................................................	  152	  
6.3	   MCM2	  is	  transiently	  associated	  with	  the	  nuclear	  matrix	  at	  
initiation……………………	  .................................................................................................	  153	  6.3.1	   Effect	  of	  kinase	  inhibitors	  on	  transient	  nuclear	  matrix	  binding	  of	  MCM2……………………	  ..................................................................................................................	  153	  6.3.2	   Additional	  proteins	  bound	  to	  nuclear	  matrix	  .................................................	  154	  6.3.3	   Identification	  of	  novel	  proteins	  involved	  in	  DNA	  replication	  initiation……………………	  ............................................................................................................	  155	  
6.4	   Regulated	  hMCM	  loading	  ..................................................................................	  155	  6.4.1	   What	  component	  of	  late-­‐G1	  phase	  extract	  inhibits	  hMCM	  loading?	  .....	  156	  6.4.2	   Ability	  of	  ATPase	  deficient	  mutant	  hMCM	  to	  functionally	  load	  onto	  chromatin	  .......................................................................................................................................	  156	  6.4.3	   Does	  hMCM	  bind	  to	  the	  nuclear	  matrix?	  ...........................................................	  157	  6.4.4	   Effect	  of	  DDK	  on	  in	  vitro	  DNA	  replication	  initiation	  .....................................	  157	  
6.5	   MCM2	  undergoes	  a	  structural	  change	  by	  the	  sequential	  action	  of	  cyclin	  
A/CDK2	  followed	  by	  DDK	  ............................................................................................	  157	  6.5.1	   Effect	  of	  phosphorylation	  on	  hMCM	  hexamer	  ................................................	  158	  6.5.2	   Role	  of	  phosphorylated	  MCM2	  in	  DNA	  replication	  .......................................	  158	  6.5.3	   Analysis	  of	  phosphorylation	  sites	  on	  hMCM	  ...................................................	  159	  6.5.4	   Is	  the	  mobility	  shift	  of	  MCM2	  due	  to	  a	  conformational	  change?	  .............	  160	  
6.6	   How	  does	  MCM2-­‐7	  unwind	  DNA?	  ...................................................................	  160	  
7
 6.7	   Conclusions	  ...........................................................................................................	  161	  
Appendix A ................................................................................................................... 163	  
Appendix B ................................................................................................................... 177	  
Appendix C ................................................................................................................... 180	  
Appendix D ................................................................................................................... 194	  
Abbreviations ............................................................................................................... 218	  
References ..................................................................................................................... 222	  
 
  
8
 List of Figures 
Figure 1.1. Schematic showing phases of the cell cycle…………………...……. 17 
Figure 1.2. Semi-conservative DNA replication………………………………… 23 
Figure 1.3. MCM2-7 subunit configuration……………………………………… 24 
Figure 1.4. Pre-replication complex (pre-RC) assembly………………………. 30 
Figure 1.5. Assembly of Cdc45-MCM2-7-GINS (CMG) complex in S. 
cerevisiae………………………………………………………………… 
 
39 
Figure 1.6. Electron microscopy of MtMCM in different conformational 
states……………………………………………………………………. 
 
50 
Figure 2.1. Flow diagram to show nuclear matrix protein extraction for 
analysis by SDS PAGE and western blot…………………………… 
 
73 
Figure 2.2. Flow diagram to show nuclear matrix protein extraction for 
analysis by immunofluorescence……………………………………. 
 
76 
Figure 3.1. hMCM plasmid maps and schematic of conformation…………… 85 
Figure 3.2. Summary of hMCM production from a typical 50 L bioreactor 
run……………………………………………………………………… 
 
87 
Figure 3.3. Summary of immobilised metal affinity chromatography (IMAC) 
purification of hMCM. ……………………………………………….. 
 
88 
Figure 3.4. Summary of gel filtration purification of hMCM………………...... 89 
Figure 3.5. Summary of anion exchange purification of hMCM...…………….. 90 
Figure 3.6. Summary of hMCM purification.………………………………….… 92 
Figure 3.7. Summary of immobilised metal affinity chromatography (IMAC) 
purification for mutant hMCM………………………………………. 
94 
Figure 3.8. Summary of gel filtration and anion exchange purification of 
mutant hMCM. ……………………………………………………...… 
 
95 
Figure 3.9. Screening of assay conditions for ATPase activity of hMCM…….. 96 
Figure 3.10. Effect of salt and DNA on ATPase activity of hMCM……………... 98 
9
 Figure 3.11. Effect of hMCM and ATP concentration on ATPase activity of 
hMCM and mutant hMCM…..…………………………………….. 
 
99 
Figure 3.12. hMCM shows strand displacement activity ……………………..… 101 
Figure 3.13. Negative stain electron microscopy of hMCM …...………………... 105 
Figure 3.14. hMCM undergoes a conformational change when bound to 
forked DNA..…………………………………………………………... 
 
106 
Figure 3.15. hMCM EM reconstructions fit crystal structures…………………. 107 
Figure 3.16. Additional views of hMCM reconstructions……………………….. 108 
Figure 4.1. Cell cycle re-entry from quiescence.………………………………… 114 
Figure 4.2. MCM protein levels peak at initiation.……………………………… 115 
Figure 4.3. Nuclear matrix binding revealed by DNase I digestion…………... 118 
Figure 4.4. Nuclear matrix binding revealed by DNase I digestion in G1 
phase and early S. ……………………………………………….......... 
 
119 
Figure 4.5 Using DTSP MCM2 is shown to be associated with chromatin 
after initiation…...…………………………………………………...… 
 
121 
Figure 4.6. Schematic showing three states of MCM2-7 complex binding in 
late G1 phase………...………………………………………………… 
 
125 
Figure 5.1. Schematic representation of cell free components prepared from 
cells synchronised by re-entry to the cell cycle from quiescence.… 
 
129 
Figure 5.2. Regulated binding of hMCM within late-G1 phase nuclei in vitro.. 131 
Figure 5.3. Regulated binding of hMCM within mid-G1 phase nuclei in vitro. 132 
Figure 5.4. Effect of recombinant cyclin E/CDK2 and cyclin A/CDK2 on 
hMCM loading………………………...…………………………….… 
 
134 
Figure 5.5. Effect of recombinant cyclin E/CDK2 on initiation of DNA 
replication………………………………………………............…….... 
 
135 
Figure 5.6. Effect of recombinant DDK on hMCM loading….…............…….... 137 
Figure 5.7. Increased mobility of MCM2 requires both cyclin A/CDK2 and 
DDK…………………………………………………………….………. 
 
139 
10
 Figure 5.8. MCM2 and MCM4 mobility shift is reversed by 
dephosphorylation by λ phosphatase………………………………. 
 
141 
Figure 5.9. Effect of the CDK2 inhibitor roscovitine on MCM2 and MCM4 
mobility………………………………………………………………… 
 
143 
Figure 5.10. Effect of the DDK inhibitor PHA-767491 on MCM2 and MCM4 
mobility………………………………………………………………… 
 
144 
Figure 5.11. Order of additions experiment, which shows that cyclin A/CDK2 
must act before DDK in order to induce the MCM2 mobility shift. 
………………………………………………….…………….…………. 146 
Figure 6.1. Model for MCM2-7 unwinding…...…………………………………. 162 
  
11
 List of Tables 
Table 1.1. MCM amino acid insertions comparison of S. cerevisiae (Sc) and 
Human (Hs) MCM…………………………..………..……..……..….. 
 
29 
Table 2.1. Components of SDS PAGE resolving and stacking gel……...……. 58 
Table 2.2. Primary antibody details……………………..………………………. 62 
Table 2.3. Secondary antibody details……………………..……………………. 63 
Table 2.4. Oligonucleotide sequences……………………..……………….……. 67 
Table 3.1. The fold purification and concentration of recombinant hMCM 
from a typical 50 L fermenter run………………….....…..……..…… 
 
91 
Table 3.2. MCM amino acid insertions comparison of Human (Hs) and 
Sulfolobus solfactaricus (Sso) MCM……………………...............……. 
 
104 
  
12
 Acknowledgements 
Firstly, I would like to thank Yorkshire Cancer Research for funding this PhD. I 
would also like to thank my supervisors James Chong and Dawn Coverley. 
Together they came up with a fantastic project that I have thoroughly enjoyed. I 
am also extremely grateful to all past and present members of both Chong and 
Coverley labs particularly Gill, Rose, Henry and Dorian who have provided me 
with continued help over the years and made the lab an enjoyable place to be.  
I am thankful to the members of my training advisory panel, Christoph Baumann 
and Paul Genever who have given me lots of advice that has helped with the 
completion of my thesis. I am grateful to members of the technology facility at 
York particularly Jared Cartwright and Mick Miller who helped with the 
production and purification of hMCM. I am also thankful to Elena Orlova at the 
University of Birkbeck who hosted me for a month to complete the electron 
microscopy work on hMCM. I am particularly grateful to Richard Parker-Manuel 
for the research carried out on hMCM before I started my PhD. 
And finally I would like to thank my friends and family. My friends Heather, 
Jessica, Kaylei, Lindsay and Saski who have given me infinite distractions from my 
PhD with weddings, Hen Do’s, cocktail party’s and a huge list of other exciting 
activities as well as encouragement to work hard. My Mum, Dad and sister 
Rachael who have always made me believe I can do anything I put my mind to. 
And of course Ryan who has been a great support and has listened to endless 
performances of every talk I have ever done! 
 
 
  
13
 Declaration 
All the research in this thesis is my own with the following exceptions: 
§ The constructs in Chapter 3 used to produce hMCM and ATPase deficient 
mutant hMCM were designed and created by Dr Richard Parker-Manuel. 
§ The hMCM used for electron microscopy in Chapter 3 was produced by 
Dr Richard Parker-Manuel. 
§ The negative stain electron microscopy pictures used in Chapter 3 were 
taken by Dr Yuriy Chaban. 
§ The recombinant Dbf4-dependant kinase used in Chapter 5 was produced 
and purified by Dr Richard Parker-Manuel. 
§ The recombinant cyclin E/cyclin dependent kinase 2 used in Chapter 5 
was produced and purified by Dr Dawn Coverley. 
§ The recombinant cyclin A/cyclin dependent kinase 2 used in Chapter 5 
was produced and purified by Dr Nikki Copeland. 
 
 
14
  
 
 
Chapter 1 
Introduction 
 
  
15
 1 Introduction 
Genome duplication is essential for the growth of all living organisms. Over the 
past 30 years there has been much investigation of the precise mechanism of 
DNA replication and transmission to daughter cells. Although our knowledge 
has improved, the exact mechanism underlying eukaryotic genome duplication 
is not fully understood. 
DNA replication occurs in a highly orchestrated and coordinated fashion that is 
spatially and temporally regulated (reviewed in Bell and Dutta, 2002). Errors in 
DNA replication are linked with a variety of diseases including cancer (reviewed 
in Blow and Gillespie, 2008). The primary regulation of DNA replication is at 
initiation; when the mammalian minichromosome maintenance (MCM2-7) 
complex, the putative DNA helicase in eukaryotes, is loaded onto chromatin. 
Altered levels of MCM subunits have been associated with numerous cancer 
types (reviewed in Semple and Duncker, 2004, Gonzalez et al., 2005).  
This research focuses on the loading and activation of the human MCM2-7 
complex in mammalian cells, and provides new information into how this 
fundamental process is controlled.  
1.1 Cell cycle 
As cells grow and divide they pass through a series of carefully coordinated 
events that make up the cell cycle. Proliferating cultured mammalian cells pass 
through the mitotic cell cycle roughly every 24 hours (Fig. 1.1A). During growth 
phase 1 (G1) of the cell cycle, the cell prepares for DNA replication by 
synthesising nucleotides and proteins involved in duplicating the genome. Once 
the cell is ready for DNA replication, it can pass the restriction point (R, Pardee, 
1974) and is committed to the cell cycle. Following R the cell is under the control 
of cyclin dependent kinases (CDKs, reviewed in Murray, 2004). The cell then 
moves into the synthesis (S) phase of the cell cycle when the entire genome is 
faithfully replicated, generating one complete genome per daughter cell 
(reviewed in Sclafani and Holzen, 2007).   
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AFigure 1.1 Schematic showing phases of the cell cycle. A. The mitotic cell cycle. Showing 
mitosis (M), Growth 1 (G1), Synthesis (S) and Growth 2 (G2) phases. Initiation of DNA 
replication is highlighted between G1 and S phase. B. The cell cycle following release 
from quiescence (Q). The cells pass through a prolonged G1 and the restriction point (R) 
before the initiation of DNA replication (I). The levels of DDK, cyclin E/CDK2 and cyclin 
A/CDK2 are indicated. 
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 The cell then enters growth 2 phase (G2) where cells prepare for division by 
production of proteins required for mitosis (M). During M phase the cell divides 
into two identical daughter cells, which both then continue into G1 phase and the 
cycle begins again (Norbury and Nurse, 1992). 
1.1.1 Quiescence 
In the absence of growth factors or when cells are at a high density and in 
contact, they can enter quiescence or G0 (Martin and Stein, 1976, Smith and 
Martin, 1973, reviewed in Spencer et al., 2013). Quiescence is a non-proliferating 
state where proteins required for cell growth, such as DNA replication and 
mitotic spindle formation, are down regulated (reviewed in Coller, 2007). 
Originally, cells in quiescence were thought to be withdrawn from the cell cycle 
and in a passive state. However, several lines of evidence show that quiescence is 
actually a maintained state (Zetterberg and Larsson, 1985, reviewed in Fox et al., 
2005) as quiescent cells have also been shown to up regulate many genes (Coller 
et al., 2006, Coppock et al., 1993, Polyak et al., 1994). In our laboratory, cells are 
driven into quiescence by a combination of contact inhibition and serum 
depletion under a precise regime. When cells are stimulated to re-enter the cell 
cycle from quiescence, they pass through a prolonged G1 phase where a series of 
coordinated events that control the assembly of the pre-replication complex (pre-
RC) takes place with precise timing (Fig. 1.1B, Coverley et al., 2002). In adult 
tissues the majority of cells are quiescent. Failure to maintain quiescence leading 
to unscheduled re-entry to the cell cycle is thought to underlie the formation of 
some cancers. 
1.2 Cell cycle control  
The cell cycle is controlled by its regulated passage through checkpoints. The cell 
can only pass through a checkpoint if the prior stage of the cell cycle has been 
successfully completed. The restriction point (Fig. 1.1B) occurs in late-G1 phase 
(Pardee, 1974). At this point the cell must decide if conditions are favourable and 
to continue with the cell cycle or, if the extracellular environment is not ideal, the 
cell will enter quiescence (Zetterberg and Larsson, 1985). Once the cell passes 
through the restriction point it is committed to the cell cycle even if the 
18
 extracellular environment changes (Pardee, 1974). The cell can only pass through 
the restriction point and into S phase if it is fully prepared for DNA replication 
(Blagosklonny and Pardee, 2002). Cyclins are regulatory proteins which integrate 
information from outside the cell and subsequently bind and activate cyclin 
dependent kinases (CDK, Sherr and Roberts, 2004). Cyclin D transfers 
extracellular information to the cells nucleus during G1 phase prior to the 
restriction point (Sherr and Roberts, 1999, Sewing et al., 1993). Cyclin D binds 
and activates CDK4 and CDK6, and phosphorylates retinoblastoma protein 
(pRb) which in turn releases the transcription factor E2F (reviewed in Sherr, 
1994). This allows expression of a number of target genes including cyclin E 
(Nevins, 1998, Dyson, 1998), cyclin A and components of the pre-RC (Harbour et 
al., 1999, reviewed in Sherr, 1994). Cyclin E/CDK2 phosphorylates multiple 
proteins driving the cell through the restriction point (Dahmann et al., 1995).  
Following the restriction point the cell’s activities, including initiation of DNA 
replication, are controlled by cyclins and their associated CDK (Aguda, 2001). 
Here I will focus on kinases that are thought to target and control the activity of 
pre-RC components, in particular the MCM2-7 complex. 
1.2.1 Cyclin dependent kinase (CDK) 
CDK’s phosphorylate substrate proteins at serine or threonine residues to control 
their activity (reviewed in Malumbres and Barbacid, 2005). In Saccharomyces 
cerevisiae (S. cerevisiae) and Schizosaccharomyces pombe (S. pombe) there is one type 
of cyclin active around G1/S, commonly known as S-CDK (Nguyen et al., 2001). 
S-CDK is expressed in S phase of the cell cycle and has been shown to control a 
number of DNA replication initiation proteins by phosphorylation (reviewed in 
Blow and Dutta, 2005). 
In mammals there are more than ten identified CDKs, controlled differentially by 
cyclins (reviewed in Malumbres and Barbacid, 2005). CDK2 has numerous 
targets including components of the pre-RC, and so its activity was thought to be 
essential for replication. However, mice can develop normally and survive in the 
absence of CDK2 (Ortega et al., 2003, Berthet et al., 2003). The activity of CDK2 is 
controlled by both cyclin A and cyclin E, which have separate, sequential and 
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 concentration-dependent functions in the initiation of mammalian DNA 
replication (Coverley et al., 2002). The expression levels of cyclin A and E varies 
throughout the cell cycle (Morgan, 1997) and therefore so does the activity of 
CDK2.  
1.2.2 Cyclin A/CDK2 
Cyclin A expression increases throughout G1 phase and peaks in S phase (Sherr, 
1996). Its initial involvement in DNA replication was hypothesised from its 
expression in relation to the cell cycle (Erlandsson et al., 2000) and its localisation 
at sites of DNA replication (Cardoso et al., 1993). Mammalian cells encode both 
cyclin A1 and A2 (Nieduszynski et al., 2002). Cyclin A1 is germ cell specific 
(Ravnik and Wolgemuth, 1999) whereas cyclin A2 is expressed in all proliferating 
cells (Pines and Hunter, 1990). Ablation of cyclin A1 and A2 in embryonic cells 
inhibits cell cycle progression. However in fibroblasts, cyclin A is redundant 
(Kalaszczynska et al., 2009). It appears cyclin E can replace cyclin A under these 
conditions to ensure cell cycle progression (Kalaszczynska et al., 2009).  
1.2.3 Cyclin E/CDK2 
There are two E type cyclins, E1 and E2, both of which bind and activate CDK2 
(Morgan, 1997). Cyclin E1 and cyclin E2 are expressed in proliferating cells (Geng 
et al., 2001). Expression of cyclin E begins just after the restriction point, peaks 
before S phase and is down regulated shortly after passing into S phase (Ekholm 
et al., 2001, Dulic et al., 1992). Embryonic development of mice is normal when 
cyclin E1 and E2 is ablated, as was the phosphorylation of pRB, a known target of 
cyclin E (Geng et al., 2003). These data suggest that, cyclin A is able to substitute 
for cyclin E, however under these conditions the association of MCM proteins 
with chromatin during exit from quiescence was decreased (Geng et al., 2003). 
Consistent with this, over expression of cyclin E in cultured mammalian cells 
speeds up G1 phase (Ohtsubo and Roberts, 1993) possibly by increasing MCM2-7 
loading. 
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 1.2.4  DDK 
The gene encoding Cell division cycle 7 (Cdc7) was first identified in S. cerevisiae 
(Hartwell et al., 1974), and was shown to be conserved in humans (Sato et al., 
1997, Jiang and Hunter, 1997, Hess et al., 1998). Cdc7 is a serine/threonine (S/T) 
kinase that targets S/T residues followed by either an aspartic acid (D), a 
glutamic acid (E) or a S/T that has been phosphorylated by another kinase 
(Montagnoli et al., 2006, Cho et al., 2006, Charych et al., 2008). The activity of 
Cdc7 is controlled by regulatory subunits Dbf4 (Dumbbell-forming 4, Jiang et al., 
1999, Jackson et al., 1993, Kumagai et al., 1999, Masai et al., 2000) or Drf1 (Dbf4 
related factor 1, Montagnoli et al., 2002). Drf1 is specific to metazoans and it is 
hypothesised that Drf1 and Dbf1 have different roles in controlling Cdc7 activity, 
similar to the control of CDK2 by both cyclin A and cyclin E (Montagnoli et al., 
2002). However, the reciprocal role of Drf1 and Dbf1 are yet to be defined. 
Collectively, Cdc7 bound to either Dbf1 or Drf1 are commonly referred to as 
Dbf4/Drf1 dependent kinase (DDK). The levels of Cdc7 within S. cerevisiae 
remain constant throughout the cell cycle (Weinreich and Stillman, 1999). 
However, Cdc7 appears to be degraded in quiescent mammalian cells and 
resynthesised following release as the cell passes into S phase, similar to the 
profile of cyclin A (Montagnoli et al., 2006). DDK binds to chromatin in G1 phase 
after loading of the MCM2-7 complex and stays bound throughout S phase 
(Weinreich and Stillman, 1999). It appears that DDK acts locally at each 
replication origin as Dbf4 can be isolated using origin DNA as bait (Dowell et al., 
1994). DDK activity is thought to be restricted to S phase (Bousset and Diffley, 
1998, Donaldson et al., 1998, Patel et al., 2008).  
Cdc7 is essential for G1/S phase transition (Kumagai et al., 1999) and plays a 
crucial role in activation of the pre-RC at each origin (Donaldson et al., 1998, 
Bousset and Diffley, 1998). Its importance is demonstrated by specific inhibition, 
which leads to cell cycle arrest in S phase (Kim et al., 2002). Cdc7 is often found 
to be over expressed in tumour cell lines (Hess et al., 1998). As a result, Cdc7 
inhibitors are being developed as cancer therapeutics and such drugs have been 
shown to preferentially kill cancer cells (Swords et al., 2010, Montagnoli et al., 
2008, Poh et al., 2014).  
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 1.3 DNA replication 
The initiation of DNA replication is critical for correct and timely genome 
duplication, it is highly controlled to ensure duplication occurs once and only 
once per cell cycle. All living organisms replicate their DNA with the same 
underlying mechanism. Initiation begins at origins of replication where a set of 
specialised activities results in the formation of a ‘protein machine’ to unwind 
DNA and provides a template strand for semi conservative DNA replication (Fig. 
1.2, Meselson and Stahl, 1958). The more evolutionarily advanced an organism, 
the more complex initiation of DNA replication. With this in mind, from the 
study of prokaryotes, archaea and lower eukaryotes we have learnt a huge 
amount regarding DNA replication initiation. Eukaryotic DNA replication is 
increasingly well understood in unicellular eukaryotic systems such as yeast, 
where many of the steps of the initiation process can be reconstituted in vitro, and 
the regulation of the putative replicative helicase, MCM2-7, has been studied in 
detail (reviewed in Labib, 2010, Li and Araki, 2013, Sclafani and Holzen, 2007). It 
is, however, becoming apparent that there are a number of differences between 
the domains of life and also between lower eukaryotes and metazoans (reviewed 
in Shen and Prasanth, 2012). This leads to the need to study more advanced 
mammalian systems. 
1.4 Minichromosome maintenance (MCM2-7) complex  
MCM proteins were first discovered via a number of temperature sensitive 
mutants in S. cerevisiae (Maine et al., 1984). The mammalian orthologue of S. 
cerevisiae MCM3 was initially identified in cultured human cells and shown to 
localised within the nucleus (Thömmes et al., 1992). MCM proteins are conserved 
from archaea to eukaryotes (Maiorano et al., 2006). Most archaea contain a single 
MCM protein (with the exception of three species to date), which form 
homohexameric complexes in vivo (Chong et al., 2000, Wasserfallen et al., 2000, 
Kelman et al., 1999, Shechter et al., 2000, Poplawski et al., 2001, Carpentieri et al., 
2002). Eukaryotes are unique in possessing six highly related MCM subunits that 
form a heterohexameric complex (MCM2-7, Chong et al., 1996). Each MCM 
subunit is evolutionarily related to the other but each subunit is unique and 
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Figure 1.2. Semi-conservative DNA replication. Duplex DNA is unwound to provide 
template strands for DNA polymerase to copy. 
 
conserved throughout eukaryotes (reviewed in Bell and Dutta, 2002). In Xenopus 
laevis (Xenopus) all six MCM subunits have been shown to associate with 
chromatin before the onset of DNA replication suggesting that all six MCMs are 
required for DNA replication initiation (Thömmes et al., 1997). Consistent with 
these findings, deletion of any MCM subunit in S. cerevisiae or S. pombe causes 
lethality (reviewed in Dutta and Bell, 1997, Kelly and Brown, 2000) indicating 
each subunit has its own independent function. In addition, MCM2-7 complex 
assembly has been demonstrated to be essential in S. cerevisiae as mutants that 
disrupt complex formation are not viable (Dalton and Hopwood, 1997, Lei et al., 
2002).  
The requirement for MCM proteins called for a detailed functional analysis. In S. 
cerevisiae studies utilising degron-tagged proteins, where immediately after 
production tagged proteins are directed for degradation, demonstrated that all 
six MCM genes are required for DNA replication initiation and elongation (Labib 
et al., 2000). Consistent with this, immunodepletion in Xenopus egg extracts 
showed that MCM proteins are required for replication initiation (Chong et al., 
1995) and MCM7 was shown to be essential for replication elongation (Pacek and 
Walter, 2004). In S. pombe, little MCM2-7 is required for initiation but significant 
amounts are required for completion of DNA replication (Liang et al., 1999), 
suggesting that MCM2-7 is involved in events after replication initiation. This is 
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 consistent with the idea that the MCM2-7 complex is a genomic DNA helicase 
(reviewed in Tye, 1999).  
The six distinct classes of MCM proteins assemble in a ring conformation and 
examination of subunit pairs has led to the suggestion that the order of the MCM 
subunits in the ring is 5-3-7-4-6-2 (Fig. 1.3A, Davey et al., 2003). Later studies 
confirmed this subunit arrangement, using subunit dimer association 
experiments (Bochman et al., 2008) and negative stain electron microscopy (EM, 
Costa et al., 2011). The interaction between subunits MCM2 and MCM5 is weak 
(Davey et al., 2003, Bochman et al., 2008, Crevel et al., 2001) and the MCM2-7 ring 
appears to break open between these two subunits (Fig. 1.3B, Costa et al., 2011, 
Lyubimov et al., 2012, Samel et al., 2014). The opening between MCM subunits 2 
and 5 is now commonly referred to as the ‘2/5 gate’. To date ring opening has 
not been seen in archaeal MCMs.  
 
Figure 1.3. MCM2-7 subunit configuration. A. Schematic representation of the MCM2-7 
heterohexamer. B. MCM2-7 heterohexamer opens at the ‘2/5 gate’. 
MCM proteins are able to form sub-complexes. Purified S. cerevisiae MCM 
subunits form hexameric complexes containing just MCM4, 6 and 7 or just 
MCM4 and 7 in vitro (Bochman and Schwacha, 2008, Kanter et al., 2008, Biswas-
Fiss et al., 2005). Sub-complexes of hexameric MCM have also been found in vivo. 
A dimer of trimers of MCM4, 6 and 7 has been purified from HeLa cells (Ishimi, 
1997). However, this may be an unregulated form of MCM that only appears in 
cancer cells, as to date there is no evidence of this complex in ‘normal cells’. It 
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 appears that the dominant form of the MCM complex within cells is 
heterohexameric as when replication complexes are purified from Drosophila 
melanogaster (Drosophila) and S. cerevisiae, all six MCM subunits are present – as 
well as accessory proteins (Gambus et al., 2006, Moyer et al., 2006). In addition, 
only heterohexameric MCM2-7 is capable of inducing DNA replication in 
Xenopus egg extracts (Prokhorova and Blow, 2000). 
As the eukaryotic replicative helicase, the MCM2-7 complex has been studied in 
great detail in a range of organisms. In addition to playing a key role in DNA 
replication, the eukaryotic MCM2-7 complex has been implicated in transcription 
(Fitch et al., 2003, Snyder et al., 2005), chromatin remodelling (Groth et al., 2007, 
Tan et al., 2006, Burke et al., 2001, Iizuka and Stillman, 1999) and genome 
stability including a role in DNA damage responses and checkpoint signaling 
(Honeycutt et al., 2006, Shima et al., 2007). 
1.4.1 Localisation of MCM proteins 
MCM2 and MCM3 have nuclear localisation sequences (NLS) in S. cerevisiae and 
mammals (Ishimi et al., 2001, Pasion and Forsburg, 1999, Takei and Tsujimoto, 
1998, Young et al., 1997). However the NLS of MCM2 is not sufficient for 
transportation into the nucleus suggesting MCM2 must be complexed with other 
MCM subunits for transport (Pasion and Forsburg, 1999). MCM3 also contains a 
nuclear export sequence (NES, Liku et al., 2005). In cycling mammalian cells, 
MCM proteins are mainly nuclear (Kimura et al., 1994, Todorov et al., 1995, Fujita 
et al., 1996, Krude et al., 1996) and a large number of studies have shown MCM 
proteins to be stably bound to chromatin in G1 phase in a range of eukaryotes 
(Donovan et al., 1997, Chong et al., 1995, Symeonidou et al., 2013, Krude et al., 
1996, Ohta et al., 2003, Kuipers et al., 2011, Mendez and Stillman, 2000). In S. 
cerevisiae, MCM proteins enter the nucleus at mitosis where they remain until the 
initiation of DNA synthesis, after which MCM proteins are exported to the 
cytoplasm (Dalton and Whitbread, 1995), presumably to prevent re-initiation by 
promiscuous MCM2-7-chromatin binding. In S. pombe and metazoans, MCM 
proteins remain in the nucleus throughout S phase (Lei and Tye, 2001) indicating 
that there are other mechanisms for regulating MCM2-7-chromatin binding. 
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 Mammalian MCM proteins do not co-localise with newly synthesised DNA at 
the replication fork in isolated nuclei (Krude et al., 1996, Dimitrova et al., 1999). 
More recently consistent results were obtained using fluorescently tagged MCM 
proteins in living mammalian cells (Kuipers et al., 2011). Furthermore, the 
abundance of MCM proteins is far higher than other components of the pre-RC 
(Lei et al., 1996, Donovan et al., 1997) and excess MCM2-7 is loaded at each 
replication origin (reviewed in Laskey and Madine, 2003). These two 
observations raise questions regarding the function of MCM2-7 and together are 
commonly known as the ‘MCM paradox’. There are a number of hypotheses to 
explain the MCM paradox. One hypothesis is at DNA replication initiation, the 
majority of MCM proteins are evicted from the replication foci and the remaining 
MCM proteins are undetectable (Dimitrova and Gilbert, 1999). Analysis of HeLa 
cells demonstrated that MCM proteins co-localise with newly synthesised DNA 
from the previous cell cycle, agreeing with this hypothesis (Aparicio et al., 2012). 
In both Xenopus and human cells, excess chromatin bound MCM proteins can be 
activated along with dormant origins when the cell experiences replication stress 
(Woodward et al., 2006, Ibarra et al., 2008, Ge et al., 2007) and checkpoint 
activation (Cortez et al., 2004). The MCM paradox has also lead to a hypothesis 
regarding the mechanism of MCM2-7 unwinding, suggesting that MCM2-7 
complexes are located away from replication fork and pump ssDNA towards 
replication foci, i.e. where DNA is synthesised (reviewed in Laskey and Madine, 
2003).  
1.4.2 MCM complexes hydrolyse ATP  
Each MCM subunit has an ATPase domain (Koonin, 1993) and is a member of 
the AAA+ superfamily of ATPases (Iyer et al., 2004, Erzberger and Berger, 2006). 
Crystal structures of the archaeal Sulfolobus solfataricus (Sso) MCM showed 
functional ATPase sites are formed between two MCM subunits (Brewster et al., 
2008). One subunit contains both Walker A and Walker B motifs responsible for 
ATP binding and hydrolysis respectively (Neuwald et al., 1999, Walker et al., 
1982) and the adjoining subunit contributes an essential arginine finger (Davey et 
al., 2003). No MCM subunit alone is capable of hydrolysing ATP, as it requires an 
arginine finger and P-loop motif in the neighbouring subunit (Davey et al., 2003). 
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 The first in vitro analysis of the MCM complex able to hydrolyse ATP was from a 
sub-complex containing MCM4, 6 and 7 purified from HeLa cells (Ishimi, 1997). 
Subsequently ATP hydrolysis activity was demonstrated for homohexameric 
archaeal MCM complexes (Jenkinson and Chong, 2006, Kelman et al., 1999, 
Chong et al., 2000, Shechter et al., 2000, McGeoch et al., 2005, Kasiviswanathan et 
al., 2004). The Walker A motif contains a conserved lysine residue (K). When the 
conserved K is mutated to a glutamic acid (E), ATP hydrolysis by 
Methanothermobacter thermautotrophicus (Mt) MCM is significantly reduced 
(Chong et al., 2000). This essential residue is conserved from archaea to 
eukaryotes and subsequent work on S. cerevisiae confirmed the essentiality of the 
conserved K residue, as when mutated to an alanine (A) in one of the MCM 
subunits, ATP hydrolysis by MCM2-7 is notably reduced (Schwacha and Bell, 
2001). Taken together this suggests each individual MCM subunit contributes to 
ATPase activity. Recently ATPase sites of different MCM subunits have been 
demonstrated to be essential in different stages of its loading and activation in S. 
cerevisiae (Kang et al., 2014, Coster et al., 2014). In S. cerevisiae, the ATP hydrolysis 
activity of MCM2-7 does not appear to be affected by the presence of DNA 
(Schwacha and Bell, 2001, Davey et al., 2003, Bochman and Schwacha, 2008). This 
contrasts with archaeal MCM complexes and eukaryotic MCM hexamers 
containing only MCM4, 6, 7 which have been shown to be stimulated by 
exogenous DNA (Ishimi et al., 1998, Lee and Hurwitz, 2000, Lee and Hurwitz, 
2001, You et al., 2003, Liew and Bell, 2011, McGeoch et al., 2005, Kasiviswanathan 
et al., 2004).  
1.4.3 MCM as a helicase 
MCM proteins are members of the Superfamily 6 (SF6) helicases (reviewed in 
Singleton et al., 2007, Lyubimov et al., 2011). Robust helicase activity by MCM 
proteins was first demonstrated in archaea (Kelman et al., 1999, Chong et al., 
2000, Shechter et al., 2000). Analysis of the K to E mutation, which inhibits ATP 
hydrolysis, also inhibits helicase activity, consistent with a role for ATP 
hydrolysis in DNA unwinding (Chong et al., 2000, You et al., 1999). However, 
mutation of the Walker A motif does not affect in vivo helicase activity in S. pombe 
(Gomez et al., 2002).  
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 Early analysis showed that a sub-complex of eukaryotic MCM, presumably 
existing as a dimer of trimers containing only MCM4, 6, 7, possesses ATP-
dependent DNA helicase activity (Lee and Hurwitz, 2001, You et al., 2003, Ishimi, 
1997, Lee and Hurwitz, 2000). Moreover, addition of MCM2 or MCM2/5 to the 
MCM4, 6, 7 complex inhibited helicase activity suggesting a regulatory role for 
MCM2 and MCM5 (Lee and Hurwitz, 2000, Ishimi et al., 1998, Lee and Hurwitz, 
2001) and, despite intense experimentation, helicase activity of heterohexameric 
MCM2-7 could not be detected. However, salt-sensitive DNA helicase activity of 
S. cerevisiae heterohexameric MCM2-7 purified after Baculovirus expression has 
been achieved (Bochman and Schwacha, 2008). To date, DNA unwinding activity 
of higher eukaryotic heterohexameric MCM2-7 alone has not been reported. 
However, a complex purified from S. cerevisiae, Drosophila and Xenopus 
containing all six MCM subunits as well as accessory proteins has been shown to 
have helicase activity (Gambus et al., 2006, Moyer et al., 2006, Pacek et al., 2006). 
Analysis of archaeal MCM has yielded information regarding functional MCM 
residues as well as insight into the mechanism by which MCM unwinds DNA. 
MtMCM forms a double hexamer, which is dependent on the N-terminus (Chong 
et al., 2000). Subsequently, formation of double hexamers has also been shown 
for complexes containing MCM4, 6, 7 from S. pombe (Lee and Hurwitz, 2001), 
heterohexameric S. cerevisiae MCM2-7 when loaded on to DNA (Remus et al., 
2009, Evrin et al., 2009) and Xenopus heterohexameric MCM2-7 (Gambus et al., 
2011). From the study of MtMCM and a hexamer of MCM4, 6, 7 a preference for 
unwinding DNA in the 3’ – 5’ direction was identified (Chong et al., 2000, Ishimi, 
1997). Also from the analysis of MtMCM, a conserved domain known as the helix 
2 insert (h2i) was identified and mutation of the h2i domain inhibits helicase 
activity but not ATP hydrolysis (Jenkinson and Chong, 2006). 
1.5 MCM2-7 loading  
In cycling cells the nucleus is ‘licensed’ for DNA replication in G1 phase when 
MCM2-7 is loaded onto chromatin (Chong et al., 1995). Loading of MCM2-7 is 
dependent on a number of accessory proteins that form a large protein machine 
known as the pre-RC. To ensure nuclear DNA is only replicated ‘once per cell 
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 cycle’, pre-RCs can only form when CDK levels are low (in G1 phase, reviewed 
in Sclafani and Holzen, 2007). 
S. cerevisiae have a closed mitosis, requiring proteins that would not normally do 
so, to cross the nuclear envelope (Byers and Goetsch, 1975). MCM subunits are 
good examples of such proteins and the S. cerevisiae MCM subunits possess 
significant insertions to cater to this requirement (Table 1.1). Moreover, in recent 
years a number of metazoan specific proteins have been discovered that are 
essential for MCM2-7 loading (reviewed in Shen and Prasanth, 2012). It is 
therefore not surprising that as well as a number of unifying similarities among 
all eukaryotes with regards to DNA replication, there are also a number of 
significant differences in the details regarding these systems. The pathway for 
MCM2-7 loading in metazoans is shown in fig. 1.4 and described below. 
Table 1.1. MCM amino acid insertions comparison of S. cerevisiae and Human 
(Hs) MCM. The number of amino acids present in S. cerevisiae and human 
MCM2-7 are compared. In all MCM subunits other than MCM2 an increase in the 
number of amino acids in S. cerevisiae is observed. These extra amino acids are 
observed in the N-terminus of S. cerevisiae MCM subunits.   
MCM S. cerevisiae 
(aa*) 
Human  
(aa) 
aa difference 
(Sc-Hs) 
insertion 
locations 
2 868 904 -36 (-4%) C 
3 971 808 163 (20%) N, C 
4 933 863 70 (8%) N 
5 775 734 41 (6%) N 
6 1017 821 196 (24%) N, (C) 
7 845 719 126 (18%) N 
* amino acids  
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Figure 1.4. Pre-Replication Complex (pre-RC) assembly. ATP binding is required for the 
assembly of ORC subunits. ORC bound to ATP binds origin DNA and subsequently 
recruits Cdc6 (bound to ATP). Mcm9 assists Cdt1 in MCM2-7 binding with at least one 
MCM subunit bound to DNA. Cdt1 is released and MCM2-7 hydrolyses ATP before the 
second MCM2-7 is loaded making a double hexamer. Both Cdc6 and Cdt1 are released 
in addition to ATP hydrolysis by MCM2-7. For simplicity Geminin, HBO1, MCM8, and 
Hox-D13 are omitted. Adapted from Coster et al., 2014.
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 1.5.1 Origins 
Replication origins specify where pre-RC components bind to chromatin and so 
where DNA replication begins. Due to the large size of eukaryotes genomes, 
replication originates at multiple chromosomal origins. In mammalian cells it is 
predicted there are tens of thousands of origins (reviewed in Edenberg and 
Huberman, 1975). This allows the full genome to be replicated in a relatively 
short period of time. In S. cerevisiae, origins are defined by an autonomous 
replication sequence (ARS, Stinchcomb et al., 1979) that contains the ARS 
consensus sequence (ACS, Deshpande and Newlon, 1992) and in S. pombe, 
origins contain an adenosine and thymidine rich segment (Chuang and Kelly, 
1999, Lee et al., 2001). However in higher eukaryotes, origins are not simply 
defined by nucleotide sequence but appear to be defined by chromosomal 
environment and structure (reviewed in Mechali, 2010). Extensive evidence 
places origins at the nuclear matrix, a ribo-proteinaceous structure found in the 
nuclei of metazoans (reviewed in Wilson and Coverley, 2013, see section 1.9). 
Pre-RC assembly occurs in a stepwise manner (reviewed in Bell and Dutta, 2002) 
and begins by the binding of the Origin Recognition Complex (ORC) to origins. 
1.5.2 ORC 
ORC is essential for the initiation of DNA replication and for MCM2-7 binding to 
chromatin in higher eukaryotes (Carpenter et al., 1996, Rowles et al., 1996, 
Aparicio et al., 1997). ORC is a complex of six proteins (Orc1-6). Subunits 1 - 5 
contain AAA+ ATPase domains (Iyer et al., 2004, Clarey et al., 2006). However in 
S. cerevisiae only Orc1 is capable of ATP hydrolysis (Speck et al., 2005, Randell et 
al., 2006). Orc6 is essential for MCM2-7 loading onto DNA in S. cerevisiae (Chen et 
al., 2007) but is not essential for ORC-origin binding (Lee and Bell, 1997). S. 
cerevisiae and S. pombe ORC have extremely high affinity for DNA and bind 
sequence specific origins and usually one ORC binds per origin (Rowley et al., 
1995). ORC-origin binding is dependent on Orc1 binding ATP but not hydrolysis 
(Bell and Stillman, 1992, Lee and Bell, 1997, Klemm and Bell, 2001, Rowley et al., 
1995). Using purified proteins from S. cerevisiae, ATP hydrolysis by ORC has 
been shown as non-essential for functional loading of MCM2-7 (Coster et al., 
2014, Bowers et al., 2004, Evrin et al., 2013). Mammalian ORC requires ATP to 
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 promote the ordered assembly of its subunits and stimulate DNA binding 
(Ranjan and Gossen, 2006, Vashee et al., 2001). However mammalian ORC does 
not appear to have specificity for a sequence and other unknown factors must 
affect its origin binding. This may be due to additional metazoan specific 
proteins such as HMGA1, which preferentially binds the minor groove of regions 
of DNA rich in adenosine and thymidine (Thomae et al., 2008).  
The expression of Orc1 peaks in G1 phase, its activity is inhibited at the G1/S 
phase transition and it is degraded in S phase. The cell cycle dependent 
expression and activity of ORC is known as the ‘ORC cycle’ (reviewed in 
DePamphilis, 2003) and is an important mechanism used to ensure ORC only 
binds to origins in G1 phase once per cell cycle. In S. cerevisiae, phosphorylation 
of ORC by CDK causes inactivation (Nguyen et al., 2001, Wilmes et al., 2004, 
Chen and Bell, 2011). 
1.5.3 Cdc6 
The next step in MCM2-7 loading is the binding of Cell division cycle 6 (Cdc6) to 
ORC. In S. cerevisiae, S. pombe and metazoans, Cdc6 is essential for initiation of 
DNA replication and binding of MCM proteins to chromatin (Coleman et al., 
1996, Cocker et al., 1996, Tanaka et al., 1997, Hateboer et al., 1998, Kelly et al., 
1993, Lau et al., 2006, Santocanale and Diffley, 1996). 
Cdc6 is an AAA+ ATPase (reviewed in Lee and Bell, 2000) and ATP hydrolysis 
by Cdc6 in S. cerevisiae, is essential for MCM2-7 loading (Randell et al., 2006, Seki 
and Diffley, 2000). In S. cerevisiae the initial function of Cdc6 is to ensure ORC is 
bound to origin DNA. Cdc6 preferentially binds to ATP bound Orc1 and so 
origin bound ORC (Klemm and Bell, 2001). In addition, when Cdc6 binds ORC 
bound to non-origin DNA, Cdc6 hydrolyses ATP and dissociates (Speck and 
Stillman, 2007) and so Cdc6 binding increases the origin sequence specificity of 
ORC (Mizushima et al., 2000, Speck et al., 2005). A stable interaction between 
Cdc6 and origin bound ORC requires ATP binding by Cdc6 (Evrin et al., 2013, 
Coster et al., 2014, Frolova et al., 2002), but not ATP hydrolysis (Kang et al., 2014). 
Structural studies of S. cerevisiae proteins indicate together ORC and Cdc6 make a 
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 ring shaped structure, which is similar to the surface of MCM2-7 (Speck et al., 
2005). This is predicted to act as a MCM2-7 loading machine.  
In S. cerevisiae, Cdc6 is phosphorylated by CDK when cells pass into S phase 
causing release from origins, ubiquination and degradation (Drury et al., 1997, 
Weinreich et al., 2001). Over expression of Cdc6 in S. cerevisiae causes re-initiation 
(Nishitani et al., 2000). In addition to Cdc6 degradation, in mammalian cells the 
localisation of Cdc6 is also controlled by CDK phosphorylation (Pelizon et al., 
2000, Delmolino et al., 2001). Free Cdc6 not bound to origins is destroyed by 
proteolysis triggered specifically by cyclin A/CDK2 in S phase (Coverley et al., 
2000). However analysis of cancer cell lines, show Cdc6 is protected from 
degradation by cyclin E/CDK2 dependent phosphorylation (Mailand and 
Diffley, 2005). 
1.5.4 Cdt1 
The next step in MCM2-7 loading involves Cdc10-dependent transcription factor 
(Cdt1). Cdt1 was first identified as an essential component of the replication 
licensing factor in Xenopus egg extracts (Chong et al., 1995) and is required after 
Cdc6 and ORC for DNA replication initiation (Chong et al., 1995, Tada et al., 
1999). Subsequently Cdt1 homologues were discovered in S. pombe (Nishitani et 
al., 2000), S. cerevisiae (Tanaka and Diffley, 2002), Drosophila (Whittaker et al., 
2000) and mammals (Cook et al., 2004). 
In S. cerevisiae, Orc6 contains two binding sites for Cdt1 (Chen et al., 2007, Takara 
and Bell, 2011). Cdt1 is also capable of binding MCM2-7 prior to loading (Tanaka 
and Diffley, 2002, Remus et al., 2009), leading to the suggestion that the main role 
of Cdt1 is as a chaperone for guiding MCM2-7 to ORC-Cdc6 (Chen and Bell, 
2011). A more recent study suggests MCM2-7-Cdt1 initially binds chromatin via 
an interaction between the C-terminal of MCM3 and ORC-Cdc6 (Frigola et al., 
2013), suggesting Cdt1 is not required for initial MCM2-7 recruitment. In 
addition Cdt1 binding to MCM2-7 is not sufficient for MCM2-7 origin binding 
(Evrin et al., 2013). Following MCM2-7 loading Cdt1 is released from chromatin 
by the hydrolysis of ATP by Cdc6 (Randell et al., 2006). Metazoan Cdt1 has also 
been shown to interact with MCM2-7 (Cook et al., 2004), specifically MCM6 
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 (Yanagi et al., 2002, Teer and Dutta, 2008, Ferenbach et al., 2005) and this 
interaction facilitates MCM2-7 loading onto chromatin by inducing a 
conformational change in MCM6 (Zhang et al., 2010). 
Cdt1 accumulates in G1 and is destabilised after initiation or exported from the 
nucleus in S. cerevisiae and S. pombe (Nishitani et al., 2001, Tanaka and Diffley, 
2002). In these lower eukaryotes, cellular location appears to be the main 
mechanism for controlling Cdt1 (reviewed in Blow and Dutta, 2005). However in 
metazoans, if excess Cdt1 is present in S phase or G2 it causes illegitimate re-
replication (Arias and Walter, 2005, Li and Blow, 2005, Maiorano et al., 2005, 
Yoshida et al., 2005, Lutzmann et al., 2006). Cdt1 is the only member of the pre-
RC that is capable of this in metazoans and so cells have evolved numerous 
mechanisms for Cdt1 regulation. In both Xenopus and human cells, Cdt1 is 
negatively regulated by ubiquitination-mediated proteolysis when cells enter S 
phase (Arias and Walter, 2005, Nishitani et al., 2006, Arias and Walter, 2006, 
Senga et al., 2006). In human cells, Cdt1 is also degraded in G2, mediated by 
FBXO31 which ubiquitinates Cdt1 (Johansson et al., 2014). 
The action of Cdt1 is also controlled by Geminin, a metazoan specific protein 
expressed in S and G2 phase (Wohlschlegel et al., 2000, Tada et al., 2001). 
Geminin binds Cdt1 in a 2:1 complex (Lee et al., 2004), which dimerises to mask 
Cdt1 regions required for initiation (De Marco et al., 2009). 
1.5.5 MCM2-7 
Together Cdt1 and MCM2-7 are bound to chromatin. In S. cerevisiae ATP 
hydrolysis by Cdc6 promotes a stable association of MCM2-7 with DNA (Bowers 
et al., 2004, Randell et al., 2006), presumably mediating the transition from 
chromatin bound MCM2-7 to loaded MCM2-7 (Fernandez-Cid et al., 2013). ATP 
hydrolysis by ORC is required for MCM2-7 loading (Bowers et al., 2004, Evrin et 
al., 2013). A recent study of S. cerevisiae MCM2-7 analysed the individual MCM 
ATP binding and hydrolysis sites between each MCM subunit ATPase motif. As 
two MCM subunits contribute to ATP hydrolysis activity, analysis of the effect of 
MCM ATP binding and hydrolysis was assessed between subunit pairs. Only 
mutants between subunits MCM3/7 did not effect MCM loading and so ATPase 
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 activity in all four other subunit interfaces are required (Kang et al., 2014). This 
work demonstrates ATPase sites of different MCM subunits are implicated and 
essential in different stages of its loading and activation (Kang et al., 2014). 
Conversely, in a Xenopus cell free system MCM2-7 ATPase activity is not 
required for pre-RC formation (Ying and Gautier, 2005). Following MCM2-7 
loading, Cdc6 and Cdt1 are released from chromatin when washed with high salt 
but MCM2-7 remains bound demonstrating a strong chromatin association 
(Remus et al., 2009, Evrin et al., 2009, Kawasaki et al., 2006, Bowers et al., 2004, 
Donovan et al., 1997), that could reflect encircling of DNA. 
In S. cerevisiae and Xenopus egg extracts MCM2-7 complexes have been shown to 
load as a double hexamer encircling double stranded (ds) DNA (Evrin et al., 
2009, Remus et al., 2009, Gambus et al., 2011). Once MCM2-7 is loaded it can slide 
along the dsDNA but not unwind it in an ATP independent manner (Remus et 
al., 2009, Evrin et al., 2009) suggesting another catalytic event is required to 
separate the double hexamer and stimulate DNA helicase activity. The current 
hypothesis is the MCM2-7 complex must open at the 2/5 gate in order to encircle 
chromatin. A recent study of S. cerevisiae MCM2-7, which biochemically links 
subunits MCM2 and MCM5, demonstrates opening of the MCM2-7 ring between 
2/5 is essential for pre-RC loading (Samel et al., 2014). In S. cerevisiae, opening 
and closing the MCM2/5 gate has been shown to be dependent on ATP 
(Bochman and Schwacha, 2010, Bochman et al., 2008) but ATP binding does not 
open the gate in Drosophila or Encephalitozoon cuniculi (E. cuniculi, Costa et al., 
2011, Lyubimov et al., 2012). 
Following MCM2-7 loading in S. cerevisiae, ORC, Cdc6 and Cdt1 dissociate from 
DNA and this is dependent on ATP hydrolysis (Tsakraklides and Bell, 2010). S. 
cerevisiae MCM2-7 loading is not ATP dependent suggesting MCM2-7 loading 
and double hexamer formation are separate events (Samel et al., 2014). Binding 
and hydrolysis of ATP by MCM2-7 purified from S. cerevisiae has been shown to 
be required for Cdt1 release and infers a conformational change and double 
hexamer formation (Coster et al., 2014, Evrin et al., 2014). In addition, ATP 
hydrolysis by Orc1 is required for Cdt1 release and the binding of the second 
MCM2-7 (i.e. double hexamer formation, Fernandez-Cid et al., 2013). If MCM2-7-
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 Cdt1 is not loaded correctly on chromatin ATP hydrolysis by Cdc6 releases the 
incorrectly loaded MCM2-7 (Kang et al., 2014). MCM ATP hydrolysis, 
particularly by MCM5, is required for Cdt1 release and successful MCM2-7 
loading (Kang et al., 2014), suggesting an interaction between MCM5 and Cdt1. 
Moreover, using EM a complex of MCM2-7, Cdt1, Cdc6 and ORC show Cdt1 is 
in close proximity to MCM5 (Sun et al., 2013). The formation of MCM2-7 double 
hexamer appears to be the limiting step in pre-RC assembly (Evrin et al., 2014). 
This recent work suggests loading of the first MCM2-7 is not dependant on ATP 
hydrolysis but is dependant on ORC, Cdc6 and Cdt; however, whether loading 
of the second MCM2-7 complex requires Cdc6 and Orc is not known (reviewed 
in Riera et al., 2014, Yardimci and Walter, 2014).  
Initial studies implied ORC was able to remodel DNA prior to MCM2-7 loading 
and so provided initial DNA duplex opening (Lee and Bell, 1997, Rowley et al., 
1995). However, MCM2-7 loads as a double hexamer and recent results 
demonstrate ORC can be eluted from DNA after MCM2-7 loading, and before 
unwinding, suggesting ORCs essential job is in pre-RC assembly (Gros et al., 
2014). Indicating that initial unwinding is dependent on MCM2-7. 
1.5.6 Metazoan specific proteins involved in MCM2-7 loading 
There are a number of newly identified proteins, specific to metazoans that are 
involved in controlling MCM2-7 loading (reviewed in Shen and Prasanth, 2012). 
Many of these proteins, like Geminin (Wohlschlegel et al., 2000), appear to 
specifically modulate Cdt1. For example MCM9, a metazoan specific MCM2-7 
homologue, was shown to be required for MCM2-7 loading in Xenopus egg 
extract (Lutzmann and Mechali, 2008). MCM9 is an activating binding partner for 
Cdt1 appearing to have an opposing role to Geminin (Lutzmann and Mechali, 
2008). However, a second study in Xenopus egg extract demonstrates MCM9 is 
not essential for DNA replication initiation and an interaction with Cdt1 could 
not be found (Gambus and Blow, 2013). Consistent with this, MCM9 is 
dispensable for DNA replication initiation in mouse cells (Hartford et al., 2011).  
Histone acetylase binding to Orc1 protein (HBO1) interacts with Orc1 (Iizuka and 
Stillman 1999). Knockdown of HBO1 in mammalian cells has no effect on ORC 
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 and Cdc6 chromatin binding but affects MCM2-7 loading (Iizuka et al., 2008). 
HBO1 associates with origins in G1 phase and interacts with Cdt1 (Miotto and 
Struhl, 2008), suggesting the role of HBO1 is to assist Cdt1 in MCM2-7 loading 
(Miotto and Struhl, 2008, Wu and Liu, 2008, Iizuka et al., 2008). 
In addition MCM8, another MCM2-7 homologue, is believed to facilitate Cdc6 
loading and interacts with Cdc6, Orc2 and MCM4, 6, 7 (Kinoshita et al., 2008, 
Volkening and Hoffmann, 2005). However a recent study in Xenopus egg extracts 
demonstrates MCM8 is not essential for DNA replication initiation (Gambus and 
Blow, 2013). Homobox protein Hox-D13 (HOXD13) is also believed to facilitate 
Cdc6 loading (Salsi et al., 2009). 
1.6 MCM2-7 activation 
Once loaded onto chromatin, MCM2-7 remains inactive until the initiation of 
DNA replication at the G1/S boundary (reviewed in Boos et al., 2012, Li and 
Araki, 2013, Labib, 2010). The temporal separation of MCM2-7 loading and 
activation stops cells from re-loading MCM2-7 once the cell passes into S phase 
ensuring once per cell cycle DNA replication (Bell and Stillman, 1992, Diffley et 
al., 1994). It has been suggested this gap is also used to ensure enough MCM2-7 is 
loaded to replicate the whole genome before passing into S phase (Ge and Blow, 
2009, Liu et al., 2009). 
As discussed above, MCM2-7 complexes are loaded as a double hexamer 
presumably to provide a mechanism for bi-directional replication. However, 
some evidence suggests otherwise. In S. cerevisiae and human cells, live cell 
imaging suggests sister replication forks stay close together during replication 
(Kitamura et al., 2006, Ligasova et al., 2009). In addition, coupling of sister 
chromatids is not required for replication as replication was equally efficient 
whether one or both ends of the DNA are immobilised (Yardimci et al., 2010). 
DDK in S. cerevisiae is referred to as the ‘activating’ kinase. However DDK 
activity alone is not sufficient for separating MCM2-7 double hexamers, although 
it does stimulate a small conformational change (On et al., 2014). Together, the 
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 cellular kinases DDK and CDK appear to control the formation of the Cdc45-
MCM2-7-GINS (CMG) complex via the pre-Loading Complex (pre-LC, 
Muramatsu et al., 2010) and the pre-Initiation Complex (pre-IC, Zou and 
Stillman, 1998). Much less is known about the formation of the pre-LC, pre-IC 
and CMG complex, particularly in metazoans. What is known about CMG 
assembly in S. cerevisiae is detailed below and shown in fig 1.5. 
1.6.1 Pre-IC 
In S. cerevisiae, the pre-IC is a large protein machine that requires DDK to 
assemble (Zou and Stillman, 2000). S. cerevisiae pre-IC consists of Cell division 
cycle 45 (Cdc45), Synthetically lethal with Dpb11 (Sld)3, Sld7 and MCM2-7 
(Kamimura et al., 2001, Kanemaki et al., 2003, Zou and Stillman, 2000, Tanaka et 
al., 2011). Sld3 and Cdc45 are able to bind to MCM2-7 in late G1 phase when the 
levels of CDK are low (Aparicio et al., 1999, Kamimura et al., 2001, Kanemaki and 
Labib, 2006, Heller et al., 2011, Tanaka and Araki, 2011) and this binding is 
promoted by DDK activity (Gros et al., 2014, Heller et al., 2011). Consistent with 
this, S. pombe Sld3 requires DDK phosphorylation but not CDK phosphorylation 
for chromatin binding and DNA replication initiation (Nakajima and Masukata, 
2002). However chromatin association of the Sld3 metazoan homologue, 
Treslin/Ticrr (Kumagai et al., 2010, Kumagai et al., 2011, Sanchez-Pulido et al., 
2010, Boos et al., 2011), is dependent on phosphorylation by CDK (Kumagai et 
al., 2010). In a similar way to S. cerevisiae, Treslin/Ticrr binds Cdc45 and is 
required for association of Cdc45 with chromatin (Kumagai et al., 2010, Sanchez-
Pulido et al., 2010). MTBP is a metazoan specific protein that has been suggested 
as a candidate for the homologue of Sld7 due to its association with 
Treslin/TICRR (Boos et al., 2013). 
1.6.2 Pre-LC 
The pre-LC assembles away from chromatin. In S. cerevisiae, the pre-LC consists 
of Sld2, DNA polymerase B possible subunit 11 (Dpb11), polymerase (pol) ε and 
Go-Ichi-Ni-San (GINS) and its assembly is dependent on CDK and DDK 
(Muramatsu et al., 2010). Origin binding of Sld2 and Dbp11 is dependent on both 
DDK and CDK activities (Gros et al., 2014, Zegerman and Diffley, 2007, Tanaka et   
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Figure 1.5. Assembly of Cdc45-MCM2-7-GINS (CMG) complex based on analysis in S. 
cerevisiae. MCM2-7 is loaded as an inactive double hexamer. Activation involves the 
binding of Sld3-Sld7-Cdc45 complex to each MCM2-7 hexamer (for simplicity only one is 
shown). This is dependent on DDK activity. The pre-Loading Complex (pre-LC) composed 
of Sld2, Dpb11, GINS and polymerase DNA Pol ε form the pre-Initiation Complex (pre-IC) 
on chromatin in a CDK-dependent manner. Components of the pre-IC are released 
leaving the CMG complex. Mcm10 binds to chromatin following CMG formation. Adapted 
from Li and Araki 2013. 
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 al., 2007). This agrees with cell cycle studies showing that Sld2 and Dbp11 bind to 
chromatin during initiation when both CDK and DDK are present (Tanaka et al., 
2007, Zegerman and Diffley, 2007, Muramatsu et al., 2010).  
In metazoans RecQ4 is the homologue of Sld2. RecQ4s interaction with 
chromatin is dependent on TopBP1 (metazoan Dpb11 homologue) and 
independent of CDK activity (Matsuno et al., 2006, Sangrithi et al., 2005), in 
contrast to the function of Sld2 in S. cerevisiae, which is dependent on CDK 
activity. RecQ4 has also been shown to associate with chromatin after GINS and 
Cdc45 loading and depletion of RecQ4 in Xenopus egg extracts did not affect 
Cdc45 and GINS loading (Sangrithi et al., 2005). However in human cells, 
depletion of RecQ4 significantly reduced Cdc45 and GINS chromatin loading (Im 
et al., 2009). Agreeing with S. cerevisiae data, RecQ4 has been shown to be 
essential for DNA replication initiation in Drosophila and Xenopus (Wu et al., 
2008, Sangrithi et al., 2005).  
In human cells TopBP1 is essential for activation of cyclin E/CDK2 and the 
loading of replication components onto chromatin (Jeon et al., 2007) suggesting 
TopBP1 behaves similarly to Dpb11. In addition TopBP1 knockout mice 
exhibited early embryonic lethality (Jeon et al., 2011). However the essentiality of 
TopBP1 in human cells has been controversial. In two different osteosarcoma cell 
lines (Saos-2 and U2OS cells) depletion of TopBP1 using siRNA demonstrated 
cell cycle arrest at the G1/S phase transition showing TopBP1 is essential for 
DNA replication initiation (Jeon et al., 2007, Kumagai et al., 2010). Conversely 
another study analysing aggressive cervical carcinoma cells (HeLa), again using 
siRNA to deplete TopBP1, demonstrated TopBP1 had no effect on CMG 
formation (Im et al., 2009) suggesting, in this cell line, TopBP1 is not essential for 
DNA replication initiation.  
In S. cerevisiae, the pre-LC is recruited to origins via an interaction between 
Dpb11 and origin bound Sld3 (Tanaka et al., 2007, Zegerman and Diffley, 2007, 
Tanaka and Araki, 2010). This is dependent on Sld3 phosphorylation by DDK 
(Heller et al., 2011). Consistent with this, binding of Treslin/Ticrr (Sld3) to 
chromatin in metazoans is independent of TopBP1 (Dbp11) chromatin binding 
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 (Kumagai et al., 2010). In addition TopBP1 and Treslin/Ticrr associate in Xenopus 
egg extracts (Kumagai et al., 2010). It appears the main function of the pre-IC and 
pre-LC is to form the CMG complex as all proteins other than Cdc45, MCM2-7 
and GINS disassociate from chromatin soon after binding (Kanemaki and Labib, 
2006, reviewed in Labib, 2010).  
1.6.3 Cdc45 
S. cerevisiae and Xenopus Cdc45 have been shown to be required for initiation and 
replication fork progression (Aparicio et al., 1997, Labib et al., 2000, Pacek and 
Walter, 2004). Moreover, in human cells Cdc45 is a limiting factor for DNA 
replication initiation (Wong et al., 2011). Cdc45 is unique in replication proteins 
as it can be re loaded at replication origins where previously lost (Tercero et al., 
2000). S. cerevisiae, Xenopus and human Cdc45 is recruited to chromatin in G1 
phase and at initiation tightly associates with origin DNA dependent on DDK 
and CDK activities (Jares and Blow, 2000, Masuda et al., 2003, Owens et al., 1997, 
Aparicio et al., 1999, Zou and Stillman, 2000, Sheu and Stillman, 2006, Walter and 
Newport, 2000, Im et al., 2009). Recently Cdc45 has been shown to contain a 
conserved RecJ exonuclease domain that is catalytically inactive but is capable of 
binding ssDNA (Sanchez-Pulido and Ponting, 2011, Krastanova et al., 2012, 
Szambowska et al., 2014). 
Knockout of Cdc45 in mice is embryonically lethal (Yoshida et al., 2001). Cdc45 is 
degraded in quiescent human cells and once the cell passes the restriction point, 
expression of Cdc45 increases until S phase (Pollok et al., 2007). In mammalian 
cells Cdc45 is also controlled by ubiquitin mediated degradation (Pollok and 
Giosse, 2007). 
1.6.4 GINS 
GINS is a tetramer comprising Partner of Sld five (Psf)1, Psf2, Psf3 and Sld5 
subunits (Kanemaki et al., 2003, Kubota et al., 2003, Takayama et al., 2003, Labib 
and Gambus, 2007). GINS is highly conserved from S. cerevisiae to humans 
(Kubota et al., 2003, Takayama et al., 2003). The structure of human GINS has 
been solved by x-ray crystallography demonstrating a stable complex (Kamada 
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 et al., 2007). In the absence of DNA, S. cerevisiae GINS has a high ATP 
independent affinity for MCM2-7 (Bruck and Kaplan, 2011). GINS is required for 
recruiting pol ε to origins (Kanemaki and Labib, 2006). In human cells, GINS is 
expressed in cycling cells and depleted in quiescent cells (Aparicio et al., 2009). 
Down regulation of GINS in human cells impairs entry to S phase and S phase 
progression (Aparicio et al., 2009), suggesting a role in both initiation and 
elongation of DNA replication.  
1.6.5 MCM10  
The involvement of MCM10 in origin activation is unclear. Some studies in S. 
cerevisiae suggest MCM10 binds to pre-RCs in G1 phase (van Deursen et al., 2012, 
Ricke and Bielinsky, 2004). Moreover in human cells MCM10 has been shown to 
promote Cdc45 and RecQ4 (Sld2) chromatin binding (Xu et al., 2009). However 
other studies in S. cerevisiae and S. pombe suggest the role of MCM10 comes much 
later following CMG formation and is dependent on both CDK and DDK 
(Watase et al., 2012, Heller et al., 2011, Gros et al., 2014, Kanke et al., 2012). In S. 
cerevisiae, MCM10 has also been shown to regulate the association of Pol α with 
chromatin (Eisenberg et al., 2009).  
1.6.6 Ctf4 
Ctf4 is conserved in eukaryotes. In S. cerevisiae it is not essential for viability 
(Gambus et al., 2009). In mammalian cells, Ctf4 is required for both CMG 
assembly and Pol α chromatin recruitment (Im et al., 2009). After initiation Ctf4 
moves with the replication fork and is believed to be involved in linking Pol α to 
MCM2-7 in S. cerevisiae (Gambus et al., 2009, Tanaka et al., 2009). Using both EM 
and X-ray crystallography, a recent study shows S. cerevisiae Ctf4 naturally forms 
a trimer and provides a link between CMG and two Pol α molecules (Simon et 
al., 2014). 
1.6.7 Metazoan specific initiation proteins 
A geminin related protein, geminin coiled coil containing protein (GEMC1), is 
required for initiation in Xenopus egg extracts and mouse cells in culture 
(Balestrini et al., 2010). GEMC1 is phosphorylated by CDK in vitro and co-
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 immunopreticipates with cyclin E/CDK2 from Xenopus egg extract (Balestrini et 
al., 2010). TopBP1 promotes GEMC1 chromatin binding stimulating DNA 
replication initiation (Balestrini et al., 2010, Piergiovanni and Costanzo, 2010).  
DUE-B (DNA unwinding element binding protein) is required for the association 
of Cdc45 and TopBP1 with chromatin in Xenopus eggs (Chowdhury et al., 2010). 
Levels of DUE-B in human cancer cells remained constant throughout the cell 
cycle with preferential phosphorylation of DUE-B in cells arrested in S phase 
(Casper et al., 2005). Inhibition of DUE-B in human cancer cells slowed G1 - S 
phase progression and induced cells to die in S phase (Casper et al., 2005).  
1.6.8 CMG activation 
In vivo, the ability of MCM2-7 to processively unwind DNA is hypothesised to 
only be possible when associated with both Cdc45 and GINS in the CMG 
complex. Comparison of the helicase activity of MCM2-7 alone and CMG 
complex purified from Xenopus egg extract demonstrates significantly higher 
DNA unwinding activity when MCM2-7 is in a complex with Cdc45 and GINS 
(Ilves et al., 2010). Also, following initiation Cdc45, GINS and MCM2-7 move 
with the replication fork (Gambus et al., 2006, Kanemaki et al., 2003, Labib et al., 
2000, Takayama et al., 2003). 
S. cerevisiae, Drosophila and Xenopus replication complexes have been shown to 
contain a single MCM2-7 hexamer within the CMG complex (Gambus et al., 2006, 
Moyer et al., 2006, Pacek et al., 2006). Using Xenopus egg extracts CMG has been 
shown to translocate along template DNA in 3’ to 5’ direction (Fu et al., 2011). 
‘Roadblocks’ on the leading strand, but not the lagging strand, inhibited CMG 
mediated unwinding (Fu et al., 2011), if the CMG translocated along dsDNA a 
roadblock on either strand would inhibit unwinding. Purified human CMG 
complex has also been shown to have a preference for unwinding DNA on the 
leading strand opposed to the lagging strand (Kang et al., 2012). Moreover, EM 
reconstructions of Drosophila and E. cuniculi MCM2-7 found in an open ring 
conformation, which is closed in EM reconstructions of CMG (Costa et al., 2011, 
Lyubimov et al., 2012). Suggesting Cdc45 and GINS close the open ring of 
MCM2-7 to induce a conformational change and a side channel, which is 
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 hypothesised to partition the lagging strand for DNA unwinding (Costa et al., 
2011). A recent EM study identified Drosophila CMG complexes in both dimer 
and single CMG when analysed in the presence on a non-hydrolysable ATP 
analogue (Costa et al., 2014), suggesting formation of the CMG is not sufficient 
for splitting the double hexamer.  
1.7 Phosphorylation of MCM proteins  
Exactly how MCM2-7 double hexamers separate and are activated to unwind 
DNA is not understood. Many lines of evidence suggest the precise 
phosphorylation of MCM2-7 proteins directly affect the activity of MCM2-7 in 
terms of, i) MCM2-7 ring opening and loading, ii) MCM2-7 ring closing around 
single stranded and double stranded DNA and iii) MCM2-7 activation for duplex 
unwinding. 
Protein kinases CDK and DDK control MCM2-7 loading and activation in all 
eukaryotes. A number of studies have analysed the effects of CDK and DDK on 
MCM proteins (reviewed in Labib, 2010, Araki, 2010). This work has been 
controversial and it would seem the concentration as well as order of kinase 
addition has an effect on phosphorylation (reviewed in Sclafani and Holzen, 
2007).  
1.7.1 Phosphorylation by DDK 
MCM2-7 is a crucial target of Cdc7 and many subunits are phosphorylated 
during DNA replication initiation (reviewed in Forsburg, 2004, Labib, 2010). 
Initially, biochemical studies indicated MCM proteins were important targets for 
Cdc7 (Sato et al., 1997, Brown and Kelly, 1998, Takeda et al., 1999) and 
phosphorylation of MCM2 by Cdc7 is thought to be physiologically important 
(Lei et al., 1997, Hardy et al., 1997, Masai and Arai, 2002). In S. cerevisiae, DDK 
has been shown to interact with MCM2 and phosphorylate MCM2 in vivo and in 
vitro (Brown and Kelly, 1998, Lei et al., 1997). Subsequently in vitro 
phosphorylation of S. cerevisiae MCM3, MCM4, MCM6 and MCM7 was 
demonstrated (Weinreich and Stillman, 1999, Young and Tye, 1997). MCM5 has 
not been shown to be phosphorylated by DDK in any species. In Xenopus egg 
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 extract and mammalian cells Cdc7 has been shown to phosphorylate MCM2, 4 
and 6 complex proteins (Masai et al., 2000, Montagnoli et al., 2006, Takahashi and 
Walter, 2005, Takeda et al., 1999, Walter, 2000, Ishimi and Komamura-Kohno, 
2001, Randell et al., 2010, Cho et al., 2006). 
Dbf4 interacts with MCM2-7 complex via conserved motifs (Varrin et al., 2005, 
Jones et al., 2010). Dbf4 and Cdc7 have been shown to have differential binding 
partners within the S. cerevisiae MCM2-7 hexamer. Dbf4 interacts most strongly 
with MCM2 (Bruck and Kaplan, 2009, Ramer et al., 2013). Whereas MCM4 and 
MCM5 interact most strongly with Cdc7 (Ramer et al., 2013), suggesting a 
mechanism to recruit both Cdc7 and Dbf4 to the pre-RC. In addition mutation of 
Cdc7 and Dbf4 binding sites in MCM proteins strongly inhibits cell growth in S. 
cerevisiae (Ramer et al., 2013). This indicates spatial regulation of DDK is an 
important feature of its regulation. Studies suggest that the phosphorylation of 
MCM proteins differs depending on the context. For example, when MCM2-7 is 
origin bound, MCM4 and MCM6 are preferentially phosphorylated (Francis et 
al., 2009). Whereas when MCM2-7 is free from chromatin MCM2 
phosphorylation is preferential (Francis et al., 2009).  
In S. cerevisiae a requirement for Cdc7 is partially bypassed by introducing 
mutant MCM5 containing a substitution of Proline 83 to a Lysine, this mutant is 
known as the MCM5-bob1 mutant (Hardy et al., 1997, Hoang et al., 2007). As 
MCM5 itself is not phosphorylated by DDK, it is hypothesised the MCM5-bob1 
mutant bypasses the requirement for DDK by causing a conformational change 
in the MCM2-7 complex (Hardy et al., 1997, Hoang et al., 2007). Crystal 
structures of MtMCM further support the idea that MCM5-bob1 mutation may 
induce a conformational change (Fletcher et al., 2003, Chen et al., 2005). 
Furthermore, mutation of a DDK phosphorylation site in MCM2 at Ser170 causes 
lethality in S. cerevisiae (Bruck and Kaplan, 2009). This lethality is bypassed by the 
addition of the MCM5-bob1 mutant (Bruck and Kaplan, 2009). 
1.7.2 MCM4 phosphorylation 
A number of studies suggest that in S. cerevisiae and S. pombe MCM4 is the 
primary target for DDK during DNA replication initiation (Francis et al., 2009, 
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 Masai et al., 2000, Masai et al., 2006, Sheu and Stillman, 2006, Lee et al., 2003). 
MCM4 has also been shown to be phosphorylated by DDK in Xenopus extracts 
(Pereverzeva et al., 2000). The N-terminal of MCM4 is not conserved but is rich in 
serine and threonine (24% of hMCM4’s first 148 amino acids) and contains 
multiple Cdc7 phosphorylation motifs (reviewed in Labib, 2010). The N-terminal 
of MCM4 also contains sites where CDK could prime MCM4 for phosphorylation 
by Cdc7 (Masai et al., 2000, Devault et al., 2008).  
The initial biochemical effects of phosphorylation were noted by 
phosphorylation at CDK dependent sites on MCM4 which lead to loss of helicase 
activity of mouse MCM4, 6, 7 (Ishimi and Komamura-Kohno, 2001). Subsequent 
experiments demonstrated that in S. cerevisiae, the association of MCM2-7 with 
Cdc45 and Sld3 is stimulated by DDK activity (Sheu and Stillman, 2006, Heller et 
al., 2011). DDK binds to MCM4 via a kinase-docking domain, preferentially 
when MCM2-7 is origin bound (Sheu and Stillman, 2006, Masai et al., 2006). This 
allows significant phosphorylation by DDK in the N-terminal domain of MCM4 
(Sheu and Stillman, 2006). The N-terminal domain of MCM4 has been shown to 
be inhibitory in MCM2-7-Cdc45 binding and DDK dependent phosphorylation of 
N-terminal MCM4 alleviates this inhibition (Sheu and Stillman, 2010).  
1.7.3 MCM2 phosphorylation 
MCM2 phosphorylation is noted by its unusual increased mobility shift in SDS 
PAGE (Coverley et al., 2002 and others). This form of MCM2 is detected in S 
phase through to mitosis (Masai et al., 2006). Analysis of mouse MCM2 
demonstrated that the N-terminal portion of the protein contains major 
phosphorylation sites (Ishimi et al., 2001). This work led to a number of studies 
that have investigated DDK phosphorylation sites on human MCM2. One study, 
analysing the bacterially expressed, recombinant N-terminal of human MCM2 
(containing amino acids 10-294), identified three DDK sites (Ser40, Ser53 and 
Ser108, Montagnoli et al., 2006). In addition the authors also identified CDK sites 
(Ser13, Ser27, Ser41). Another study, analysing N-terminal and full length human 
MCM2 expressed in bacterial cells revealed two dominant DDK sites (Ser5 and 
Ser53) and three minor DDK sites (Ser4, Ser7 and Thr59, Cho et al., 2006). A third 
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 study analysed human MCM proteins produced in insect cells and identified 
three major (Ser27, Ser41 and Ser139) and two minor (Ser53 and Ser108) 
phosphorylation sites (Tsuji et al., 2006). These serine residues are conserved 
from Drosophila through to humans. The discrepancies within these results 
maybe due to the different methods of MCM production or may be in fact due to 
the concentration of DDK used, as previous studies suggest different outcomes 
depending on concentration gradients of kinases (Coverley et al., 2002). 
Interestingly, phosphorylation of MCM2 at Ser53 was found in all three studies. 
Arresting cells using hydroxyurea prevents DNA replication (Aparicio et al., 
1997, Rialland et al., 2002), induces MCM hyperphosphorylation at sites specific 
to Cdc7 and prevents release of MCM2 from chromatin (Montagnoli et al., 2006). 
Depletion of Cdc7 using siRNA impairs MCM2 phosphorylation at Ser40 and 
Ser53 (Tenca et al., 2007). Moreover, using antibodies specific to MCM2 
phosphorylation sites in synchronised HeLa cells showed the presence of MCM2 
phosphorylation at Ser40/41, Ser53 and Ser108 in S phase (Montagnoli et al., 
2006). Also, inhibition of DDK using a small molecule inhibitor PHA-767491 
impairs MCM2 phosphorylation at Ser40 and Ser53 (Montagnoli et al., 2008). 
Taken together these results show that MCM2 phosphorylation at Ser40 and 
Ser53 is dependent on Cdc7.  
In HeLa cells, MCM2-7 phosphorylation by DDK was shown to be essential for 
DNA replication initiation and phosphorylation of MCM2 by DDK was 
demonstrated to be critical for MCM2-7 ATPase activity in vitro (Tsuji et al., 
2006). A couple of studies have analysed the effect of DDK phosphorylation on 
MCM2-7 loading, with conflicting results. In Xenopus egg extract, loading of 
MCM2-7 was not affected by DDK phosphorylation (Tsuji et al., 2006). On the 
other hand, analysis of human cells released from quiescence, showed 
phosphorylation of MCM2 at Ser5 by DDK promotes chromatin loading of 
MCM2 (Chuang et al., 2009). 
1.7.4 Order of CDK and DDK kinase activity 
Studies in S. cerevisiae have shown DDK and CDK are required throughout S 
phase for firing of both early and late origins (Bousset and Diffley, 1998, 
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 Donaldson et al., 1998). In mammalian cells CDK is also required throughout S 
phase (Thomson et al., 2010). The order cells require CDK and DDK kinase 
activity is unclear due to conflicting results in different eukaryotic systems. In 
Xenopus egg extracts Cdc7 can complete its role in the absence of CDK but CDK 
cannot complete its role without Cdc7 (Jares et al., 2000, Walter, 2000). However 
in S. cerevisiae, Cdc7 cannot complete its activity in the absence of CDK activity 
(Nougarede et al., 2000). In vitro, phosphorylation of human MCM2 by CDK 
facilitates phosphorylation by DDK (Masai et al., 2000), suggesting 
phosphorylation of MCM2 by CDK induces a conformational change allowing 
DDK to access different sites. Dependence on prior CDK phosphorylation was 
only apparent when MCM2 was complexed in a tetramer of subunits MCM2, 4, 6 
and 7 (Masai et al., 2000) and not when tested on MCM2 monomer. 
Despite the precise mapping of MCM subunit phosphorylation sites, the 
significance of these phosphorylation sites within a hexamer and how the kinases 
render the complex functional is still not understood. The prevailing generalised 
hypothesis is that phosphorylation of MCM subunits causes a structural change 
within the MCM2-7 hexamer, regulating events in MCM2-7 loading and causes 
activation to occur. 
1.8 Structure of MCM2-7 complexes 
The first EM images of MCM2-7 were generated from purified S. pombe (Adachi 
et al., 1997). These images illustrated the hexameric shape of MCM2-7 with a 
deep cavity down the centre of the protein. More recently EM was used to 
produce a three dimensional (3D) reconstruction of archaeal MtMCM (Yu et al., 
2002, Pape et al., 2003) and analysis of a number of mutant MtMCM complexes 
depict conformational changes in the MCM double hexamer (Jenkinson et al., 
2009). The reconstruction showed similar features to that shown in the original 
EM images - a two tiered protein with a central channel. Hexameric (Pape et al., 
2003) and heptameric (Yu et al., 2002) complexes have been identified as well as 
helical filaments, although it is not expected to form filaments in vivo (Chen et al., 
2005). When bound to dsDNA MtMCM forms a double hexamer (Costa et al., 
2006). Analysis of MtMCM in the presence of a large segment of dsDNA using 
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 cryo-EM demonstrates a single hexameric ring with DNA bent around the 
outside of the ring (Costa et al., 2008), possibly showing an intermediate step in 
MCM DNA loading (Fig 1.6).  
To date there are no crystal structures of eukaryotic MCM2-7 complexes. 
Inherently MCM2-7 complexes are difficult to crystalise and so homohexameric 
MCM complexes from archaea have been useful models for crystal structure 
analysis. The crystal structure of the N-terminal domain from MtMCM was 
shown to form a double hexamer through the interdigitation of zinc finger motifs 
and hydrogen bonding (Fletcher et al., 2003, Liu et al., 2008). More recently a 
near-full length structure of the SsoMCM and a high-resolution structure of a 
recombinant, redundant and functionally inactive in vitro MCM from 
Methanopyrus kandleri have provided additional structural information that can 
be related to the eukaryotic heterohexameric complex (Bae et al., 2009, Brewster 
et al., 2008). 
A recent crystal structure of N-terminal Pyrococcus furious (Pf) MCM bound to 
ssDNA revealed a MCM single-stranded binding motif (MSSB) which is 
suggested to be important in helicase activation (Froelich et al., 2014). 
Subsequently the same group produced a chimera of N-terminal SsoMCM and 
the ATPase domain of PfMCM (Miller et al., 2014). This chimeric MCM is active 
and the crystal structure has led to a hypothesis for MCM DNA unwinding 
activity. They suggest the h2i clamps down on the leading strand of DNA in 
order to facilitate strand retention and regulate ATP hydrolysis (Miller et al., 
2014). 
1.9 Nuclear matrix 
The term nuclear matrix was first used in 1974 by Berezney and Coffey (1974) to 
refer to the insoluble RNA and protein fraction of the nucleus which remained 
after salt extraction. The nuclear matrix consists of a network of 10 nm filaments 
that can be visualised by EM, which persist when chromatin, soluble proteins 
and lipids are removed (Capco et al., 1982, Wan et al., 1999). This nuclear 
structure has been sub-categorised and is known as the nuclear scaffold, nuclear   
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Figure 1.6. Electron microscopy of MtMCM in different conformational states. A. Repro-
duced from Pape et al., 2003. Electron density of MtMCM without DNA. B. Reproduced 
from Costa et al., 2008. MtMCM bound to long dsDNA. Top shows electron density. Bottom 
shows placement of DNA by fitting in crystallographic structures. Blue – Cdc6, Red – AAA+ 
domain of MtMCM, Green – N-terminal of MtMCM, Orange - roughly 80 base pairs of 
dsDNA. 
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 skeleton or the nuclear matrix dependent on the method used to extract it. 
Although the term the nuclear matrix has become the most widely adopted name 
for the proteins which resist aggressive methods of extraction, it referred 
originally to those proteins resistant to extraction with 2.0 M NaCl (Berezney and 
Coffey, 1974). This method has been criticised because of its potential to cause 
aggregation of proteins and so a new method was developed by Capco et al. 
(1982), which used more physiological buffers with lower salt (0.5 M NaCl) and 
included nucleases (DNase I) to digest chromatin. This was termed the ‘in situ 
nuclear matrix’ as the cytoskeleton is also maintained (for more information see 
appendix A). A role of the nuclear matrix as the site for; transcription (Jackson 
and Cook 1985), DNA repair (Qiao et al., 2001), splicing (Zeitlin et al., 1987), 
chromatin remodelling (Reyes et al., 1997) and DNA replication (Jackson and 
Cook, 1986, Cook, 1999) has been demonstrated.  
Here I will focus on the role of the nuclear matrix in initiation of DNA replication 
(reviewed in Wilson and Coverley, 2013). Chromatin is periodically attached to 
the nuclear matrix, specifying its characteristic loop organisation in interphase 
nuclei. DNA sequences that are associated with the nuclear matrix are known as 
matrix attached regions (MARs) and the size of intervening loops correlates with 
the length of replicons (Buongiorno-Nardelli et al., 1982, Lemaitre et al., 2005). 
Extensive evidence places replication origins, components of the pre-RC and 
machinery that supports cell-cycle regulated initiation (Radichev et al., 2005, 
Buckler-White et al., 1980, Dijkwel et al., 1979, Dijkwel et al., 1991, Razin et al., 
1986, van der Velden et al., 1984, Lagarkova et al., 1998, Berezney and Coffey, 
1975) in proximity to the nuclear matrix within what are referred to as DNA 
replication factories; aggregates of replication proteins and multiple co-regulated 
origins (reviewed in Wilson and Coverley, 2013). 
Experiments show that a number of replication proteins remain in extracted 
nuclei when chromatin is depleted using nucleases (reviewed in Cook, 1991), 
although the relationship of MCM proteins with the nuclear matrix is not 
understood. A number of studies have looked into the association of MCM 
proteins in different cell lines. In human cancer cells (Raji cells), MCM3 was 
solubilised by nuclease and so not nuclear matrix bound (Mendez and Stillman, 
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 2000), which is in agreement with work in another human cancer cell line (HeLa 
cells) showing MCM3, MCM2 and MCM7 to be solubilised by nuclease (Fujita et 
al., 1997, Todorov et al., 1995). Studies in asynchronous fibroblast cells (REF-52 
and NIH3T3 cells) showed MCM2, MCM3, MCM5 and MCM7 were solubilised 
by nuclease (Cook et al., 2002, Cook et al., 2004, Stoeber et al., 1998). However 
other studies of HeLa cells showed MCM7 and MCM3 to be resistant to nuclease 
digestion and so nuclear matrix bound (Fujita et al., 2002, Burkhart et al., 1995). 
Proteomic screens of human and Drosophila cell lines identified MCM2, 3, 4 and 7 
in nuclear matrix preparations (Mitulovic et al., 2004). In addition, MCM2 has 
been shown to interact with the nuclear matrix anchoring protein AKAP95 in 
HeLa cells (Eide et al., 2003). This lack of consensus may be in part because 
interaction is transient, and in asynchronous cells masked by the bulk fraction of 
MCM protein. Evidence also suggests that tumours, transformed cells in culture, 
and stem-like cells appear to have a compromised or immature nuclear matrix 
(Gerner et al., 2002, Varma and Mishra, 2011) raising questions about its role in 
DNA replication.  
1.10 Aims 
The aims of this thesis are to integrate two related strands of research into the 
structure and function of mammalian MCM2-7 complexes, using a combination 
of biochemistry and cell based biology. Specifically I aimed to: 
§ Produce and purify recombinant human MCM (hMCM) in E. coli.  
§ Characterise recombinant hMCM function. 
§ Analyse the configuration and structure of recombinant hMCM 
§ Investigate the location and time of expression of endogenous MCM 
proteins in relation to initiation of DNA replication in mammalian cells.  
§ Examine the relationship of MCM2-7 complex proteins with the nuclear 
matrix. 
§ Use the information and materials acquired to reconstitute mammalian 
MCM2-7 complex assembly and the requirement for properly regulated 
function.  
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 § Unpick the requirements for MCM2-7 phosphorylation by cellular 
kinases. 
This research will expand on our current understanding of the initiation of 
DNA replication and will give insight into how this fundamental process is 
controlled in a mammalian context. The identification of differences between 
cancer cells and ‘normal’ cells has potential to generate information that can 
be used to design novel cancer therapies. 
  
53
  
 
 
 
Chapter 2 
Materials and methods 
 
  
54
 2 Material and methods 
2.1 E. coli cell culture 
2.1.1 Growth media  
E. coli cells were cultured in Luria – Bertani (LB) growth media (10 g/L tryptone, 
5 g/L yeast extract and 171 mM sodium chloride (NaCl, Bertani, 1951) unless 
stated otherwise. For growth on agar plates LB-agar was used (LB plus 15 g/L 
agar). LB and LB-agar were autoclaved immediately after preparation.  
2.1.2 Antibiotics  
Antibiotics were made as 1,000x stocks, filter sterilised and stored at -20°C for up 
to one year. The final concentration of the antibiotics used were: carbenicillin 50 
µg/ml, chloramphenicol 34 µg/ml, kanamycin 30 µg/ml and spectinomycin 50 
µg/ml. 
2.1.3 Preparation of heat shock competent E. coli cells with rubidium 
chloride 
E. coli cells were streaked onto an agar plate (with the appropriate antibiotic if 
required) and grown overnight at 37°C. A single colony was picked into two 3 ml 
Super Optimal Broth (SOB, 171 mM NaCl, 5 g/L yeast extract, 20 g/L tryptone, 
10 mM magnesium chloride (MgCl2) and 10 mM magnesium sulphate (MgSO4)) 
and incubated at 37°C at 225 revolutions per minute (rpm) for five hours. The 
cultures were used to inoculate 100 ml of SOB and incubated at 37°C at 225 rpm 
overnight. 
Cultures were cooled on ice for five minutes and spun at 4,000 x g at 4°C for five 
minutes. The supernatant was discarded and the cells were re-suspended in ice-
cold TFB1 buffer (100 mM rubidium chloride (RbCl), 50 mM manganese chloride 
(MnCl2), 30 mM potassium acetate (KAc), 10 mM calcium chloride (CaCl2), 15% 
v/v glycerol. The pH was adjusted to 5.8 with 1 M acetic acid). Cells were 
incubated on ice for 90 minutes before spinning at 4,000 x g at 4°C for five 
minutes. The supernatant was discarded and the cells were re-suspended in ice-
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 cold TFB2 buffer (10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15% v/v glycerol. 
The pH was adjusted to 6.8 with 1 M potassium hydroxide (KOH)). Cells were 
aliquoted and snap frozen in liquid nitrogen.  
2.1.4 E. coli transformation 
For protein production Rosetta 2 E. coli competent cells (Novagen) were used. 
These contain a chloramphenicol resistant plasmid allowing the expression of 
tRNAs normally rare in E. coli cells.  
The competent cells were thawed on ice and 50 ng of plasmid DNA was added to 
50 µl of competent cells. The cells were incubated on ice for 30 minutes, 
incubated at 42°C for 30 seconds and immediately returned to ice for two 
minutes. 250 µl of 37°C SOB was added to the cells and incubated for one hour at 
37°C at 225 rpm to allow the antibiotic resistance to develop. 125 µl of the culture 
was spread onto an agar plate containing the suitable antibiotic and incubated 
overnight at 37°C.  
2.2 Mammalian cell culture 
2.2.1 Growth media and conditions 
Mammalian cells were grown in Dulbecco’s modified eagle medium (DMEM), 
low glucose (1 g/L), supplemented with GlutaMAX and pyruvate (Gibco). The 
GlutaMAX supplement reduces ammonia build up that can be toxic to cells. It 
also improves cell viability and growth. DMEM was supplemented with 10% v/v 
fetal bovine serum (Biosera) and penicillin/streptomycin/glutamine (10 
units/ml, 10 µg/ml, 2.92 mg/ml, respectively, Gibco). Henceforth this is referred 
to as 3T3 media. 
All cells were grown on Nunclon polystyrene tissue culture dishes (Nunc) at 
37°C in a humidified (with the relative humidity approximately 80%) incubator 
with 5% v/v CO2. S3 HeLa cells were cultured in 2 L roller bottles (Corning) at 
37°C and gassed every 24 hours with 5% v/v CO2 in air through a Maximum 
recovery filtered pipette tip (Axygen). 
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 Cells were passaged by washing once in Dulbecco’s phosphate buffered saline 
without calcium, magnesium or phenol red (dPBS, Gibco), followed by 
incubation with 0.1% w/v trypsin-Ethylenediaminetetraacetic acid (EDTA, 
Gibco) for approximately five minutes in a humidified chamber in 5% v/v CO2 at 
37°C or until the cells had detached from the plate. The trypsin was quenched 
with an equal volume of media.  
All three cell lines used are morphologically distinct, and exhibit different and 
specific responses to synchrony agents that were previously characterised and 
reported (Coverley et al., 2002, Marheineke et al., 2005). Any non-experimental 
deviations from the expected kinetics for passage through the cell cycle triggered 
reversion to a fresh liquid nitrogen stock as a precaution against accumulation of 
genetic drift. 
2.2.2 Cell synchrony 
2.2.2.1 G1 phase synchrony 
Mouse 3T3 cells were grown until confluent. This usually took three to four days. 
Care was made to ensure no cycling cells were present. The media was changed 
and the cells were left for a further four days to make sure cells were in deep 
quiescence. Cells were released into fresh media by passaging as described in 
section 2.2.1 with a split by ¼ (i.e. if the total volume of cells in solution was 4 ml, 
1 ml of culture was used to inoculate a new plate of the same dimensions). When 
releasing cells special attention was made to ascertain each cell was individual 
and not in contact with any others to optimise release from quiescence (Stoeber et 
al., 1998, Coverley et al., 2002). 
2.2.2.2 S phase synchrony 
S3 and flat HeLa cells were synchronised at the G1/S phase boundary by 
culturing in the presence of 2.5 mM thymidine for 24 hours (Krude et al., 1997). 
Cells were washed extensively in warm dPBS, fresh media was added and the 
cells incubated in a humidified chamber (with the relative humidity 
approximately 80%) in 5% v/v CO2 at 37°C for one hour to release into early S 
phase. 
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 2.3 Protein analysis 
2.3.1 SDS PAGE 
2.3.1.1 Preparation and running of gels 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) gels 
were run on either; the Mini-PROTEAN gel system (Bio-Rad), minigel system 
(CBS Scientific) or slab size electrophoresis system (Atto). The resolving gel was 
poured and left to polymerise, unpolymerised acrylamide was washed away 
with dH20 (PURELAB Ultra, 18.2 MΩ-cm conductivity, Elga), the stacking gel 
was poured on top of the resolving gel and a comb inserted. The components of 
the resolving and stacking gels are listed in Table 2.1. Gels were run in 1 x SDS 
running buffer (25 mM Tris, 0.19 M glycine and 3.5 mM SDS) at 80 mA for one to 
six hours. Occasionally SDS PAGE Precast gels (Expedeon) were used according 
to the manufacturers guidelines. Protein standard were run on each gel so that 
the molecular weight of each band could be estimated. For gels that were to be 
Coomassie blue stained (see 2.3.3); 10 µl of Precision Plus Protein Unstained 
standards (Bio-Rad) were loaded onto the gel. For gels that were to be western 
blotted (see 2.3.4), 10 µl of either; PageRuler Plus Prestained Protein Ladder 
(Thermo scientific) or Precision Plus Protein standards (Bio-Rad) were used. 
Table 2.1 Components of SDS PAGE resolving and stacking gel 
Components 8% w/v resolving gel 10% w/v resolving gel 5%  w/v stacking gel 
Acrylamide  
(Proteogel 
mix 37.5:1) 
26.6% v/v 33% v/v 17% v/v 
Tris pH 8.8  37.5% v/v 37.5% v/v - 
Tris pH 6.8 -- - 12.5% v/v 
 
Water 34% v/v 27.8% v/v 67% v/v 
 
10% w/v APS* 0.8% v/v 0.4% v/v 1% v/v 
 
TEMED** 0.13% v/v 0.2% v/v 0.2% v/v 
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 10% w/v 
SDS*** 
1% v/v 1% v/v 2% v/v 
 
*APS – ammonium persulphate (prepared daily) 
**TEMED – N,N,N’,N’-Tetramethylethylenediamine 
***SDS - Sodium dodecyl sulphate  
2.3.1.2 Sample preparation 
4x SDS PAGE loading buffer (240 mM Tris pH 6.8, 8% w/v SDS, 40% v/v 
glycerol, 0.1% w/v bromophenol blue and 6.8% v/v β mecaptoethanol) was 
added to protein samples. Samples were mixed and heated to 100°C for five 
minutes and vortexed before loading on to the gel.  
2.3.2 Native PAGE 
2.3.2.1 Preparation and running of gels 
Mini protean TGX precast gels (Bio-rad) were run in 1x Tris/glycine running 
buffer for Native PAGE (Bio-Rad). Wells were washed thoroughly prior to 
loading with running buffer. NativeMark™ (Life Technologies) protein standard 
were run on each gel so that the molecular weight of each band could be 
estimated. Native gels were soaked in denaturing buffer (2% w/v SDS, 1x Tris 
glycine buffer (Bio-Rad) for 30 minutes prior to transfer to nitrocellulose as 
described in 2.3.4).  
2.3.2.2 Sample preparation 
Native PAGE loading buffer (Bio-Rad) was added to samples at a 1:1 ratio. 
Samples were stored on ice prior to gel loading.  
2.3.3 Coomassie blue staining 
Protein gels were stained to visualise proteins in one of two ways. Firstly by 
staining with Coomassie blue R250 stain (40% v/v methanol, 10% v/v acetic acid 
and 0.1% w/v Coomassie blue R250 (Fisher)) for 10 minutes and destained for 
one to 12 hours using destain (40% v/v methanol, 10% v/v acetic acid). Or 
secondly, using SimplyBlue Safe Stain (Life Technologies) according to the 
manufacturers guidelines. 
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 2.3.4 Western blotting 
2.3.4.1 Transfer 
SDS PAGE gels were transferred to nitrocellulose membrane using an iBlot (Life 
Technologies) using proprietary kits (SDS PAGE gels were transferred using 
program P0 for seven minutes, native PAGE gels was transferred using P8 for 13 
minutes) or to PROTRAN nitrocellulose transfer membrane (Whatman) using a 
semi dry blotter (Sigma Aldrich) by the following method. The gel was soaked 
for 15 minutes in semi dry blotting buffer (297 mM Tris, 10 mM CAPS, 10% v/v 
methanol and 0.02% w/v SDS) and laid on top of four pieces of 3MM 
chromatography paper (Whatman) wetted in semi dry blotting buffer. Another 
four pieces of wet 3MM were laid on top of the gel and all air bubbles were 
removed. The semi dry blotter was run at 0.8 mA per cm2 for two hours. Gels 
were transferred to a PVDF membrane (GE Healthcare) using a Transblot-SD 
semi dry transfer cell (Bio-Rad). The transfer stack was assembled with two 
pieces of 3MM chromatography paper soaked in anode I buffer (0.3 M Tris pH 
10.4 and 10% v/v methanol), one piece of chromatography paper soaked in 
anode II buffer (25 mM Tris pH 10.4, and 10% v/v methanol) followed by the 
PVDF membrane prepared by soaking in 100% v/v methanol for 15 seconds, 
ddH20 water for two minutes and anode II buffer for a minimum of five minutes. 
The gel was added to the stack pre-soaked in cathode buffer (25 mM Tris pH 9.4, 
40 mM glycine and 10% v/v methanol) for at least 15 minutes and three pieces of 
chromatography paper soaked in cathode buffer (any air bubbles were removed). 
The semi dry blotter was run at 1.2 mA per cm2 for one hour.  
2.3.4.2 Antibody detection 
Nitrocellulose membranes were stored at -20°C and processed by putting straight 
into blocking buffer. PVDF membranes were stored at room temperature 21 ± 
2˚C. (RT) and re-wetted by soaking in 100% v/v methanol for two minutes, dH20 
water for five minutes and then blocked. Membranes were blocked for 30 
minutes to one hour in blocking buffer (Tris buffered saline and tween 20 (TBST); 
50 mM Tris pH 7.6, 150 mM NaCl and 0.05% v/v tween and 5% w/v dried milk 
(Marvel, 0% fat)). Membranes were incubated with the primary antibody for two 
hours at RT or overnight at 4°C. See Table 2.2 for primary antibody details and 
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 dilutions. Membranes were washed for 30 minutes in TBST with four to six 
buffer changes (blocking buffer). The membrane was incubated with the 
appropriated secondary antibody (see Table 2.3) in blocking buffer for one hour 
at RT. Membranes were washed for 30 minutes in TBST with four to six buffer 
changes. Proteins were detected using EZ-ECL (Biological Industries) or 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) western 
blotting reagents and exposed to Hyperfilm ECL (GE Healthcare). Film was 
developed using an XO graph compact X9 analyser (Packard) and quantified 
using ImageJ software (1.47v, National Institutes of Health, USA). Relative 
protein concentrations were quantified, corrected for background and 
normalised by dividing by a loading control.  
2.3.5 Immunofluorescence (IF) 
Cells on glass coverslips (MIC3306, 13 mm diameter, No. 1 (0.13 – 0.155mm), 
henceforth referred to as ‘coverslips’) were washed in 0.5% v/v Triton X-100 in 
dPBS. Cells were fixed by incubation in 4% w/v neutral pH paraformaldehyde 
(PFA) for ten minutes, and then washed for five minutes in 0.5% v/v Triton X-
100 in dPBS thrice. The coverslips were blocked for 30 minutes in antibody buffer 
(10 mg/ml nuclease and protease free bovine serum albumin (BSA, Jackson, Cat: 
001-000-162), 0.02% w/v SDS, 0.1% v/v Triton X-100 in PBS). Coverslips were 
incubated at 37°C for two hours with primary antibody diluted in antibody 
buffer (see Table 2.2). Coverslips were then washed for five minutes in antibody 
buffer thrice. The appropriate secondary antibody (see Table 2.3) and Hoechst 
33258 at 1/100,000 in dPBS was incubated with the cells for one hour at 37°C in 
the dark. Coverslips were washed for a final three times in antibody buffer for 
five minutes at RT.  
2.3.5.1 Mounting coverslips  
The coverslips were dipped in water and mounted onto Vectashield (Vector). 
Once dry coverslips were analysed using fluorescent microscope (Axiovert 200M, 
Zeiss). 
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 2.3.5.2 Image analysis  
All microscopy images were captured using a Zeiss Axiovert 200M inverted light 
microscope fitted with an AxioCam HRm digital camera and Openlab software 
(Perkin Elmer) using a 63x or 40x oil immersion objective. Microscope was 
illuminated using a halogen lamp. Zeiss filter sets 2, 10 and 15 were used for 
analysis. Filter set 2 excites at wavelengths 365 - 395 nm, filter set 10  excites at 
wavelengths 450 – 490 nm and filter set 15 excites at 580 – 590 nm.  
All images in a dataset were collected with constant exposure parameters 
(between 100 – 300 ms for Alexa 488 and Alexa 568 and 5 – 20 ms for Hoechst 
33258). To measure intensity the perimeter of the nuclei were measured using the 
polygon tool in ImageJ software (National Institutes of Health, USA). For each 
dataset over 98 images were randomly selected for quantification and corrected 
for background. All quantification was carried out before any manipulation. 
Example images shown were adjusted using Adobe Photoshop CS4 to increase 
image intensity for reproduction. In all cases, control and test samples were 
treated identically.  
Table 2.2 Primary antibody details 
Antibody 
(clone)  
Host/Isotype 
Dilution for 
WB and buffer 
Dilution 
for IF 
Supplier 
(Order No.) 
hMCM2 Rabbit/ 
Polyclonal 
1/10,000 
5% milk*, TBST 
N/A (Ekholm-Reed 
et al., 2004) 
hMCM3  
(3A2) 
Mouse/ 
Monoclonal 
1/1,000 
5% BSA**, TBST 
N/A MBL*** (M038-
3) 
hMCM4  
(C-10) 
Mouse/ 
Monoclonal 
1/400 
5% BSA**, TBST 
N/A SC Biotech**** 
(sc48407) 
hMCM5  
(33) 
Mouse/ 
Monoclonal 
1/2,000 
5% BSA**, TBST 
N/A BD Biosciences 
(611750) 
hMCM6 
(1/MCM6) 
Mouse/ 
Monoclonal 
1/2,000 
5% BSA**, TBST 
N/A BD Biosciences 
(611622) 
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 hMCM7 
(141.2) 
Mouse/ 
Monoclonal 
1/5,000 
5% milk*, TBST 
N/A SC Biotech**** 
(sc9966) 
MCM7 
(EP1974Y) 
Rabbit/ 
Monoclonal 
1/5,000 
5% milk*, TBST 
N/A Abcam  
(ab52489) 
MCM2/BM28 
(46) 
Mouse/ 
Monoclonal 
1/1,000 
5% milk*, TBST 
1/50 BD Biosciences 
(610700) 
MCM3 
[EPR7081] 
Rabbit/ 
Monoclonal 
1/1,000  
5% milk*, TBST 
N/A Abcam 
(ab126723) 
Cyclin A 
(CY-A1) 
Mouse/ 
Monoclonal 
1/1,000 
5% milk*, TBST 
N/A Sigma Aldrich 
(C4710) 
Actin 
(AC40) 
Mouse/ 
Monoclonal 
1/1,000 
5% milk*, TBST 
N/A Sigma Aldrich 
(A4700) 
Lamin B2 
(EPR9700(B)) 
Rabbit/ 
Monoclonal 
1/1,000 
5% milk*, TBST 
1/100 Abcam 
(ab138516) 
Histone H3 
 
Rabbit/ 
Polyclonal 
1/10,000 
5% milk*, TBST 
N/A Abcam 
(ab1791) 
* 5% w/v dried milk (Marvel, 0% fat) 
** 5% w/v Bovine Serum Albumin  
*** Medical and Biological Laboratories 
**** Santa Cruz Biotechnology Inc. 
 
Table 2.3 Secondary antibody details 
Antibody Host 
Dilution for 
WB 
Dilution 
for IF 
Supplier (Order No.) 
Anti-mouse HRP 
(ZyMAX) 
Rabbit 
 
1/20,000 
 
N/A Life Technologies  
(81-672) 
Anti-mouse HRP 
 
Rabbit 1/10,000 
 
N/A Abcam (ab6789) 
Anti-rabbit HRP 
 
Goat 1/10,000 
 
N/A Abcam (ab6721) 
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 Anti-mouse, 
Alexa, 488  
 
Goat N/A 1/2,000 Life Technologies 
(A1101) 
Anti-rabbit, 
Alexa, 568 
 
Goat N/A 1/2,000 Life Technologies 
(A11011) 
 
2.3.6 Determining protein concentration 
To determine protein concentration a Bio-Rad Protein Assay Dye Reagent 
Concentrate kit was used according to manufactures guidelines (Cat: 500-0006). 
2.4 hMCM production and purification  
WT hMCM was encoded by three plasmids, each encoding two of the hMCM 
subunits. ATPase deficient mutant hMCM constructs were produced using site-
directed mutagenesis on each of the hMCM subunits in the above constructs. 
Each hMCM was mutated by modifying the conserved lysine in the Walker A 
motif to a glutamic acid. All constructs were made previously by Richard P. 
Parker-Manuel. WT and mutant hMCM were expressed and purified in the same 
way.  
2.4.1 Expression of hMCM  
The three hMCM constructs were transformed into E. coli Rosetta 2 (DE3, 
Novagen) and grown in LB broth containing carbenicillin, chloramphenicol, 
kanamycin and spectinomycin at 37°C and rotating at 225 rpm. The starter 
culture (5 ml) was grown for eight hours and 750 µl of the starter culture was 
used to inoculate a medium culture (750 ml) and grown overnight. The medium 
culture was used to inoculate a 50 L fermenter. Once the optical density (OD600) 
of the cultures reached 0.4, minus a media only control, the temperature was 
shifted to 18°C in anticipation the OD600 would be 0.6 once the temperature 
reached 18°C. The production of hMCM was induced by the addition of 1 mM 
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 Isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubated at 18°C for a 
further 21 hours until the OD reached approximately 6.0 at 600 nm.  
Cell pellets were harvested by centrifugation at 7,500 x g, for ten minutes at 3˚C 
and re-suspended in buffer 1 (25 mM Tris, 300 mM NaCl, pH 8.0) containing 
protease inhibitors (Pepstatin A 1 µg/µl, Aprotinin 2 µg/µl, Leupeptin 2 µg/µl, 
Bestatin 5 µ M, 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
(AEBSF) 0.1 M and 2 mM β mecaptoethanol). Re-suspended pellets were stored 
at -80˚C.  
2.4.2 hMCM purification 
Re-suspended cell pellets were thawed and 5 mM MgCl2 and 5 mg/ml DNase I 
was added. Cells were lysed using an automated cell disrupter (Constant cell 
disruption systems, UK) at 21 Kilopound per square inch (Kpsi). Cells were 
clarified by centrifugation at 10,000 x g for 40 minutes. His-Select Cobalt Affinity 
gel (Sigma) was prepared by washing thrice in 25 ml per 1 ml bead bed of buffer 
1. Washing was carried out by re-suspending and centrifugation at 3220 x g for 
five minutes. The clarified lysate was mixed with 1 ml of beads per 25 ml lysate. 
10 ml of buffer 1 was added and the beads were mixed gently at 4°C for 30 
minutes. The beads were collected by centrifugation at 3220 x g for 10 minutes 
(supernatant = flow through). The beads were packed into a XK16/20 column, 
washed with five column volumes (CV) of buffer 2 (as buffer 1 plus 1 mM 
imidazole) at 2 ml/min. The column was washed with 5 CV of buffer 3 (as buffer 
1 plus 7.5 mM imidazole and 5% v/v glycerol) at 1 ml/min. To elute the proteins 
bound to the cobalt beads buffer 4 (buffer 1 plus 250 mM imidazole and 5% v/v 
glycerol) was added and 1 ml elution fractions were collected. The peak elution 
fractions were pooled and applied to a HiLoad 26/600 Superdex 200 gel filtration 
column (GE Healthcare Life Sciences). The column was initially equilibrated with 
buffer 5 (25 mM Tris-HCl, 150 mM NaCl, 5% v/v glycerol, pH 8.0, 1 mM 
dithiothreitol (DTT) and 0.1 mM AEBSF). The proteins were collected in 4 ml 
fractions. Eluted fractions of the expected hMCM molecular weight were pooled 
and loaded onto a 1 ml MonoQ anion exchange column (GE Healthcare Life 
Sciences). The column was initially equilibrated in buffer 5 and 0.5 ml fractions 
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 were eluted over a 10 CV linear gradient (buffer 5 with 1 M NaCl). Fractions 
containing hMCM were pooled, dialysed against buffer 6 (25 mM HEPES, pH 
8.0, 200 mM sodium glutamate, 1 mM DTT and 0.1 mM AEBSF), flash frozen 
using liquid nitrogen in small aliquots and stored at -80°C. 
2.5 ATP hydrolysis assay 
Reaction mixes contained PDB buffer (30 mM K2HPO4/KH2PO4 buffer, pH 8.5, 1 
mM DTT, 100 µg/ml BSA (New England Biolabs (NEB)), 2% v/v glycerol, 10 
mM magnesium acetate (MgAc), 1.5 nmol cold adenosine triphosphate (ATP, GE 
Healthcare), 3.08 pmol of [α-32P] ATP (800 Ci/mmol, (ICN)), DNA (double 
stranded circular (pUC119, 3,162 base pair (bp)), single stranded circular (M13, 
6,407 bases) or duplex (Appendix B, Fig. B1) as stated in text and 176 nM of 
protein (unless stated otherwise) were assembled on ice. Reactions were 
incubated at 37°C for 45 minutes and were stopped by the addition of EDTA to 
20 mM. ATP hydrolysis was visualised by using thin-layer chromatography 
(TLC). Reactions were spotted onto TLC polyethylenimine (PEI) Cellulose F 
plates (Merck). Plates were developed in 1 M formic acid and 0.5 M lithium 
chloride (LiCl), dried, and exposed to a phosphor imaging plate. Signals were 
detected using a personal molecular imager (PMI, Bio-Rad) and quantified by 
using Quantity One software (Bio-Rad). To determine ATP concentration, data 
were calibrated by using a dilution series of the ATP stock performed in parallel 
with the experiment. The standard concentration of cold ATP in the reaction was 
75 pmol/µl and the concentration of hot ATP was determined using the 
following equation (specific activity of  [α-32P] ATP = 30 KBq/pmol). 
N = N0 e –(0.693t/14.3) 
N0 = initial activity (KBq/µl), t = decay time in days, N = final activity (KBq/µl), 
14.3 days is 32P half-life.  
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 2.6 DNA helicase assay 
2.6.1 Substrate preparation 
2.6.1.1 Oligonucleotide labelling 
Oligonucleotide (oligo) HS2 (Table 2.4) was radiolabelled using γ[32P]ATP 3,000 
Ci/mmol (Perkin Elmer). Labeling reaction (5 µM HS2 oligo, 1 unit T4 
polynucleotide kinase (PNK, Promega), 1x PNK buffer (Promega) and 3.6 µl 
γ[32P]ATP) was incubated at 37°C for one hour. The PNK was denatured by 
heating to 90°C for ten minutes. The labelled substrate was stored at 4°C. 0.5 µl of 
the annealed substrate was mixed with 24.5 µl of T0.1E buffer (10 mM Tris pH 
8.0, 25 mM NaCl and 0.1 mM EDTA) and used as a 100 nM control sample for 
quantification. 
2.6.1.2 Oligonucleotide annealing 
Radiolabelled labelled HS2 was annealed to oligo HS1 (Table 2.4) to produce a 
forked DNA substrate with a 26 bp double-stranded region. The 40 µl annealing 
reaction (5 µM HS2, 5 µM HS1, 200 mM HEPES pH7.5, 250 mM NaCl and 5 mM 
EDTA) was heated to 95°C and cooled at 0.02°C per second to 20°C. Annealed 
oligos were stored at -20˚C.  
Table 2.4 Oligonucleotide sequences 
Oligo name Oligo sequence (5’ – 3’) 
HS1 GGGACGCGTCGGCCTGGCACGTCGGCCGCTGCGGCCAGG
CACCCGATGGCGTTTGTTTGTTTGTTTGTTTGTTT 
HS2 TTTGTTTGTTTGTTTGTTTGTTTGTTTGTTTGCCGACGTGCCA
GGCCGACGCGTCCC 
HF150 CCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCC
TTTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTT 
HR80 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAAAGGGGG
ATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGG 
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 2.6.1.3 Substrate purification  
6x loading dye (50% v/v glycerol, 0.1% w/v xylene cyanol FF and 0.1% w/v 
bromophenol blue) was added to the substrate. The substrate was run on a 12% 
w/v acrylamide gel (1x Tris/borate/EDTA (TBE, 0.09 M Tris, 0.09 M boric acid 
and 0.08 M EDTA), 12% v/v acrylamide:bis-acrylamide from a 19:1 20% w/v 
stock, 0.07% w/v APS, 0.1% v/v TEMED) for one hour at 80 V in 1x TBE. The gel 
was exposed to Hyperfilm ECL (GE Healthcare) for five minutes and developed 
using an XO graph compact X9 analyser (Packard). The band containing the 
annealed substrate was excised and placed in a clean, pre-weighed micro 
centrifuge tube. The substrate was eluted from the gel by adding 3 µl of PAGE 
elution buffer (0.5 M sodium acetate (NaAc), 10 mM MgAc, 1 mM EDTA and 
0.1% w/v SDS) per 1 µg of gel slice.  
The slice was incubated in PAGE elution buffer for two hours at 4°C. The 
supernatant was removed and the same volume of PAGE elution buffer was 
added to the gel slice which was incubated overnight at 4°C rotating. The gel and 
buffer was spun at 16,000 x g for two minutes and the supernatant was removed 
and added to that previously collected. Glycogen (20 µg) was added to the eluted 
substrate. The DNA was ethanol precipitated by; adding 3x sample volume of 
100% v/v ethanol and mixing. The sample was centrifuged at 16,000 x g for 20 
minutes at RT. The supernatant was removed and discarded. 750 µl of 80% v/v 
ethanol was added and centrifuged at 16,000 x g for five minutes. The 
supernatant was discarded, 500 µl of 100% v/v ethanol was added and 
centrifuged at 16,000 x g for five minutes. The supernatant was discarded and the 
pellet was dried in a DNA Speed Vac (Savant) for 20 minutes. The DNA pellet 
was re-suspended in 50 µl of buffer (10 mM Tris pH 8.0, 10 mM NaCl, 0.1 mM 
EDTA). 
2.6.1.4 Substrate quantification 
The labelled substrate was quantified by spotting onto DE81 paper (Whatman) 
using the 100 nM control substrate (see 2.6.1.1) as a control. The DE81 paper was 
washed for five minutes in 0.5 M K2HPO4/KH2PO4 buffer pH 7.0 thrice. The 
paper was subsequently washed for ten minutes each in 70% v/v ethanol and 
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 100% v/v ethanol. The paper was air dried and exposed to a phosphor imaging 
plate. The plate was developed using a PMI system (Bio-Rad) and quantified 
using Quantity One software (Bio-Rad). The concentration of the substrate was 
determined using the following equation.  
       average signal substrate        x 100 nM = [substrate] nM 
             average signal 100 nM sample 
 
2.6.2 Assay conditions 
Helicase reactions (4 nM forked substrate, hMCM as indicated, 30 mM 
K2HPO4/KH2PO4 buffer, pH 8.5, 300 mM potassium glutamate (KGlut), 1 mM 
DTT, 100 µg/ml BSA (NEB), 2% v/v glycerol, 10 mM MgAc, 4 mM ATP) were 
incubated (one hour, 37°C) and stopped by the addition of ¼ volume of 5x stop 
buffer (80 mM EDTA, 0.8% w/v SDS, 40% v/v glycerol, 0.04% w/v xylene 
cyanol, 0.04% w/v bromophenol blue). Reaction products were separated on 11% 
w/v polyacrylamide TBE gel (two hours, at a constant voltage of 80 V). Gels 
were fixed in 7% v/v acetic acid for five minutes and dried for 20 minutes at 
80°C using a gel dryer (Bio-Rad). The dried gel was exposed to a phosphor 
screen overnight. The phosphor screen was imaged and quantified using a PMI 
system and Quantity One software (Bio-Rad).  
2.7 Electron microscopy (EM) 
2.7.1 Binding of duplex DNA to hMCM for EM 
hMCM was bound to duplex DNA. 5x No salt annealing buffer (200 mM HEPES 
pH 8.0, 5 mM EDTA) was added to 1 µM HF150 oligo (150 bp) and 1 µM HR80 
oligo (80 bp, see Table 2.4). The DNA was annealed using a Biometra (T-
personal) by placing it under the following heat cycle; 95°C for three minutes, 
cool at 0.02°C per second until reached 23°C. 8 µg of hMCM was incubated with 
60 nM duplex DNA in annealing buffer (50 mM HEPES pH 7.5, 2 mM DTT, 50 
µg/ml BSA (NEB), 10 mM MgAc and 4 mM ATP) for one hour at 37°C to bind 
the hMCM and duplex DNA. The samples were snap frozen in liquid nitrogen. 
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 2.7.2 Negative stain EM 
Electron microscopy of hMCM was carried out by Yuriy Chaban at Birkbeck 
Collage London with the following method. hMCM samples were applied to 
continuous carbon grids and stained with freshly made methylamine tungstate, 
pH 7. Data were collected on a FEI T12 microscope at magnification 67,000 and 
accelerating voltage 120 kV. Data were recorded on to Kodak SO-163 films and 
digitised using a Zeiss Photoscan densitometer (14 µm scanning step, 
corresponding to 2.5 Å/pixel) before analysis. 
2.7.3 Image processing 
Particle picking was carried out automatically using the program ‘Boxer’ (EMAN 
suite, Tang et al., 2007). Analysis of the CTF and correction was completed using 
the program ‘CTFIT’ (EMAN suite, Tang et al., 2007). The following image 
analysis was performed using IMAGIC-5 (van Heel et al., 1996): Images were 
normalised to the same standard deviation and band-pass filtered; the low-
resolution cut-off was ~100 Å to remove uneven background in particle images 
and the high-resolution cut-off was ~7 Å. Then images were subjected to an 
alignment procedure followed by statistical analysis. Alignment and 
classification of images was performed as previously described (van Heel et al., 
1996) and yielded classes representing characteristic views of the molecule. 
Primary structural analysis for hMCM and hMCM plus DNA complexes were 
performed using an ab initio approach where the orientations of the best 10-15 
image classes were determined by angular reconstitution using C1 start up. 3D 
maps were calculated using the exact-filter back projection algorithm (van Heel 
et al., 1996). Structural analysis was performed using several starting models 
with several different sets of image classes for ab initio reconstructions. The first 
reconstructions were used for the following rounds of alignment and 
classification of images. The structures of the complexes were refined by an 
iterative procedure with the number of classes gradually increased. The final 
reconstruction for hMCM alone was calculated from the best 100 classes 
containing ~11 images each. For hMCM plus DNA, the final reconstruction was 
calculated from the best 155 classes containing ~10 images each. Resolution of the 
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 map was assessed using the 0.5 threshold of Fourier Shell Correlation (van Heel 
et al., 2000), which corresponds to 23 Å. 
2.7.4 Domain fitting 
Domain fitting into the 3D map of hMCM and hMCM plus DNA complexes was 
performed manually with Chimera (Goddard et al., 2007). Illustrations were 
generated using Chimera. Surface representations (unless stated otherwise) are 
displayed at a threshold level of 1σ (standard deviation of densities within EM 
maps) that corresponds to ~100% of the expected mass at the specific protein 
density of 0.84 kDa/Å3.  
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 2.8 Mammalian cell analysis 
2.8.1 Assay for DNA synthesis 
The percentage of cells in S phase was determined using (5-ethynyl-2-
deoxyuridine) Edu. Edu is a nucleoside analogue and is incorporated into DNA 
during DNA synthesis. The Click-iT Edu Cell Proliferation Assay kit (Life 
Technologies, Cat: C10337) was used. Cycling cells grown on glass coverslips 
were incubated with 0.01 mM Edu in media (see 2.2.1) at 37°C, 5% v/v CO2 for 30 
minutes. Coverslips were fixed in 4% w/v PFA for 15 minutes, then stored at -
20°C for future processing or processed immediately. Coverslips were washed 
twice in 3% w/v BSA (Jackson, Cat: 001-000-162) in dPBS. The cells were made 
permeable by incubating the coverslips in 0.5% v/v Triton X-100 in dPBS and 
then washed twice in 3% w/v BSA in dPBS. Edu is detected by covering the 
coverslip in 20 µl of Click iT cocktail (1x Click-iT reaction buffer, 4 mM aqueous 
copper sulphate (CuSO4), 0.24% v/v Alexa Flour 488 azide, 1x Click-iT reaction 
buffer additive) for 30 minutes in the dark at RT. Coverslips were subsequently 
washed in 3% w/v BSA in dPBS and once in dPBS. The DNA was detected by a 
30 minute incubation in Hoechst 33258 (1/10,000 in dPBS) at 37°C in the dark. 
Coverslips were washed twice in dPBS before mounting (as described in 2.3.5.1). 
2.8.2 Protein extraction for western blot 
Cells were grown as described in 2.2. Samples were processed to reveal i.) total 
protein, ii.) detergent resistant pellet (insoluble proteins and those attached to 
insoluble structures), iii.) detergent soluble proteins, iv.) 0.5 M NaCl soluble 
proteins, v.) DNase I resistant proteins (bound to the nuclear matrix), vi.) DNase 
I sensitive proteins (chromatin bound proteins), vii.) high salt resistant proteins 
(Mock sample which contains protein tightly bound to chromatin or the nuclear 
matrix) and viii.) control sample to show proteins released during 37°C 
incubation period. This method is summarised in figure 2.1. A protocol for this 
method was accepted for publication during the course of this PhD (Wilson et al., 
2014, Appendix A).   
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wash cells 1x in dPBS and 2x in CSK
CSK 0.5 M NaCl
DNase buffer wash
DNase I or mock incubation
CSK 0.5 M NaCl
ii. Detergent insoluble proteins
(P)
iii. Detergent soluble proteins 
(SN)
iv. High salt wash
(SN, weakly chromatin bound)
i. Total protein
3T3 cells on plates
Centrifuge
Centrifuge
v. DNase I resistant
(P, nuclear matrix) 
vii. Mock DNase I resistant
(P, chromatin or nuclear matrix)
vi. DNase I soluble 
(SN, tightly chromatin bound)
viii. Mock soluble
(SN, proteins released during incubation)
Centrifuge
CSK 0.1% Tx100
scrape cells into microcentrifuge tubes
Figure 2.1. Flow diagram to show nuclear matrix protein extraction for analysis by 
SDS-PAGE and western blot. dPBS (Dulbecco’s phosphate buffered saline without 
calcium, magnesium or phenol red), CSK (cytoskeletal buffer ), Tx100 (triton x-100, P 
(pellet), SN (supernatant). 
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 Tissue culture plates were washed once in dPBS and twice in cytoskeletal buffer 
(CSK, 10 mM Pipes pH 6.8, 300 mM sucrose, 100 mM NaCl, 1 mM MgCl2, 1 mM 
ethylene glycol tetraacetic acid (EGTA), 1 mM DTT and protease inhibitors 
(cOmplete®, EDTA-free; Roche)). The plates were tilted on a 45° angle for two 
minutes and excess buffer was removed before harvesting the cells by scraping. 
The volume of cells was measured and put into a clean micro centrifuge tube. 
Final concentrations of 2 mM phenylmethanesulfonylfluoride (PMSF) and 0.1% 
v/v Triton X-100 were added to the cells.  
The volume of cells was split between four micro centrifuge tubes (1x vol) and 
one tube (i.) was prepared for SDS PAGE as described in section 2.3.1.2. The 
remaining three tubes were incubated on ice for two minutes and spun at 6,800 x 
g for two minutes at 4°C. The supernatant from ii. was transferred to a clean 
micro centrifuge tube labelled iii. (detergent soluble proteins) and the pellet ii. 
(insoluble fraction) was re-suspended in 1x volume CSK buffer plus 0.1% v/v 
Triton X-100. ii. and iii were prepared for SDS PAGE as described in section 
2.3.1.2. The supernatant from the remaining two tubes was discarded and the 
pellet washed (by re-suspending and centrifugation at 6,800 x g for three minutes 
at 4°C) in 1x volume CSK plus 0.1% v/v Triton X-100 and 0.5 M NaCl. The 
supernatant from one tube was transferred to a clean micro centrifuge tube iv. 
(high salt wash) and prepared for SDS PAGE as described in section 2.3.1.2. The 
supernatant from the remaining tube was discarded and both pellets re-
suspended in 100 µl DNase I incubation buffer (400 mM Tris-HCl, 100 mM NaCl, 
60 mM MgCl2, 10 mM CaCl2 at pH 7.9). Samples were centrifuged at 9,500 x g for 
three minutes at 4°C and the supernatant was discarded. Pellets were re-
suspended in 1x volume DNase I incubation buffer. 1/30th of volume DNase I, 
RNase free (Roche) was added to v. Both samples were incubated at 37°C for one 
hour flicking every ten minutes. 1/10th of volume 5 M NaCl was added to the 
samples and incubated at 37°C for a further five minutes. Samples were 
centrifuged at 9,500 x g for five minutes. The supernatant was transferred to 
clean micro centrifuge tubes. Pellets were re-suspended in 1x volume DNase I 
incubation buffer. Remaining samples were prepared for SDS PAGE as described 
in section 2.3.1.2. Samples plus DNase I give v. DNase pellet (nuclear matrix 
bound proteins) and vi. DNase supernatant (chromatin bound proteins). Samples 
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 minus DNase I give vii. Mock pellet (chromatin and nuclear matrix bound 
proteins) and viii. Mock supernatant (proteins released during incubation 
period).  
Samples were analysed by SDS PAGE and western blotting as described in 2.3.1 
and 2.3.4. 
2.8.3 Protein extraction for immunofluorescence 
Throughout the procedure coverslips are processed with the cells on the top 
surface. Coverslips were processed to reveal i. total protein, ii. detergent resistant 
proteins, iii. high salt and DNase I resistant proteins (nuclear matrix bound 
proteins) and iv. high salt resistant proteins (chromatin or nuclear matrix bound 
proteins). This method is summarised in figure 2.2. A protocol for this method 
was accepted for publication during the course of this PhD (Wilson et al. (in 
press), Appendix A).  
Cells grown on coverslips were removed from media and washed in dPBS in a 24 
well plate. i. was moved to 4% w/v PFA to fix the cells for ten minutes at RT then 
dPBS at 4°C. Remaining coverslips were moved into CSK plus 0.1% v/v Triton 
X-100 for one minute at RT. ii. was moved to dPBS and processed as i. above. The 
remaining coverslips were moved to CSK plus 0.1% v/v Triton X-100 and 0.5 M 
NaCl for one minute at RT. Coverslips were washed twice in DNase I incubation 
buffer by incubation for one minute at RT. Coverslips were incubated at 37°C for 
one hour, iii. in 20 µl of DNase I incubation buffer plus 1/10th volume DNase I, 
RNase free (Roche), iv. in 20 µl of DNase I incubation buffer. Coverslips were 
washed in CSK plus 0.1% v/v Triton X-100 and 0.5 M NaCl for one minute at RT, 
then moved to dPBS and processed as i. above. 
Following extraction coverslips were analysed straightaway by IF as described in 
2.3.5.  
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Figure 2.2. Flow diagram to show nuclear matrix protein extraction for analysis by 
immunofluorescence. dPBS (Dulbecco’s phosphate buffered saline without calcium, 
magnesium or phenol red), PFA (paraformaldehyde), CSK (cytoskeletal buffer ), Tx100 
(triton x-100, P (pellet), SN (supernatant).  
wash cells 1x in dPBS
i. Total protein
3T3 cells on glass coverslips
4% PFA
ii. Detergent insoluble proteins
CSK 0.1% Tx100
dPBS
4% PFA
CSK 0.5 M NaCl
DNase buffer wash x 2
DNase I or mock incubation
CSK 0.5 M NaCl
iii. DNase I and high salt resistant
(nuclear matrix)
vi. High salt resistant proteins
(chromatin or nuclear matrix bound) 
dPBS
4% PFA
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 2.8.3.1 Cross-linking  
Where stated cells were treated prior to extraction with a cell-permeable 
reducing cross-linker dithiobis succinimidyl propionate (DTSP) which binds 
proteins to proteins (Baumert and Fasold, 1989). DTSP is a reversible cross linker 
that reacts specifically with amine functional groups via N-hydroxysuccinimide 
(NHS) esters in DTSP. Cells growing on 15 cm dishes were washed three times 
with dPBS at RT then incubated 15 ml cross-link buffer (dPBS, 1 mM MgCl2, 
0.01% v/v Triton X-100) with DTSP (Sigma) at 200 µg/ml, on a rotary shaker for 
10 minutes at RT (Ainscough et al., 2007). Reactions were quenched with 15 ml 10 
mM Tris-HCl pH 7.6, 1 mM EDTA. 
2.9 Cell free system 
2.9.1 Harvesting of nuclei and cytoplasmic extracts 
Cells were synchronised as described in 2.2.2. Nuclei and cell extracts were 
prepared at precise time points after release from quiescence in order to harvest 
cells in a particular phase of the cell cycle. For 3T3 cells, mid-G1 phase nuclei and 
cytoplasmic extracts were prepared 15 hours after release and late-G1 phase 
nuclei and cytoplasmic extracts were prepared 17 hours after release. HeLa cells 
were harvested one hour following synchrony at the G1/S phase boundary (see 
2.2.2.2). 
Tissue culture dishes were washed once in ice-cold dPBS and twice in ice-cold 
hypotonic buffer (20 mM K–HEPES pH 7.8, 5 mM KAc, 0.5 mM MgCl2, 1 mM 
DTT). At 4°C dishes were incubated in hypotonic buffer plus protease inhibitors 
(cOmplete®, EDTA-free; Roche) at half the recommended concentration for ten 
minutes. The hypotonic buffer was removed and the plates were tilted at a 45° 
angle for ten minutes at 4°C. Excess buffer was discarded before scraping the 
cells from the plates into a 1 ml Dounce homogeniser (Wheaton). The cells were 
gently homogenised to release the nuclei but keep the nuclear membrane intact. 
Sufficient homogenisation was verified by viewing a small sample 
microscopically. Approximately ten strokes for 3T3 cells or 20 strokes for HeLa 
cells were required for adequate homogenisation. The cell mixture was 
centrifuged at 980 x g at 4°C for two minutes. The pellet (nuclei) was re-
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 suspended in an equal volume of hypertonic buffer plus protease inhibitors (as 
above) and frozen as 10 µl beads in liquid nitrogen. The nuclei concentration was 
approximately 2.5 x 104 per µl. The supernatant was removed and re-centrifuged 
for 20 minutes at 16,000 x g. This high-speed centrifugation separated the fraction 
into three parts: the top lipid layer, the middle cytoplasmic extract and the pellet. 
The middle layer was isolated and frozen as 20 µl beads in liquid nitrogen 
(Coverley et al., 2000, Krude et al., 1997). 
2.9.2 DNA initiation assays 
DNA initiation assays were adapted from the following: Coverley et al. (2005), 
Krude et al. (1997), Copeland et al. (2010), Coverley et al. (2002). Typically 
reactions contained 10 µl of cytosolic extract supplemented with the following in 
the proceeding order; 1:10 PreMix (400 mM HEPES-KCl pH 7.8, 70 mM MgCl2, 30 
mM ATP (Sigma), 1 mM each of GTP, CTP, UTP (all Sigma), 1 mM each of dATP, 
dGTP, and dCTP (all Sigma), 0.5 mM DTT and 400 mM phosphocreatine; PreMix 
was made in bulk and stored in small aliquots at -80°C), 1:75 0.1 M MgCl2 and 
1:50 creatine phosphate kinase (CPK; Calbiochem, stored in aliquots at -20°C and 
made fresh before use by diluting 0.1 g/ml in CPK buffer; 50% v/v glycerol, 100 
mM HEPES-KCl pH 7.8, 1 nM DTT). For experiments to be analysed at the next 
step by fluorescence microscopy 1:100 1 mM biotin-16-dUTP (Roche) was added. 
The final concentration of the components in a DNA initiation assay were: 40 
mM HEPES-KCl pH 7.8, 7 mM MgCl2, 3 mM ATP, 0.1 mM each of GTP, CTP, 
UTP, 0.1 mM each of dATP, dGTP, and dCTP, 0.05 mM DTT, 40 mM 
phosphocreatine, 2 mg/ml creatine phosphokinase and 10 µM biotin-16-dUTP 
when required. Recombinant proteins were added at this point and mixed 
thoroughly (please see results for details). 2 µl nuclei were added last and mixed 
by careful pipetting. The nuclei and supplemented extracts were incubated 
together for 30 minutes at 36.5°C (Coverley et al., 2005, Stoeber et al., 1998, Krude 
et al., 1997, Coverley et al., 2000, Coverley et al., 2002). 
2.9.2.1 Two-step assays 
To analyse the capability of nuclei to initiate DNA synthesis, DNA initiation 
assays (see 2.9.2) were centrifuged at 3,300 x g for one minute. Between 10 and 12 
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 µl of the supernatant was removed and prepared for SDS PAGE as described in 
2.3.1.2. The nuclei were resuspended in 20 µl of S phase extract supplemented 
with 1:10 PreMix, 1:75 MgCl2, 1:50 CPK and 1:100 biotin-16-dUTP as described in 
2.9.2. Reactions were incubated for 30 or 60 minutes at 37°C and prepared for 
microscopic analysis (2.9.2.2). 
2.9.2.2 Analysis by fluorescence  
To visualise DNA synthesis, cell free reactions were quenched by addition of 200 
µl 0.2% v/v Triton X-100 in dPBS and 200 µl 8% w/v PFA and incubated at RT 
for 20 minutes. Poly-lysine coated coverslips were prepared by dipping clean, 
glass coverslips in 2 mg/ml poly-L-lysine hydrobromide (4,000 – 15, 000 Da, 
Sigma) and leaving to dry overnight. The polylysine-coated coverslips were 
placed at the bottom of a tube, with a diameter similar to the size of the cover 
slip, and 0.5 ml 20% w/v sucrose was placed on top of the coverslip. The DNA 
initiation reaction was loaded on top of the sucrose. The nuclei were bound to 
polylysine-coated coverslips by centrifugation at 500 x g for seven minutes. The 
sucrose solution was discarded before removing the coverslip from the tube. 
Coverslips were washed in 0.5% v/v Triton X-100 in dPBS for five minutes twice. 
Incorporated biotinylated-nucleotides were detected with streptavidin–FITC 
(Trevigen) diluted 1/400 in dPBS and DNA was stained with Hoechst 33258 
(1/100,000) in dPBS. These dyes were incubated with the coverslips in the dark 
for one hour at 37°C. The amount of light available to the coverslips was 
minimised. The coverslips were washed for five minutes in 0.5% v/v Triton X-
100 in dPBS thrice. Coverslips were mounted and analysied as described in 
2.3.5.1. 
2.9.2.3 Analysis by western blotting 
For analysis of nuclei and soluble fraction by SDS PAGE and western blotting 10 
µl of ice cold 0.2% v/v Triton X-100 in dPBS was added to DNA initiation assays 
(see 2.9.2). Reactions were mixed and spun at 3,300 x g for one minute. The 
supernatant was isolated and prepared for SDS PAGE and western blotting (see 
2.3.1 and 2.3.4). The pellet was re suspended in 20 µl of 0.2% v/v Triton X-100 in 
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 dPBS and prepared for SDS PAGE and western blotting as described in 2.3.1 and 
2.3.4. 
2.9.3 in vitro phosphorylation assays 
To examine the capability of recombinant kinases to phosphorylate recombinant 
hMCM reactions were carried out in the presence of buffer, an ATP regenerating 
system and recombinant proteins only. Reactions contained 10 µl hMCM dilution 
buffer (25 mM HEPES, pH 8.0, 200 mM sodium glutamate) supplemented with 
1:10 PreMix (400 mM HEPES-KCl pH 7.8, 70 mM MgCl2, 30 mM ATP (Sigma), 1 
mM each of GTP, CTP, UTP (all Sigma), 1 mM each of dATP, dGTP, and dCTP 
(all Sigma), 5 mM DTT and 400 mM phosphocreatine), 1:75 0.1 M MgCl2, 1:50 
CPK (0.1 g/ml in CPK buffer; 50% v/v glycerol, 100 mM HEPES-KCl pH 7.8, 1 
nM DTT). Recombinant hMCM (88 nM), cyclin E/CDK2 (6.8 nM), cyclin 
A/CDK2 (1.72 µM) and/or DDK (71 nM or 35.5 nM) were added as described in 
the results. Reactions were mixed thoroughly before incubation at 37°C for 30 
minutes. Reactions were prepared for SDS PAGE and western blotting as 
described in 2.3.1 and 2.3.4. 
2.9.3.1 Phosphatase assays 
Lambda Protein Phosphatase (P0753S, NEB) was used according to the 
manufacturers guidelines. 
2.9.3.2 Inhibitors 
Stock solutions of 20 mM, PHA-767491 (DDK inhibitor, Sigma) and Roscovitine 
(CDK inhibitor, Sigma) were aliquoted and stored at -80°C. Inhibitors were 
added to reactions at concentrations indicated in the text, mixed thoroughly and 
incubated on ice for two minutes prior to kinase addition.  
2.10 Statistical analysis 
All statistical analyses were performed using students T-test in Microsoft Excel 
(version 14.3.8). Statistical significance is indicated by stars. Exact values are 
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 shown in the figure legend. Error bars are standard error of the mean (SEM) or 
standard deviation (SD) as indicated. 
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 3 Production and purification of recombinant 
hMCM 
The following work has been prepared for publication as is shown in paper 
format in Appendix C.  
3.1 Introduction 
Historically, isolation of intact, functional MCM2-7 heterohexamers has proved 
challenging. The first functional MCM2-7 complex was purified from Xenopus 
egg extracts using a “replication licensing factor” (RLF) assay (Chong et al., 
1995). The biochemical characterisation of the eukaryotic MCM2-7 complex is 
less than complete, although recently significant progress has been made in the 
purification of functional recombinant MCM2-7 complexes from S. cerevisiae 
(Bochman and Schwacha, 2008, Bochman and Schwacha, 2007, Schwacha and 
Bell, 2001). A S. cerevisiae MCM2-7 complex expressed in insect cells has been 
purified and demonstrated to possess helicase activity in vitro (Bochman and 
Schwacha, 2008). Helicase activity of S. cerevisiae MCM2-7 is boosted by the 
addition of potassium glutamate and is inhibited by the addition of potassium 
chloride (Bochman and Schwacha, 2008), suggesting for helicase activity MCM2-
7 requires specific salt conditions. In metazoan systems, in addition to the 
Xenopus system, a “CMG” (Cdc45-MCM2-7-GINS) complex has been isolated 
from Drosophila egg extracts that displays robust DNA helicase activity (Moyer et 
al., 2006, Ilves et al., 2010). To date helicase activity involving human MCM 
proteins has been limited to that described for a sub-complex (probably a dimer 
of trimers) consisting of human MCM4, 6 and 7 (Ishimi, 1997, You et al., 2003). 
This chapter describes the production of recombinant human MCM (hMCM) that 
displays ATP hydrolysis activity and is capable of unwinding duplex DNA. 
Using single particle asymmetric electron microscopy reconstruction, we 
demonstrate that hMCM forms a hexamer that undergoes a conformational 
change when bound to a forked DNA substrate. Recombinant hMCM provides 
an important tool for the biochemical reconstitution of the putative human 
replicative helicase. 
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 3.2 Aims 
§ To produce and purify recombinant hMCM. 
§ To analyse the activity of hMCM in vitro. 
§ To determine the asymmetric three dimensional (3D) structure of hMCM. 
3.3 Experimental design 
In vitro, MCM2-7 is targeted by CDKs and DDKs that phosphorylate MCM 
subunits to control loading and activation of the MCM2-7 complex (see Chapter 1 
for details). If grown in eukaryotic systems there is a high chance hMCM would 
be phosphorylated by cellular kinases that could potentially inhibit hMCM 
activity. In order to understand the role of post-translational modifications in the 
functional loading of hMCM it is important to analyse naïve hMCM (i.e. without 
any post-translational modifications). Subsequently a method for production of 
naïve, recombinant hMCM in E. coli was devised. 
3.4 Results and discussion 
3.4.1 Production and Purification of Recombinant hMCM 
Dr Richard P. Parker-Manuel, a previous member of the Chong lab, devised a 
protocol to produce recombinant hMCM in E. coli (Hesketh et al., under review). 
Three constructs were designed each encoding two hMCM proteins. hMCM5, 6 
and 7 have an N-terminal His-tag to allow purification and hMCM7 also has two 
antibody tags, S tag and Trx tag, to aid future analysis (Fig. 3.1A). A schematic of 
the expected hMCM conformation is depicted in figure 3.1B. The three constructs 
encoding hMCM were co-expressed in a single E. coli cell to increase solubility of 
the complex. hMCM was grown from a single colony to a 50 L culture as shown 
in the flow diagram in figure 3.2A (for details see Chapter 2.4). The 50 L culture 
was grown in a fermenter to allow the pH, dissolved oxygen and temperature to 
be monitored. The growth of the E. coli culture was monitored by measuring the 
OD at 600 nm (Fig. 3.2B). The temperature was reduced to 18°C prior to 
induction to enhance production of soluble protein. Soluble and insoluble 
samples were isolated from aliquots at numerous time points after induction to 
84
Figure 3.1. hMCM plasmid maps and schematic of conformation. A. Plasmid maps of 
each construct. The lac operon, origin (grey box), resistance marker (spectinomycin 
(spec), kanamycin (kan), carbenicillin (carb), purification tags (His6-Tag) and antibody 
tags (S-Tag and Trx-Tag) and each hMCM subunit is shown. The commercial name and 
full length of each construct is indicated in base pairs (bp). A number of restriction sites 
are indicated. B. Schematic of the expected conformation of hMCM showing purification 
tags (His6-Tag) and antibody tags (S-Tag and Trx-Tag). These plasmids were made 
previously by Dr Richard P. Parker-Manuel.
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 monitor the expression of each hMCM subunit by western blotting. Each hMCM 
subunit was expressed in the soluble fraction of harvested culture (Fig 3.2C, D). 
The recombinant hMCM was purified according to the scheme outlined in figure 
3.3A. Immobilised metal affinity chromatography (IMAC) was used to purify the 
His-tagged proteins. The elution profile and Coomassie stained SDS PAGE gel of 
elution fractions (Fig. 3.3B) shows the peak of protein. Elution fractions E10 – E16 
were pooled and further purified by gel filtration to separate the proteins by size 
(Fig. 3.4). The elution fractions corresponding to the predicted molecular weight 
of hMCM (567 KDa) were pooled for further purification (A5 – A10, Fig. 3.4B, C). 
The subsequent peaks are thought to be single his-tagged hMCM subunits (such 
as hMCM5) or smaller hMCM complexes such as dimers or trimers. The pooled 
elutant was subsequently purified by anion exchange to separate proteins by 
charge (Fig. 3.5). Elution fractions were analysed by western blotting to 
determine which peak corresponded to hMCM containing all six hMCM 
subunits (Fig 3.5D). Human, Xenopus, Drosophila S. pombe and S. cerevisiae MCM 
proteins have been previously isolated as a sub-complex of MCM hexamer 
containing only subunits MCM4, 6, and 7 (Ishimi, 1997, Kanter et al., 2008, 
Schwacha and Bell, 2001). To ensure purification of heterohexameric hMCM, 
western blots were probed for subunits hMCM2 and 4 and fractions containing 
both these subunits were pooled (A15 – B11, Fig. 3.5D).  
The presence of all six hMCM subunits in the purified complex was 
demonstrated by western blotting using specific antibodies (Fig 3.6A). Putative 
degradation products in addition to all six full-length hMCM subunits were 
detected. To show the extent of purification, samples from each purification step 
were analysed by SDS PAGE and stained with Coomassie blue (Fig 3.6B). The 
results depict the concentration of a band running at approximately 100 KDa, 
which is the approximate size of hMCM4 and hMCM6, and the loss of a lower 
non-specific 60 KDa band. The extent of purification determined by protein 
concentration was calculated and is shown in Table 3.1. The clarified E. coli lysate 
was purified nearly 90,000 fold to produce 2.5 mg of hMCM at a concentration of 
1 mg/ml. Typically 82.5 µg of hMCM per litre E. coli culture is produced. This is 
the first report of production of a recombinant human MCM2-7 complex, and 
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Figure 3.2. Summary of hMCM production from a typical 50 L bioreactor run A. Flow 
diagram of the scheme outlined for hMCM production. B. The growth of E. coli in a 50 L 
bioreactor expressing hMCM monitored by measuring the optical density at 600 nm at 
numerous time points after inoculation. The addition of IPTG and temperature change to 
18°C is indicated with downwards arrow. Arrows pointing up indicate when samples were 
taken for western blot analysis (C). C. Western blots probed for each hMCM subunit, of 
soluble (S) and insoluble (I) samples taken from the 50 L fermenter at a number of time 
points after induction. The highlighted lane in the harvest (H) sample shows the sample 
purified. D. Western blot probed for hMCM6 showing soluble samples only as in C. 
Western blot in D is a higher exposure. Marker is Precision Plus Protein standards 
(Bio-Rad). 
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Figure 3.3. Summary of immobilised metal affinity chromatography (IMAC) purification of 
hMCM. A. Schematic of hMCM purification. B. Elution profile for IMAC purification step. 
hMCM was bound to 24 ml His-Select cobalt beads by batch binding before packing into 
a XK16/20 column. * indicates elution samples taken to the next purification step. C. 
Coomassie stained SDS-PAGE gel to show extent of purification. CL - clarified lysate, W 
- wash, FT - flow through, E1 - E19 - Elution fractions 1-19. Elution fractions E10 - E16 
were taken to the next purification step (indicated by *). Marker is Precision Plus Protein 
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Figure 3.4. Summary of gel filtration purification of hMCM. A. Schematic of hMCM 
purification. B. Elution profile for gel filtration (S200) purification step. Pooled fractions 
from IMAC were further purified using a 320 ml HiLoad 26/600 Superdex 200 column. * 
indicates elution samples taken to the next purification step. C. Coomassie stained 
SDS-PAGE gel to show extent of purification. IMAC pool - pooled samples from previous 
purification step, A4 - B5 - elution fractions. Elution fractions A5 – A10 were taken to the 
next purification step (indicated by *). Marker is Precision Plus Protein standards 
(Bio-Rad).
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Figure 3.5. Summary of anion exchange purification of hMCM. A. Schematic of hMCM 
purification. B. Elution profile for anion exchange (MonoQ) purification step. Pooled 
fractions from gel filtration were further purified using a 1 ml MonoQ column. Insert focuses 
on the pooled fractions. * indicates elution samples taken to the next purification step. C. 
Coomassie stained SDS-PAGE gel to show extent of purification. GF pool - pooled 
samples from previous purification step, FT - flow through, A3 - B8 - Elution fractions. 
Marker is Precision Plus Protein standards (Bio-Rad). D. Western blots of elution fractions 
A2 - B7 and FT probed for MCM2 and MCM4. Marker is PageRuler Plus Prestained 
(Thermoscientific). Elution fractions A15 – B11 were pooled (indicated by *).
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 will enable the first detailed human protein-specific analysis of MCM2-7 
function. 
Table 3.1. The fold purification and concentration of recombinant hMCM from a 
typical 50 L fermenter run. The protein concentration is determined using a Bio-
Rad Protein Assay Dye Reagent (see Chapter 2.3.6 for details). 
Purification Step 
[Protein] 
(mg/ml) 
Volume 
(ml) 
Total 
Protein (mg) 
Percentage 
yield (%) 
Extract 34.29 600 20576.65 N/A 
IMAC* 
(Cobalt His-Select) 
11.448 9 103.03 0.5 
Gel filtration 
(S200) 
0.554 24 13.31 0.06 
Anion exchange 
(MonoQ) 
0.999 2.5 2.5 0.012 
*IMAC – immobilised metal affinity chromatography 
 
The protocol used to produce hMCM has been demonstrated to be reproducible. 
A further 14 mg of hMCM has been produced, through three fermentations, 
during the course of this PhD. The 14 mg of hMCM was sent to collaborators at 
University of Southern California who are attempting to produce crystal 
structures.  
The western blot of purified hMCM (Fig. 3.6A) shows multiple hMCM bands 
indicating degradation of the hMCM sample. When producing more hMCM an 
improved method to reduce proteolysis is required. In addition to the current 
protease inhibitors used (please see Chapter 2.4), EGTA could be used after 
IMAC purification to inhibit any metallo-proteases.   
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AFigure 3.6. Summary of hMCM purification A. Western blot of purified hMCM probed with 
each hMCM subunit. The correct molecular weight substrate is indicated with a red box 
for each subunit. B. Coomassie stained gel of hMCM from different stages in the 
purification; clarified lysate (CL), immobilised metal affinity chromatography (IMAC), gel 
filtration (GF), anion exchange (AE). C. Coomassie stained gel of hMCM at a higher 
concentration than shown in B. to allow visualisation of all hMCM subunits. Marker is 
Precision Plus Protein standards (Bio-Rad).
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 3.4.2 Production and purification of mutant hMCM 
An ATPase deficient mutant was produced using three constructs, each encoding 
two of six hMCM subunits harbouring a point mutation to inactivate the Walker 
A motif for each hMCM subunit (Schwacha and Bell, 2001, Chong et al., 2000). 
These constructs were produced previously by (Dr Richard P. Parker-Manuel). 
Point mutations were in MCM2 - K529E, MCM3 - K351E, MCM4 - K516E, MCM5 
- K387E, MCM6 - K402E and MCM7 - K387E. These constructs were transformed 
into E. coli Rosetta 2 (DE3, Novagen) and mutant hMCM was purified in the 
same way as WT hMCM (Fig. 3.7, 3.8). This protein will be used as a negative 
control in future experiments and is referred to as ‘mutant hMCM’. 
3.4.3 ATP hydrolysis activity of hMCM 
Previously, ATP hydrolysis has been demonstrated for MCM complexes derived 
from archaea (Chong et al., 2000, Jenkinson and Chong, 2006, Kelman et al., 1999) 
and eukaryotes (Schwacha and Bell, 2001, Tye, 1999, Davey et al., 2003, Ishimi, 
1997). In order to identify the optimal conditions for ATP hydrolysis, purified 
recombinant WT hMCM was tested for its ability to hydrolyse ATP to ADP 
under a variety of conditions. The percentage of ADP released from ATP over 45 
minutes was calculated for initial experiments (Fig 3.9). Control reactions in the 
presence and absence of 76 nM hMCM and 3.5 nM DNA were used to 
demonstrate background ADP release, which ranged from 2% to 6.5% as 
radiolabelled ATP decayed. Nevertheless, ADP release was shown to increase 
with time (Fig. 3.9A), was optimal in phosphate buffer pH 8.5 (Fig 3.9B) and at a 
magnesium concentration of 15 mM (Fig 3.9C). As a result future experiments 
were carried out under these conditions for 45 minutes.  
For subsequent experiments the amount of ADP produced was calculated over 
time using a dilution series of radiolabelled ATP stock in parallel with each 
experiment. Based on previous reports of specific salt requirements for S. 
cerevisiae MCM2-7 activity in vitro (Bochman and Schwacha, 2008), the ability of 
hMCM to hydrolyse ATP in the presence of sodium chloride, sodium glutamate, 
potassium chloride and potassium glutamate was examined (Fig. 3.10A). 
Increased sodium chloride concentrations resulted in a statistically significant 
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AFigure 3.7. Summary of immobilised metal affinity chromatography (IMAC) purification for 
mutant hMCM. A. Coomassie stained SDS-PAGE gel to show extent of purification using 
IMAC. hMCM was bound to 20 ml His-Select cobalt beads by batch binding before 
packing into a XK16/20 column. FT - flow through, E4 -E26 - elution fractions. Elution 
fractions E11 - E23 were taken to the next purification step (indicated by *). B. Western 
blot of peak IMAC elution fractions probed with MCM3, MCM4 and MCM6.  Marker is 
Precision Plus Protein standards (Bio-Rad).  
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AFigure 3.8. Summary of gel filtration and anion exchange purification of mutant hMCM. A. 
Elution profile for gel filtration purification. IMAC pooled fractions were further purified 
using a 320 ml HiLoad 26/600 Superdex 200 column. Pooled fractions (indicated by *) 
were A5 - A13. B. Elution profile anion exchange purification. Pooled fractions from gel 
filtration were further purified using a 1 ml MonoQ column. Pooled fractions (indicated by 
*) were A6 - A9. C. Western blots of anion exchange elution fractions A3 - B8 and flow 
through (FT) probed for MCM2 and MCM4. Marker is Precision Plus Protein standards 
(Bio-Rad). Elution fractions A6 – A9 were pooled (indicated by *). D. Western blots of 
purified mutant hMCM probed with MCM2, MCM4 and MCM6. The correct molecular 
weight substrate is indicated with a red box for each subunit. Marker is PageRuler Plus 
Prestained (Thermoscientific).
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Figure 3.9. Optimisation of assay conditions for ATPase activity of hMCM. Determined by 
thin layer chromatography of radiolabelled ATP hydrolysis. Control reactions in the 
presence and absence of 176 nM hMCM and 3.5 nM DNA are shown for each reaction. A. 
ATP hydrolysis increases over time. B. Phosphate buffer at pH 8.5 is the optimal pH for 
ATP hydrolysis. C. Optimal concentration of Magnesium acetate (Mg2+) is 15 mM. 
Reactions B and C were run over 45 minutes.
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 decrease in ATP hydrolysis. A similar effect was observed for sodium glutamate. 
The addition of 50 mM potassium chloride resulted in a pronounced inhibition of 
ATPase activity consistent with results reported for the S. cerevisiae MCM2-7 
(Bochman and Schwacha, 2008). Strikingly the presence of 300 mM potassium 
glutamate, twice the physiological salt concentration, had no effect on ATPase 
activity (Fig. 3.10A). 
ATP hydrolysis activity by MtMCM is stimulated by the presence of DNA 
(Chong et al., 2000) in contrast to reports of S. cerevisiae MCM2-7 ATPase activity 
where DNA did not stimulate ATP hydrolysis (Bochman et al., 2008, Schwacha 
and Bell, 2001) and so the ATP hydrolysis activity of recombinant hMCM was 
tested in the presence and absence of a series of DNA substrates (Fig 3.10B). 
hMCM exhibited ATP hydrolysis that was not increased by the addition of DNA 
consistent with reports of heterohexameric MCM2-7 from S. cerevisiae. It is worth 
noting that this is in contrast to the MCM4, 6, 7 sub-complex, which is stimulated 
by ssDNA (Biswas-Fiss et al., 2005, You et al., 2003). High concentrations of 
dsDNA (46 nM, with a ratio of hMCM hexamer:DNA of 3.8:1) inhibited ATP 
hydrolysis by ~50% compared to lower concentrations of dsDNA. This agrees 
with previous observations from MtMCMs (Chong et al., 2000) and is possibly 
due to a substrate competition effect preventing the MCMs from forming a 
productive complex. Or could represent productive loading of hMCM which 
requires post-translational modifications to unwind the DNA. A similar, but 
smaller, effect was observed for ssDNA. A forked substrate had negligible effect 
on hydrolysis activity at the concentrations tested. 
As expected, increasing concentrations of hMCM resulted in increased ATP 
hydrolysis (Fig. 3.11A). Addition of 20 mM EDTA significantly reduced ATP 
hydrolysis by hMCM, as did replacing the WT protein with the ATPase deficient 
mutant complex (Fig. 3.11A). This concurs with previous studies in S. cerevisiae 
and MtMCM (Schwacha and Bell, 2001, Chong et al., 2000). Using the optimal 
assay conditions identified, the rate of ATP hydrolysis for WT and ATPase 
deficient mutant hMCM was measured (Fig. 3.11B). The specific activity of ATP 
hydrolysis for WT hMCM was 16.7 pmol ADP released/min/pmol hMCM 
compared to 3.9 pmol ADP released/min/pmol for the ATPase deficient mutant 
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Figure 3.10. Effect of salt and DNA on ATPase activity of hMCM. Determined by thin layer 
chromatography of radiolabelled ATP hydrolysis. The data shown are mean values of 
three replicates, error bars indicate SEM. Reactions contain 176 nM hMCM and in the 
presence of 3.5 nM dsDNA unless stated otherwise. A. Potassium glutamate (KGlut) had 
no effect on ATPase activity, increasing the concentrations of sodium chloride (NaCl) and 
sodium glutamate (NaGlut) reduced ATP hydrolysis and addition of potassium chloride 
(KCl) substantially reduced ATP hydrolysis. Statistics compare labelled bar to 0 mM salt.  
*p=0.018, **p=0.013 and ***p=0.00027. B. DNA has little effect on ATP hydrolysis at low 
concentrations. At 46 nM (when the molar ratio of [hMCM hexamer]:[DNA] was [3.8:1]) 
single stranded (ss) DNA (6,407 bases) reduced ATP hydrolysis by one third and double 
stranded (ds) DNA (3,162 bp) reduced ATP hydrolysis by ~50%. Forked DNA (Fig D1), 
had little overall effect. Statistics compare labelled bar to 0 nM DNA *p=0.022 and 
**p=0.0019.
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Figure 3.11. Effect of hMCM and ATP concentration on ATPase activity of hMCM and 
mutant hMCM. Determined by thin layer chromatography of radiolabelled ATP hydrolysis. 
Reactions contain 176 nM hMCM and in the presence of 3.5 nM dsDNA unless stated 
otherwise A. ATPase activity increases with protein concentration and is inhibited by the 
addition of 20 mM EDTA to chelate the Mg2+. Mutant hMCM shows 6-fold lower ATP 
hydrolysis activity than wild type (WT) hMCM. The mean value of three replicates is 
shown, error bars indicate SEM. Statistics compare labelled bar to 352 nM hMCM 
*p=0.0015 and **p=0.00014. B. The rate of ATP hydrolysis by hMCM and mutant hMCM 
in pmol of ADP released per minute. The specific activity of ATP hydrolysis for WT hMCM 
is 16.7 pmol ADP produced/min/pmol hMCM and 3.9 pmol ADP produced/min/pmol 
mutant hMCM.  The mean values of two assays is shown, error bars show the standard 
deviation.
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 hMCM. It is possible that ATP hydrolysis is still shown in the hMCM mutant 
reactions due to contaminants from E. coli such as nucleases.  
Binding and hydrolysis of ATP by MCM2-7 purified from S. cerevisiae has 
recently been shown to be required for Cdt1 release and double hexamer 
formation (Coster et al., 2014). The ATPase sites of different MCM subunits have 
been implicated in different stages of its loading and activation (Kang et al., 
2014). The MCM ‘2-5 gate’ is thought to be controlled by ATP hydrolysis 
(Bochman and Schwacha, 2008) and has obvious implications in MCM2-7 loading 
and activation. The recombinant hMCM produced here is an important tool to 
further analyse these findings. 
3.4.4 ATP-dependent DNA unwinding by hMCM 
MCM2-7 complexes from S. cerevisiae (Bochman and Schwacha, 2008), and a 
human MCM4, 6, 7 complex purified from tissue culture cells (Ishimi, 1997) have 
previously been shown to exhibit ATP-dependent DNA helicase activities. 
However, DNA unwinding activity of higher eukaryotic MCM2-7 complexes has 
only been observed with the CMG complex from Drosophila (Moyer et al., 2006). 
In addition, previous studies indicate MCM2-7 complexes require very specific 
conditions for DNA duplex unwinding and so the optimal conditions derived 
from ATP hydrolysis experiments were used in the helicase experiments 
(detailed in Chapter 2.6). The DNA helicase activity of recombinant hMCM was 
analysed to examine if post-translational modifications or accessory proteins 
were absolutely required for unwinding. The helicase assays were carried out 
using 4 nM of a forked DNA substrate incubated with increasing concentrations 
of recombinant hMCM and were tested for its ability to unwind DNA in the 
presence or absence of ATP (Fig. 3.12). hMCM exhibited an ATP-dependent 
DNA unwinding activity (Fig. 3.12). 352 nM WT hMCM is capable of unwinding 
over 50% of the DNA substrate available in one hour (Fig. 3.12B). The lack of 
unwinding and ATPase activities in the ATPase deficient mutant hMCM assays 
suggests that the mutant and WT protein preparations were both free from 
contaminating E. coli helicases/ATPases. Under conditions where ATP could not 
be hydrolysed – that is, either WT hMCM in the absence of ATP, or mutant 
hMCM in the presence of ATP – helicase activity was substantially reduced (Fig. 
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Figure 3.12. hMCM shows strand displacement activity. A. Heat denatured boiled 
substrate (★) and no protein lanes are included as controls. An arrow indicates the 
position of displaced substrate, an asterisk indicates substrate with unusual mobility, 
perhaps indicating hMCM that is bound to DNA. B. The amount of single stranded 
substrate (4 nM total concentration) in each reaction was quantified as a percentage of 
the boiled substrate control. The data shown are mean values for four independent 
assays, an example of which is shown in (A). Error bars indicate SEM. Statistics compare 
labelled lane to 352 nM hMCM plus ATP. ***p=0.00013 and **p=0.0014.
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 3.12B). This is consistent with ATP hydrolysis being required for helicase activity. 
Under these conditions a large proportion of the substrate migrated more slowly 
by native PAGE. Similar mobility shift effects have been previously observed for 
the MtMCM when samples have been incubated on ice (Jenkinson and Chong, 
2006). This suggests that hMCM binds to the DNA substrate in the absence of 
ATP (or ATP hydrolysis) but cannot unwind it. This is consistent with the idea 
that ATP hydrolysis is not required for DNA-protein interactions but is required 
for DNA unwinding (McGeoch et al., 2005). Recent studies suggest ATP 
hydrolysis is required for loading S. cerevisiae MCM2-7 (Kang et al., 2014, Coster 
et al., 2014). Therefore these results may indicate MCM2-7 DNA binding (DNA 
binding to the outside of MCM2-7 hexamers) rather than MCM2-7 loading 
(MCM2-7 encircling DNA).  
Recombinant hMCM is capable of unwinding duplex DNA. Under the conditions 
shown here, 38% and 50% displacement of the labelled strand by 176 nM and 352 
nM hMCM respectively was observed. This is broadly comparable to the 
reported 52% displacement by 110 nM S. cerevisiae MCM2-7 (Bochman and 
Schwacha, 2008).  
Overall, these results indicate that the recombinant hMCM complex exhibits 
DNA helicase activity and that posttranslational modifications to hMCM or 
accessory proteins such as Cdc45 and GINS are not required for the unwinding 
of naked DNA. The requirement for Cdc45 and GINS may only be required 
when loading MCM2-7 onto DNA or unwinding DNA packaged into chromatin. 
3.4.5 Structural analysis 
The following work was carried out in collaboration with Prof. E. Orlova at 
Birkbeck, University of London. hMCM samples were previously produced by 
Dr Richard P. Parker-Manuel and analysed under standard buffer conditions. 
Negative stain electron microscopy images of hMCM samples were taken by Dr 
Yuriy Chaban. Electron microscopy images were processed as described in the 
methods. The reconstruction of hMCM alone was calculated from the best 100 
classes containing ~11 images each. For hMCM plus DNA, the final 
reconstruction was calculated from the best 155 classes containing ~10 images 
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 each (Fig. 3.13). The forked DNA substrate consisted of a 45 bp duplex region, a 
35 nucleotide 5' tail and a 60 nucleotide 3' tail. Images of the samples were taken 
at 50,000 x magnification with pixel size of 2.5 Å/pix to produce a 23 Å 
resolution, 3D, asymmetric reconstruction (Fig. 3.14 and 3.15). 
The reconstructions show hMCM forms a ring-shaped single hexamer with a 
diameter of 145 Å and a height of 120 Å, consistent with the organisation of 
oligomeric complexes reported for MCM complexes from other eukaryotes 
(Costa et al., 2011, Remus et al., 2009, Pape et al., 2003, Gomez-Llorente et al., 
2005) (Fig. 3.14). The reconstructions have C1 symmetry, suggesting that the 
complexes present contain six different subunits (2-7) as opposed to a dimer of 
MCM4, 6, 7 trimers (which would produce C2 symmetry), or a trimer of MCM4, 
7 dimers (C3 symmetry). In the presence of forked DNA (Fig. 3.14B, middle 
column) the hMCM structure undergoes a conformational change and clearly 
shows a different conformation, with a more defined two-tiered hexameric shape 
and a more obviously open central cavity. Interestingly, the conformation of 
hMCM bound to DNA is more similar to what has been reported for S. cerevisiae 
MCM2-7 in the absence of DNA (Samel et al., 2014). One possible reason for the 
differences observed between the S. cerevisiae and human proteins in the absence 
of DNA could be due to the differences in the primary sequences of the S. 
cerevisiae and human proteins (outlined in Table 1.1). The prominent projection 
that appears on the top surface of one of the hMCM subunits in the presence of 
DNA (red circle) could be either the bound double-stranded portion of the DNA 
substrate, or a section of protein displaced by the presence of the DNA, such as 
the N-terminal S-Trx-His tag on MCM7, which would also be consistent with the 
clearing of the apparently occluded central channel in the DNA-free 
reconstruction when DNA is added. Currently there is no literature that shows 
preferential DNA binding to a particular subunit. 
The crystal structure of SsoMCM (Brewster et al., 2008) was fitted into the 3D 
map of hMCM and hMCM plus DNA complexes manually using Chimera 
(Goddard et al., 2007). Our reconstruction clearly fits the SsoMCM crystal 
structure (3F9V, Fig 3.15, 3.16). The 3F9V crystal structure is amino acids 7 – 601 
of SsoMCM (Brewster et al., 2008). Full length SsoMCM is 686 amino acids in 
103
 length and this crystal structure is missing 70 amino acids from the C terminal. In 
comparison to hMCM subunits, the 3F9V crystal structure is between 17% and 
34% smaller (see Table 3.2). Space in the hMCM alone reconstruction is limited 
however there is visibly more room available in the hMCM plus DNA 
reconstruction which would allow for the amino acid insertions (Fig. 3.15, bottom 
panel). 
Table 3.2. MCM amino acid insertion comparison of Human (Hs) and 
Sulfolobus solfataricus (Sso) MCM. The number of amino acids present in 
SsoMCM or the amino acids crystalised to produce the 3F9C structure are 
compared to the human MCM2-7. Each MCM subunit in hMCM is larger than 
SsoMCM subunits.   
MCM Human 
(aa*) 
aa difference 
(Hs - Sso) 
aa difference 
(Hs – 3F9V) 
2 904 218 (24%) 309 (34%) 
3 808 122 (14%) 213 (26%) 
4 863 177 (21%) 268 (31%) 
5 734 48 (7%) 139 (19%) 
6 821 135 (16%) 226 (28%) 
7 719 33 (17%) 124 (17%) 
* amino acids 
Analysis of a population of Drosophila MCM2-7 complexes revealed that they 
exist in two different states: a planar, notched ring and an open spiral shape 
(Costa et al., 2011) and reconstructions of MCM2-7 from E. cuniculi suggest that 
MCM2-7 is naturally found in the open spiral shape (Lyubimov et al., 2012). The 
reconstruction of the human complex is clearly more similar to the notched ring, 
but this does not preclude the existence of spiral shaped complexes in the 
sample, although they are clearly not the predominant form under the conditions 
used to visualise the protein.  
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Figure 3.13. Negative stain electron microscopy of hMCM. An example of the raw 
micrograph hMCM (A) and hMCM plus DNA (B). Representative images of particles are 
outlined by circles in yellow. Scale bar is 50 nm. C. hMCM classes and reprojections used 
in final reconstruction for hMCM alone. D. As in A for hMCM plus DNA. 
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Figure 3.14. hMCM undergoes a conformational change when bound to forked DNA. 
Negative stain, single particle electron microscopy (EM) asymmetric reconstruction to 
23Å resolution. Top row: C-terminal view hMCM alone (blue), hMCM bound to DNA 
(green) and schematic representation of hMCM subunit configuration. Middle: N-terminal 
view as above. Bottom: Side view as above. Red circle highlights protrusion thought to be 
DNA binding to hMCM. Size indicated in angstroms (Å). 
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Figure 3.15. hMCM EM reconstructions fit crystal structures. hMCM alone (blue) and 
hMCM bound to forked DNA (green) fitted with ‘nearly full length’ Sulfolobus solfataricus 
(Sso) MCM crystal structure (3F9V, Brewster et al., 2008). The full hMCM structure (left) 
and slice through hMCM (right) shows clear central cavity in both reconstructions.  
N-term
C-term
N-term
C-term
+ DNA
- DNA
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AFigure 3.16. Additional views of hMCM reconstructions. A. hMCM alone with 3-fold 
symmetry (C3). SsoMCM crystal structure (3F9V, Brewster et al., 2008) fitted into 
reconstruction. The full hMCM (C3) structure (left) and slice through hMCM (C3) structure 
(right) show a central cavity. B. hMCM with 6 fold symmetry (C6). SsoMCM crystal 
structure (3F9V, Brewster et al., 2008) fitted into reconstruction. The full hMCM (C6) 
structure (left) and slice through hMCM (C6) structure (right) show a central cavity.
N-term
C-term
B N-term
C-term
C3 symmetry 
C6 symmetry 
108
 3.5 Conclusion 
Recombinant hMCM provides an important tool for understanding the 
mechanisms governing human DNA replication through the reconstitution of 
replication licensing factor and DNA unwinding. The ability to produce 
significant quantities of hMCM for analysis is an important step forward. The 
biochemical findings show that the recombinant complex is active in vitro and the 
structural studies show that its conformation is altered when bound to DNA. 
Production of recombinant hMCM enables the targeted manipulation of 
individual proteins within the hMCM complex, providing the potential to 
address in detail the important differences between individual subunits in the 
hMCM heterohexamer. It could also be used in screens for clinically relevant 
hMCM inhibitors. 
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 4 Expression and localisation of endogenous 
mammalian MCM proteins 
The following work has been accepted for publication and is shown in paper 
format in Appendix D. 
4.1 Introduction 
The nuclear matrix is a biochemically defined ribonuclear protein framework in 
higher eukaryotic cells, which withstands a range of extraction conditions (see 
Chapter 1 for more details). A number of studies have begun to look at the 
relationship of MCM proteins with the nuclear matrix in asynchronous 
populations of cells, with contradictory results. MCM3, MCM5 and MCM7 have 
been shown to be resistant to nuclease digestion and therefore nuclear matrix 
bound (Fujita et al., 2002, Burkhart et al., 1995). However, numerous studies 
show MCM2, MCM3, MCM5 and MCM7 to be solubilised by nuclease digestion 
and therefore not nuclear matrix bound (Fujita et al., 1997, Stoeber et al., 1998, 
Cook et al., 2004, Cook et al., 2002, Mendez and Stillman, 2000). The lack of 
consensus may be due to a transient interaction of MCM proteins with the 
nuclear matrix, which may be undetectable in the context of the bulk MCM 
protein content when studying asynchronous cells. Additionally, the 
investigations noted above were carried out in a variety of different cell types. 
Studies have shown tumours, transformed cells in culture, and stem-like cells 
appear to have a compromised or immature nuclear matrix (Munkley et al., 2011, 
Zink et al., 2004) making the choice of cell model important. Furthermore, these 
studies do not validate the extent of nuclease activity with controls to 
demonstrate full chromatin digestion.  
This work focuses on the fine temporal resolution of the nuclear binding 
characteristics of MCM2 as cells pass through late G1 phase, in order to describe 
the types of interaction that occur during expression, assembly, initiation and 
elongation. Using mouse 3T3 cells that can be manipulated to undergo 
synchronised passage through G1 phase, without the use of chemical inhibitors, 
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 three distinct binding states of MCM2 in the G1 phase following quiescence are 
demonstrated.  
4.2 Aims 
§ To profile mammalian MCM protein expression in relation to the cell 
cycle following release from quiescence. 
§ To examine the sub-cellular localisation of mammalian MCM proteins 
during G1 – S phase of the cell cycle.  
§ To investigate MCM protein binding to the nuclear matrix in relation to 
the cell cycle. 
4.3 Experimental design 
Mouse 3T3 cells were used for all the experiments in this chapter. Cells were 
synchronised in quiescence and harvested at multiple time points following 
release (2.2.2). For immunofluorescence, cells were grown on coverslips and 
washed with a range of reagents to reveal detergent, salt or DNase-resistant sub-
populations of MCM2. For western blot analysis, cells were grown in tissue 
culture dishes and extracted to produce the same fractions, plus the supernatant 
fractions that were released after each buffer. The antibody used to detect MCM2 
is exceptionally good at recognising mouse MCM2 and so was used to give the 
majority of the data in this chapter. Other antibodies were tested but gave 
unreliable results. 
4.4 Results 
4.4.1 Cells released from quiescence enter G1 in a highly regulated manner  
Mouse 3T3 cells were synchronised in quiescence by contact inhibition and 
serum depletion, then released into cycle as a synchronous wave of cells that 
pass through G1 landmarks at defined time points (Fig. 4.1). Under the 
conditions used here, serum-independent entry to S phase is triggered at 15 
hours after release from quiescence (restriction point) and does not vary much 
between experiments (maximum one hour variance based on appearance of 
cyclins, Coverley et al., 2002). Entry to S phase is monitored by incorporation of 
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 Edu, a nucleotide analogue that is incorporated into newly synthesised DNA and 
can be monitored by fluorescent microscopy. Cells begin to enter S phase at 
around 16 hours, approximately one hour after the restriction point (Fig. 4.1A). 
The majority of cells in the population enter S phase after 20 hours, reaching a 
maximum of 60 - 70% after 24 hours, which is typical for this protocol. Cells 
released from quiescence move through G1 phase in a wave, some quiescent cells 
may have died on release or entered senescence and so never re-enter the cell 
cycle. Cyclin A expression increases dramatically after 15 hours, consistent with 
its role in the activation of DNA replication machinery, and inhibition of pre-RC 
assembly (Coverley et al., 2002). These two outputs show reproducible cell 
synchrony kinetics, confirming that the system is properly calibrated and will 
support detailed analysis of the expression, assembly and function of MCM2-7 
during G1 to S phase.  
The results in figure 4.1A and previously published work (Coverley et al., 2002) 
are summarised in a model for events that occur following release from 
quiescence (Fig. 4.1B). Cells are released from quiescence at 0 hours and an 
extended G1 phase lasts until the initiation of DNA replication at around 19 
hours. The cells are committed to the cell cycle once they pass the restriction 
point, which happens at roughly 15 hours. Between the restriction point (15 
hours) and the initiation of DNA replication (19 hours) there is a ‘window of 
opportunity’ where conditions are permissive for pre-RC assembly.  
4.4.2 MCM protein expression peaks at the initiation of DNA replication 
Whole cell lysates were harvested in the absence of protease inhibitors at late G1 
phase of the cell cycle until late S phase (17 – 24 hours after release from 
quiescence) to determine if the level of MCM proteins varied during the 
transition from G1 - S phase. The relative amounts of MCM2, MCM3 and MCM7 
were determined by western blotting and expressed relative to actin. MCM 
proteins are first evident from the restriction point onwards with a noticeable 
peak at 19 hours after release from quiescence (Fig. 4.2A). MCM proteins appear 
to be degraded immediately before and after their peak of expression at 19 hours 
suggesting a transient protection from proteolysis (Fig. 4.2A). This temporal 
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AFigure 4.1. Cell cycle re-entry from quiescence. A. The percentage of cells engaged in 
DNA synthesis over 24 hours (black). The majority of the population first incorporate 
labelled nucleotides after 20 hours. The relative concentration of total cyclin A protein, 
estimated by densitometry (averaged from two biological replicates) and expressed after 
normalisation to actin (orange) demonstrates a similar profile. Insert (top) are 
representative western blots of cyclin A and actin, and (bottom) micrographs to illustrate 
incorporation of Edu into newly synthesised DNA in replicating cells (red). The total cell 
population is stained with Hoechst 33258 (blue). Marker is PageRuler Plus Prestained 
(Thermo Scientific). Scale bar is 10 μm. B. Mouse 3T3 cells re-enter the cell cycle from 
quiescence in a temporally well-defined manor, passing out of quiescence (Q) and through 
the restriction point (R) after approximately 15 hours. They enter S phase (S) as a wave of 
cells from 16 hours onwards. The 'window of opportunity' for assembling pre-replication 
complexes lies between the emergence of cyclin E (green), which opens it, and cyclin A 
(orange), which closes it and initiates DNA synthesis. 
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Figure 4.2. MCM protein levels peak at initiation. A. Western blots of MCM2, MCM3 and 
MCM7 protein levels in whole cell lysates recovered when harvested without protease 
inhibitors. Graph shows data quantified by densitometry and normalised to actin B. 
Western blots of MCM2 protein levels in soluble extract (detergent soluble supernatant) 
and nuclei fraction (detergent-resistant pellet), graph shows data quantified and 
normalised to actin. Marker is Precision Plus Protein standards (Bio-Rad). C. The 
percentage of cells with MCM2 in the nucleus in total and detergent resistant, detected by 
immunofluorescence. All labelled cells were scored regardless of intensity.  Error bars 
show SEM of three technical replicates (n ≥ 100 for each). Representative images of total 
and detergent resistant MCM2 (green) and DNA (Hoechst 33258, blue) (left). Scale bar is 
10 μm. * p=0.01.
*
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 profile is not apparent in whole cell lysates harvested in the presence of protease 
inhibitors (see Appendix D, Fig. 1B), it appears not to act in vivo on the bulk of 
the MCM proteins in the cell, having the greatest impact when cells are disrupted 
artificially. The peak at 19 hours after release from quiescence correlates with the 
requirement for MCM proteins at initiation of DNA replication. 
4.4.3 Sub-cellular localisation of MCM2 
To corroborate the striking peak of MCM subunit expression at 19 hours the sub-
cellular location was analysed in an independent experiment. Soluble 
(supernatant) and insoluble (detergent resistant pellet) MCM2 fractions were 
quantified relative to actin in the adjacent graph (Fig. 4.2B). Intriguingly, a 
reproducible peak at 19 hours after release from quiescence was observed. 
Using immunofluorescence to measure the proportion of cells with detectable 
MCM2 in the nucleus, the data show that populations are relatively uniform with 
a similar number of positive cells at 24 hours after release, as at 15 hours (Fig. 
4.2C), in all cases exclusively nuclear. Thus, the quantity increase observed by 
western blot does not reflect expression in a greater number of cells. Looking 
specifically at the detergent-resistant fraction of MCM2, a significant fall in the 
number with detectable levels seen at 17 hours, consistent with pre-initiation 
proteolysis of this fraction.  
4.4.4 MCM2 is transiently bound to the nuclear matrix  
Analysis of the sub-nuclear location of MCM2 during the assembly window 
between the restriction point and S phase was carried out by a previous lab 
member (Dr John R. P. Knight, personal communication). By increasing NaCl 
concentration, specific proteins are sequentially eluted with different profiles. He 
found that MCM2 is transiently, and reproducibly, assembled into high salt-
resistant immobilised complexes at 19 hours after release from quiescence but not 
at 18 or 20 hours (see Appendix D, Fig. 2B).  
To investigate if this high salt-resistant complex reflects immobilisation on the 
nuclear matrix, the association of MCM2 was examined using a protocol where 
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 histones and chromatin-associated proteins are eluted along with DNA 
fragments after digestion with DNase I. Under these conditions, MCM2 is 
apparently entirely eluted from asynchronous cells, with none evident in the 
nuclear matrix fraction (Fig. 4.3A). However, when this is applied specifically to 
a 19 hour population of cells (Fig. 4.3B), a small resistant fraction is evident, 
equivalent to approximately 4% of total MCM2 (addition of detergent P and SN) 
in the cell at that time (based on densitometry, Fig. 4.3). Successful nuclear matrix 
preparations are verified by digestion of chromatin by release of over 75% 
histone H3 from the nuclear matrix fraction (DNase P) and no histone H3 release 
in mock samples (Mock SN). Lamin B2 was used as a control for the presence of 
residual nucleus (DNase P). Similar analysis with an extensive set of antibodies 
raised against other MCM subunits failed to reveal nuclear matrix-associated 
populations. This could reflect underlying biology, however a strong conclusion 
cannot be drawn because none of these antibodies are as sensitive as that used to 
detect MCM2. 
Nuclear matrix isolation was recapitulated over a time course (Fig. 4.4) with 
focus on the 0.5 M NaCl-resistant fraction of MCM2 (chromatin and/or nuclear 
matrix bound). This generated consistent results, which show a DNase I–resistant 
fraction at 19 hours partially persisting in this time-course, to 20 hours after 
release from quiescence (Fig. 4.4A). At 19 hours, 76% of this immobilised fraction 
of MCM2 is in fact nuclear matrix bound (resistant to DNase I extraction), 
compared to only 5% of histone H3 and 83% of Lamin B2 (based on 
densitometry, Fig. 4.4A). Quantification of the number of nuclei with MCM2 by 
immunofluorescence again identified a peak of resistance at 19 hours (Fig. 4.4B). 
This argues that the 0.5 M NaCl resistant fraction that exists at 19 hours reflects 
the behaviour of approximately 50% of cells. No decrease in fluorescence 
intensity was observed in the chromatin-depleted population compared to the 
mock treated population (Fig. 4.4C), showing that all of the MCM2 that resists 0.5 
M NaCl is in fact attached to the nuclear matrix at this point.  
Together the data argue that even though only a small fraction of MCM2 is 
resistant to DNase I (Fig. 4.3B), this is the case for around half of the cells at 19 
hours after release from quiescence (Fig. 4.4B). Moreover, as resistance is a 
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A
Figure 4.3. Nuclear matrix binding revealed by DNase I digestion. Protein fractions 
prepared from asynchronous 3T3 cells (A), and from late G1 phase cells harvested at 19 
hours after release from quiescence (B), showing MCM2, histone H3 and lamin B2. 
Detergent-resistant pellet (P), detergent-soluble supernatant (SN), 0.5 M NaCl wash (W), 
DNase I resistant (nuclear matrix, DNase I P), DNase I soluble (chromatin, DNase SN), 
Mock treated (nuclear matrix and chromatin, Mock P) fractions. Histone H3 shows 
efficiency of digestion and lamin B2 the residual nuclear matrix fraction (indicated with an 
white dotted lines). A small fraction of the total MCM2 in the cell resists extraction at 19 
hours, but is not detectable in the asynchronous population. Marker is PageRuler Plus 
Prestained (Thermo Scientific).
B
Nuclear matrix fractions
130 -
100 -
PP SN SNPWSN
DNase Mock
Asynchronous
 15 -
 70 -
- MCM2
- Histone H3
PP SN SNPWSN
DNase Mock
19 hours
 130 -
 100 -
 15 -
 70 -
- Lamin B2
Nuclear matrix fractions
- MCM2
- Histone H3
- Lamin B2
KDaKDa
118
AFigure 4.4. Nuclear matrix binding revealed by DNase I digestion in G1 phase and early 
S. A. Western blots of 0.5 M washed pellets after treatment with DNase I (indicated by 
white dotted line) or mock treatment, harvested at 14 hours (pre-R), 17 hours 
(pre-initiation), 19 hours (initiation) and 20 hours. B. Percentage of cells with detectable 
MCM2 after DNase I (nuclear matrix) or mock (nuclear matrix and chromatin) treatment, 
detected by immunofluorescence. The number of positive cells peaks dramatically at 19 
hours, indicating that it becomes temporarily resistant to both 0.5 M NaCl and DNase I (n
≥ 100 for each). Representative images show MCM2 (green), DNA (blue) and lamin B2 
(red) after the indicated extractions. Scale bar is 10 μm. C. Mean MCM2 fluorescence 
intensity in arbitrary units (left) of DNase (n=100) and Mock (n=110) nuclei corrected for 
background. Intensity distribution (right, showing upper bin value) in arbitrary units. 
Results show there is no difference between DNase and Mock samples indicating that all 
0.5 M NaCl-resistant MCM2 is attached to the nuclear matrix.
B
Nuclear matrix fractions
DNase Mock
P SN SNP
DNase Mock
P SN SNP
DNase Mock
P SN P
MCM2 Histone H3 Lamin B2
14 hours
19 hours
20 hours
17 hours
SN
50
60
DNase R. Mock
MCM2 DNA Lamin B2 
Mock treated 
(chromatin & nuclear matrix)
DNase resistant
(nuclear matrix)
MCM2 DNA Lamin B2
C
DNase
resistant
Mock
0
1
2
3
4
5
6
0
20
40
60
2 7 12 17 22 27 > 28F
re
qu
en
cy
 (a
rb
itr
ar
y u
nit
s)
Flourescence intensity
DNase resistant
Mock
0
10
20
30
40
50
60
15 17 19 21 23 25 27 29
Pe
rc
en
ta
ge
 o
f c
ell
s w
ith
 M
CM
2 
af
te
r e
xtr
ac
tio
n
Hours after release from quiescence
DNase resistant
Mock
Av
er
ag
e 
int
en
sit
y
(a
rb
itr
ar
y u
nit
s)
119
 transient state, which may in fact last less than an hour, it is likely that more than 
50% of the population pass through this state at around this time in late G1 
phase. 
4.4.5 MCM2 is tightly associated with chromatin after initiation 
In order to reveal further binding characteristics of MCM2, cells were treated 
(prior to serial extraction) with DTSP, a cell-permeable reducing cross-linker 
which specifically links proteins (Baumert and Fasold, 1989) and then analysed 
by immunofluorescence. Using DTSP allows identification of different MCM2 
binding states (Fig. 4.5A). i. MCM2 is bound to chromatin only (released by 
DNase I with or without DTSP), ii. MCM2 is associated with the nuclear matrix 
(recovered in the nuclear matrix fraction with or without DTSP), and iii. MCM2 
is functionally bound to chromatin and associated with proteins that are 
themselves resistant to extraction by 0.5 M NaCl (recovered in the pellet fraction 
only if cross-linked by DTSP). 
Levels remained high across the time course (with some fluctuation, Fig. 4.5B) 
with total and detergent resistant levels of MCM2 similar in the presence or 
absence of DTSP (Fig. 4.2C), demonstrating crosslinking with DTSP had little 
affect on overall levels. However, distinct time-dependent shifts were 
demonstrated in the 0.5 M NaCl-resistant fraction (Mock, Fig. 4.5B). Again a peak 
is observed at 19 hours, consistent with transient association with the nuclear 
matrix in all positive nuclei. Example images show full digestion of chromatin in 
DNase I-resistant fraction (Fig. 4.5B). At 19 hour there was no reduction in 
fluorescence intensity after depletion of chromatin indicating that all 
immobilised MCM2 is actually attached to non-chromatin structures (nuclear 
matrix, Fig. 4.5C). However at 24 hours the response to digestion with DNase I 
distinguishes a fraction that is not bound to the nuclear matrix (released by 
DNase I), but is cross-linked to proteins that are themselves tightly associated to 
chromatin (mock, possibly stabilisation of the heterohexameric ring), and which 
resist 0.5 M NaCl in a fraction of nuclei.   
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Figure 4.5. Using DTSP MCM2 is shown to be associated with chromatin after initiation. 
A. Schematic showing MCM complex proteins in three states, i. when bound to chromatin 
only (released by DNase I with or without DTSP), ii. when associated with the nuclear 
matrix (recovered in the nuclear matrix fraction with or without DTSP), and iii. when 
functionally bound to chromatin and associated with proteins that are themselves resistant 
to extraction by 0.5 M NaCl in the pellet fraction (only if cross-linked by DTSP). B. The 
percentage of nuclei with MCM2, detected by immunofluorescence, in synchronised, 
cross-linked populations showing total, detergent-resistant, DNase I-resistant, and 0.5 M 
NaCl-resistant protein (mock) (n ≥ 100 for each). Mock-treated samples reveal a more 
gradual loss of immobilisation after 19 hours than that seen when chromatin is digested 
with DNase I. Dotted line indicates peak of nuclear matrix bound MCM2 at 19 hours. All 
labelled cells were scored regardless of intensity. Representative images show MCM2 
(green), DNA (Hoechst 33258, blue) and lamin B2 (red) after the indicated extractions. 
Scale bar is 10 μm. C. Mean MCM2 fluorescence intensity after DNase I or mock 
extraction at 19 hours, (n = 99 and 105 respectively, left) and at 24 hours (n = 107 and 101 
respectively, centre). A comparison of DNase I resistant MCM2 at 19 and 24 hour is also 
shown (n = 99 and 107 respectively, right). ** p = 8.6 x 10-5, *** p = 2.4 x 10-9.
Total
Detergent 
resistant
DNase 
resistant
MCM2 DNA Lamin B2 
DNase resistant (nuclear matrix)
MCM2 DNA Lamin B2
Mock treated
(chromatin and nuclear matrix)
Mock
121
 4.5 Discussion 
Previous work in S. cerevisiae (Donovan et al., 1997), Xenopus (Chong et al., 1995) 
and cultured human cells (Symeonidou et al., 2013, Krude et al., 1996, Ohta et al., 
2003, Kuipers et al., 2011, Mendez and Stillman, 2000) all demonstrate stable 
immobilisation of MCM2 in the nucleus during G1 phase, but do not further 
define the binding properties over this crucial period by distinguishing nuclear 
matrix-bound MCM2 from chromatin-bound MCM2. MCM2 has been shown to 
interact with the nuclear matrix anchoring protein AKAP95 (Eide et al., 
2003). Disruption of this interaction inhibits both initiation and elongation of 
DNA replication hypothesised to be due to the inability to recruit MCM2 to the 
nuclear matrix (Eide et al., 2003). By applying nuclease digestion my results 
demonstrate a transient relationship between MCM2 and the nuclear matrix, 
immediately before the majority of cells first produce nascent DNA. Extensive 
evidence argues that initiation of DNA replication occurs at the base of nuclear 
matrix-associated chromatin loops in immobilised DNA replication factories 
(Radichev et al., 2005, Pardoll et al., 1980, Vogelstein et al., 1980, Jackson and 
Cook, 1986, Nakayasu and Berezney, 1989, Gerdes et al., 1994). Transient rather 
than sustained recruitment to the nuclear matrix implies a transition that 
involves function-related helicase loading or activation at the nuclear matrix. 
Furthermore, the data suggest that activity during the elongation phase of DNA 
synthesis takes place separate from the nuclear matrix, and possibly outside of 
replication factories. This is consistent with failure of MCM proteins to co-localise 
with newly synthesised DNA (Krude et al., 1996, Dimitrova et al., 1999, Madine 
et al., 1995) except when analysed in relation to labelled DNA from the previous 
cell cycle (Aparicio et al., 2012). Therefore, MCM proteins are recruited to nuclear 
matrix-associated replication factories prior to initiation, but occupy somewhat 
remote sites during DNA synthesis. The diffuse nature of replication origins in 
higher eukaryotic cells (reviewed in Mechali, 2010) implies that structural 
determinants related to transcription specify their location on the template, while 
presence of an active helicase appears to define their status as a functional site. 
Thus, MCM2-7 complex loading may be specified by activities that are 
themselves located at the nuclear matrix, with origin selection governed by 
template recruitment to these sites.  
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 The abundance of MCM proteins is far higher than other components of the pre-
RC such as ORC and Cdc6 (Lei et al., 1996, Donovan et al., 1997) and greatly in 
excess of the number of activated origins of replication, suggesting that only a 
small fraction of the total MCM protein in the cell is assembled at sites of 
initiation. In addition, using degron-tagged MCM mutants, very small amounts 
of MCM proteins were required for DNA replication initiation in S. pombe spores 
but significantly more MCM was required for elongation (Liang et al., 1999). 
Some of the excess MCM is loaded at secondary sites, such as those that are 
activated following stress by replication fork inhibition (Ge et al., 2007, Ibarra et 
al., 2008, McIntosh and Blow, 2012) and in fact multiple copies appear to be 
present at each origin (reviewed in Laskey and Madine, 2003). It is also possible 
that a stoichiometric excess of MCM2-7 complex helps to ensure enough 
availability for parallel, synchronous and complete loading at all specified 
origins, with non-functionally loaded hexamers depleted by localised proteolysis 
as implied by the data presented here.  
This study adds to the growing body of evidence that initiation of DNA 
replication is spatially constrained by immobilisation on the nuclear matrix in 
mammalian cells. It also identifies a specific point in time and location at the 
nuclear matrix offering a direct route to the identification of the factors that 
spatially constrain MCM2-7 complex loading and initiation in mammalian cells. 
Future work in the area will exploit this information to identify interaction 
partners of MCM2 at the nuclear matrix. 
4.6 Conclusions 
Taken together the data are consistent with tight temporal regulation of pre-RC 
assembly at G1/S and point to uniform presence in the nucleus, but three states 
of MCM2-7 complex binding in late G1 phase; i. resistance to detergent but 
extraction with DNase I identifies a chromatin–associated nuclear fraction before 
19 hours, ii. resistance to extraction with DNase I identifies a transient 
attachment to (and protection by) the nuclear matrix, iii. cross-linking to DNase 
I-sensitive protein that is resistant to 0.5 M NaCl identifies tight association with 
chromatin at 24 hours. Based on their timing in relation to initiation of DNA 
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 replication and cyclin A expression (Fig. 4.1A), I suggest this represents i. pre-
initiation binding, ii. functional loading at initiation, iii. and post-initiation 
helicase presence on chromatin (Fig. 4.6).  
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Figure 4.6. Schematic showing three states of MCM2-7 complex binding in late G1 
phase, superimposed on the prevailing model of DNA replication, in which the replication 
machinery is fixed to the nuclear matrix at chromatin loop bases, with newly synthesised 
DNA extruded from fixed sites at two nascent daughter loops (Cook, 1991). Our data 
suggest that i. before initiation the MCM2-7 complex exists as a chromatin–associated 
nuclear protein, ii. functional loading immediately prior to initiation takes place 
coincidently with transient attachment to (and protection by) the nuclear matrix, iii. after 
initiation the MCM2-7 complex is functionally bound to chromatin but no longer associated 
with the nuclear matrix, and contributes to progression of the DNA replication fork. Images 
were prepared by graphics department to my design.
i. Pre-initiation
ii. Intiation of DNA synthesis
iii. Post-initiation
- MCM2--7 complex
- Chromatin
Nuclear matrix
Replication machinery
Daughter loops -
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 5 Functional assembly of recombinant hMCM 
5.1 Introduction 
The initiation of DNA replication has been reconstituted in vitro using S. cerevisiae 
cell free systems. Researchers use recombinant proteins and synchronised cell 
extracts to load MCM2-7 onto template DNA (Seki and Diffley, 2000 and others). 
Usually template DNA contains a known S. cerevisiae origin and is in the form of 
a plasmid or DNA physically attached to a bead. Using G1 extracts from S. 
cerevisiae, pre-RC assembly is dependent on the presence of origin sequences 
(Bowers et al., 2004, Seki and Diffley, 2000). However, using recombinant pre-RC 
proteins assembly is not origin dependent (Evrin et al., 2009, Remus et al., 2009), 
demonstrating promiscuity in origin selection on naked template. Recently, full 
replication of plasmid DNA was achieved, independent of origin sequences, 
using a S. cerevisiae cell free system over-expressing multiple initiation proteins 
(Gros et al., 2014, On et al., 2014). Thus, initiation has been effectively 
reconstituted. However, even in the presence of defined origins from S. cerevisiae, 
initiation is independent of origin sequence. This suggests that in the context of 
whole nuclei there are other constraints controlling MCM2-7 functional loading 
that cannot be identified using naked template. Thus it is necessary to analyse 
MCM2-7 loading onto DNA packaged into chromatin, ideally within nuclei 
themselves. This is particularly important when studying mammalian DNA 
replication where origins are not defined by sequence and chromosome structure 
is believed to play a part in origin selection (reviewed in Mechali, 2010). 
This chapter demonstrates the regulated loading of recombinant hMCM in 
isolated nuclei from mammalian cells. In this system hMCM loading is functional 
and has the ability to promote the initiation of DNA replication in vitro. In 
addition, I describe the use of recombinant proteins to determine the exact 
requirements for inducing a conformational change in hMCM. This conformation 
of hMCM (monitored using a mobility shift in MCM2) is normally exclusively 
found in S phase cells. 
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 5.2 Aims 
Using purified recombinant hMCM hexamer my goals were to: 
§ Reconstitute mammalian MCM2-7 complex assembly in mammalian 
nuclei, and determine the requirement for its properly regulated function. 
§ Analyse the post-translational modifications to hMCM, and reconstitute 
conditions that induce a shift from ‘G1’ and ‘S’ phase conformation. 
5.3 Experimental design 
The production of purified recombinant hMCM in E. coli, to avoid post-
translational modifications (Chapter 3), enables the analysis of G1/S phase 
kinases on naïve hMCM complexes. In conjunction with a cell free system, using 
synchronised cell extracts and nuclei from mouse 3T3 cells (section 2.2.2), this 
permits an ideal platform to analyse the functional assembly of MCM2-7 in 
mammalian DNA replication initiation. Due to the emerging differences reported 
between S. cerevisiae, Xenopus and mammalian systems (see Chapter 1 for details) 
analysis of human MCM2-7 is essential to understand details that may be of use 
in a clinical setting.  
5.4 Results and discussion 
5.4.1 Cell free characterisation 
Cell free components are obtained by synchronising cells in quiescence (as 
described in 2.2.2 and Chapter 4) and harvesting the cells at specific time points 
following release, in order to generate extracts with stage specific composition 
(Fig. 5.1). At approximately 15 hours after release from quiescence, cells are in 
mid-G1 phase where levels of CDKs are low, at 17 hours after release from 
quiescence cells are in late-G1 phase and levels of CDKs are rising. Once in S 
phase the cell has everything required to replicate its DNA including nucleotides 
and DNA polymerase. The different levels of kinases within cells at these time 
points are believed to regulate the temporal separation of MCM2-7 loading and 
activation (reviewed in Sclafani and Holzen, 2007, Li and Araki, 2013). Protein 
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 extract isolated at 15 hours, 17 hours and in S phase represent the average of a 
population of cells enriched for the required cell cycle phase. 
 
Figure 5.1. Schematic representation of cell free components prepared from cells 
synchronised by re-entry to the cell cycle from quiescence (Q). The time the cell passes 
through G1 phase (G1), the restriction point (R), initiation of DNA replication (I) and S 
phase (S) are shown. The relative concentration gradients of cyclin E/CDK2 (green), 
cyclin A/CDK2 (orange) and DDK (purple) are also indicated. Arrows show where cells 
are harvested for 15 hour (mid-G1), 17 hour (late-G1) and S phase extracts and nuclei 
preparations. 
 
Using nuclei and cytoplasmic extracts, a working system that recapitulates 
nuclear events was developed as described previously (Krude et al., 1997, 
Coverley et al., 2002). Addition of an ATP regenerating system (phosphocreatine 
and creatine phosphokinase) and nucleotides to cell extracts enables in vitro 
initiation of DNA synthesis in isolated G1 phase nuclei. This is a powerful 
system, used here to dissect the functional loading of MCM2-7. Each batch of 
nuclei was tested for replication competency. When incubated in mid-G1 phase 
extract the number of nuclei able to replicate DNA from already initiated origins 
(i.e. run on synthesis) was compared to the number of nuclei undergoing DNA 
Figure 5.1. Schematic representation of cell free components prepared from cells 
synchronised by re-entry to the cell cycle from quiescence (Q). The time the cell passes 
through G1 phase (G1), the restriction point (R), initiation of DNA replication (I) and S 
phase (S) are shown. The relative concentration gradients of cyclin E/CDK2 (green), 
cyclin A/CDK2 (orange) and DDK (purple) are also indicated. Arrows show where cells 
are harvested for 15 hour (mid-G1), 7 hour (late-G1) and S  extracts and nuclei 
preparations.
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 replication when incubated in S phase extract (i.e. run on synthesis plus new 
initiation events). If more nuclei are able to replicate their DNA when incubated 
in S phase extract compared to mid-G1 phase extract a proportion of the nuclei 
have initiated DNA synthesis in vitro and this represents the ‘replication 
competent’ fraction within the population. Nuclei populations in which the 
replication competent fraction is large enough to be reproducibly and accurately 
scored were used for future analysis.  
5.4.2 Regulated binding of hMCM in isolated nuclei  
To determine whether recombinant hMCM can bind to chromatin within nuclei, 
a cell free assay was devised. A replication competent late-G1 phase nuclei 
population was incubated in both mid-G1 phase and late-G1 phase extracts to 
determine whether hMCM binding is more or less efficient in the two extracts 
(Fig. 5.2A). The data show that MCM2, MCM4 and MCM7 preferentially bound 
to late-G1 nuclei when incubated in mid-G1 phase (15 hour) extract compared to 
late-G1 phase (17 hour) extract (Fig 5.2B-E), demonstrating regulated assembly of 
hMCM in vitro.  
Mid-G1 phase nuclei populations contain low numbers of replicating nuclei (less 
than 10%, Fig. 4.1A) and even fewer replication competent nuclei. Moreover, 
levels of endogenous MCM proteins are also low (Fig. 4.2B). Because MCM2-7 is 
believed to load onto chromatin in mid-G1 phase (Coverley et al., 2002), these 
nuclei represent a more functionally relevant content for analysis of MCM2-7 
loading. When analysed in the same way as late-G1 phase nuclei (Fig. 5.3A), 
binding of hMCM was also most efficient in mid-G1 phase extract (Fig 5.3B and 
C). A negative control, where hMCM was incubated with extract in the absence 
of nuclei demonstrates that recovery of hMCM is dependent on nuclei (Fig. 5.3B) 
and therefore represents a detergent resistant association rather than unspecific 
recovery. These results led to the hypothesis that components in the late-G1 
phase extract inhibit hMCM loading. As cellular kinases are responsible for cell 
cycle control following the restriction point (Aguda, 2001) and levels of kinases 
are higher in late-G1 phase extracts compared to mid-G1 phase extract (Fig. 5.1) it   
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Figure 5.2. Regulated binding of hMCM within late-G1 phase nuclei in vitro. A. Schematic 
to represent cell free experiment. Late-G1 phase (17h) nuclei were incubated in either 
mid-G1 phase (15h) extract (E.) or late-G1 phase extract in the presence or absence of 
recombinant hMCM. Histograms show quantification of western blot (E) showing 
detergent resistant (Det. Res.) levels of MCM2 (B), MCM4 (C) and MCM7 (D) in 
recovered nuclei. Results are quantified by densitometry and expressed relative to 
histone H3 concentrations. Marker is PageRuler Prestained Plus (Thermo Scientific).
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 is likely that the inhibitory factors in the 17 hour extract are regulatory kinases 
(Fig. 5.3D).  
5.4.3 Recombinant cyclin A/CDK2 and cyclin E/CDK2 improve hMCM 
loading in isolated nuclei 
In order to unpick the requirements for hMCM loading, cyclin E/CDK2 and 
cyclin A/CDK2 were added to hMCM cell free loading experiments (Fig. 5.4A). 
Cyclin E/CDK2 boosted hMCM loading over two-fold when used at 6.8 nM (Fig. 
5.4B). In previous published work, endogenous MCM2 loading peaked at 2.72 
nM cyclin E/CDK2 (Coverley et al., 2002), as recombinant hMCM is added at a 
concentration approximately 10-fold higher than endogenous MCM2-7, these 
concentrations are in the same range and suggests that recombinant hMCM 
loading is regulated in a similar way to endogenous MCM2-7. Furthermore, in 
cells where cyclin E is ablated, the association of MCM proteins with chromatin 
was decreased (Geng et al., 2003) and over production of cyclin E in cultured 
mammalian cells speeds up G1 phase (Ohtsubo and Roberts, 1993) possibly by 
increasing MCM loading.  
Addition of recombinant cyclin A/CDK2 also increased the ability of hMCM to 
bind to chromatin (Fig. 5.4C). This is not expected as cyclin A/CDK2 has 
previously been shown to inhibit loading of pre-RC components (Coverley et al., 
2002, Wheeler et al., 2008). However, these results could be due to sequence and 
structural similarity between cyclins E and A and under the conditions tested, 
cyclin A may substitute for cyclin E. 
5.4.4 hMCM is functionally loaded onto chromatin in vitro 
To understand if the recombinant hMCM that is loaded in vitro is functional 
within mammalian nuclei I analysed the ability of nuclei to replicate when 
supplied with an S phase environment. As cyclin E/CDK2 was most efficient at 
promoting the ability of hMCM to load, nuclei were pre-loaded in the presence 
or absence of hMCM and/or cyclin E/CDK2. Following the loading reaction 
nuclei were transferred to an S phase extract supplemented with labelled 
nucleotides (Fig. 5.5A), this provides the nuclei with everything required for 
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AFigure 5.4. Effect of recombinant cyclin E/CDK2 and cyclin A/CDK2 on hMCM loading. A. 
Schematic to represent cell free experiment in which mid-G1 phase (15 hour) nuclei were 
incubated in mid-G1 phase extract in the presence or absence of recombinant hMCM and 
kinase. B. Concentration of detergent resistant MCM2 quantified from western blot (right) 
relative to histone H3 in the presence of decreasing concentrations of cyclin E/CDK2. C.  
As in (B) in the presence of decreasing cyclin A/CDK2. Marker is PageRuler Plus 
Prestained (Thermo Scientific).
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 DNA replication. In the absence of recombinant proteins approximately 7% of 
the nuclei were capable of DNA replication (Fig. 5.5B). When nuclei were pre-
loaded with recombinant hMCM, the number of nuclei undergoing DNA 
replication was boosted over two-fold. The number of replicating nuclei was 
further increased to over three-fold in the presence of recombinant cyclin 
E/CDK2 and hMCM. This demonstrates that in vitro loaded recombinant hMCM 
is functional. Cyclin E/CDK2 alone is also capable of increasing the number of 
nuclei able to replicate DNA (Fig. 5.5B), possibly by promoting endogenous 
MCM2-7 loading as reported previously (Coverley et al., 2002). 
 
Figure 5.5. Effect of recombinant cyclin E/CDK2 on initiation of DNA replication. A. 
Schematic to represent cell free experiment in which mid-G1 phase (15 hour) nuclei were 
incubated in mid-G1 phase extract in the presence or absence of recombinant hMCM 
and/or cyclin E/CDK2. Nuclei were recovered and incubated in S phase extract 
supplemented with labelled nucleotides. B. Nuclei undergoing DNA synthesis after 
incubation in loading reaction. Error bars show +SEM for three technical replicates, *p = 
0.03, **p = 0.07 and ***p = 0.0001. Right – micrograph showing nuclei stained with 
Hoechst 33258 (blue), and nuclei undergoing DNA synthesis in red. Scale bar is 10 μm. 
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 5.4.5 Effect of DDK on hMCM loading 
The kinase activity of DDK is associated with activating the MCM2-7 complex to 
unwind DNA (reviewed in Sclafani and Holzen, 2007, Li and Araki, 2013, Labib, 
2010). However the role of DDK in loading MCM2-7 onto chromatin is not 
understood, so I analysed the effect of DDK in cell free loading experiments (Fig. 
5.6A). DDK inhibited hMCM binding when present at low concentrations (1.8 
nM, Fig. 5.6B). However high concentrations of DDK (711 nM), appeared to have 
little effect on the amount of hMCM that is able to load onto chromatin (Fig. 
5.6B). Conversely, by analysis of human cells synchronised in quiescence and 
released into the cell cycle using a similar method to that employed here, DDK 
phosphorylation at MCM2-Ser5 has been shown to be required for endogenous 
MCM loading (Chuang et al., 2009). In the cell free system, the presence of 
endogenous DDK may be responsible for phosphorylating MCM2 at Ser5 
allowing its association with chromatin in the supplemented reaction. Together 
these results suggest that chromatin association of MCM2-7 is tightly controlled, 
however the effect of DDK on MCM2-7 loading is unclear.  
Interestingly, 711 nM DDK causes an increased mobility of MCM2 in SDS PAGE 
and 180 nM DDK caused the mobility shift in approximately half of the loaded 
MCM2, indicating two populations of MCM2 (Fig. 5.6B, right). MCM2 with 
increased mobility is recovered in both detergent resistant pellet fraction (nuclei) 
and supernatant fractions, indicating that under these conditions, both forms of 
MCM2 appear to bind to chromatin. Previously the mobility shift of MCM2 in 
SDS PAGE has been linked with phosphorylation (Masai et al., 2000, Fujita et al., 
1998, Coverley et al., 2002), though because the shift is towards increased 
mobility it must represent an unusual state of the denatured polypeptide chain. 
5.4.6 MCM2 mobility shift is dependent on both DDK and cyclin A/CDK2 
To understand if DDK is exclusively responsible for the mobility shift of MCM2 
on SDS PAGE, the effect on hMCM of recombinant kinases (analysed in the 
absence of cell extract) was investigated. This demonstrated that DDK, cyclin 
A/CDK2 and cyclin E/CDK2 seperately are not capable of causing the mobility 
shift under the concentrations tested (Fig. 5.7). However, the presence of both 
136
AFigure 5.6. Effect of recombinant DDK on hMCM loading. A. Schematic to represent cell 
free experiment in which mid-G1 phase (15h) nuclei were incubated in mid-G1 phase 
extract in the presence or absence of recombinant hMCM and DDK. B. Concentration of 
detergent resistant MCM2 quantified from western blot (right) relative to histone H3 
loading control in the presence of decreasing concentrations of DDK. Supernatant 
samples (i.e. recombinant hMCM which did not bind) are also shown. Marker is 
PageRuler Plus Prestained (Thermo Scientific). 
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 DDK and cyclin A/CDK2 are capable of causing the shift (Fig. 5.7A, *). The 
increased mobility and likely conformational change in MCM2 may reflect an 
important regulatory event related to activating the MCM2-7 helicase.   
The effect of recombinant kinases on the other MCM2-7 proteins was also 
investigated (Fig. 5.7A). The only other hMCM subunit with a notable mobility 
shift in SDS PAGE was MCM4. In the case of MCM4, addition of cyclin A/CDK2 
alone was capable of causing a large decrease in mobility, suggesting an 
increased molecular weight, presumably due to hyperphosphorylation. Addition 
of both cyclin A/CDK2 and cyclin E/CDK2 also increased the molecular weight 
of MCM4, similarly to cyclin A/CDK2 alone. Interestingly addition of cyclin 
A/CDK2 and DDK increased the molecular weight of MCM4 even more than 
cyclin A/CDK2 alone (Fig 5.7A). These differential mobility shifts have also been 
noted in endogenous chromatin bound MCM2 and MCM4 in S phase cells 
(Masai et al., 2006, Fujita et al., 1998). There also appears to be a number of 
different bands present when MCM4 is treated with DDK and/or CDK2 
demonstrating a number of different phosphorylation states. (Fig 5.7A). The 
recombinant kinases did not have a large effect on the mobility of the remaining 
hMCM subunits under the conditions tested (Fig. 5.7A). Studies indicate that in 
the context of the MCM2-7 hexamer, the main targets of DDK are MCM2, MCM4 
and MCM6 (Francis et al., 2009). Here a shift in mobility is only seen for MCM2 
and MCM4. This of course does not rule out phosphorylation of MCM6. It is 
possible that, if used at a higher concentration, cyclin E/CDK2 would be capable 
of shifting MCM4 (and MCM2 in the presence of DDK). However, the 
concentration used here (6.8 nM), was chosen based on its ability to stimulate 
endogenous MCM2 loading (Coverley et al., 2002), and so is in the 
physiologically relevant range. 
To examine the effect of recombinant kinases on the overall hMCM structure, 
kinase treated hMCM was analysed by native PAGE (Fig. 5.7B). Analysis of 
MCM2 and MCM4 gave similar results, with the most intense band containing 
MCM proteins at around 480 KDa, which is broadly consistent with the 
molecular weight of recombinant hMCM (567 KDa). On the other hand, when 
probed for MCM6, the most intense band on native PAGE ran below 720 KDa 
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Figure 5.7. Both cyclin A/CDK2 and DDK are required to shift MCM2 but only cyclin 
A/CDK2 is required to shift MCM4. A. Recombinant hMCM was incubated with 
recombinant kinases as indicated, analysed by SDS PAGE and probed for MCM2 – 
MCM7. The highlighted lane (*) shows that both DDK and cyclin A/CDK2 are required to 
induce the shift in mobility of MCM2. Marker is PageRuler Plus Prestained (Thermo 
Scientific). B. Recombinant hMCM was incubated with recombinant kinases as indicated, 
analysed by native PAGE and probed for MCM2, MCM4 and MCM6. Marker is 
NativeMark Unstained (Life technologies).
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 (Fig. 5.7B). As this is at a different weight to the band detected by MCM2 and 
MCM4 it suggests that the hMCM preparation may not be an evenly 
stoichiometrically balanced heterohexamer. It is also possible that the complex 
may fall apart when run on native PAGE. In addition it is possible MCM6 has 
aggregated causing it to run at a larger molecular weight. Interestingly addition 
of cyclin A/CDK2 caused retarded mobility of the hexamer when probed with 
MCM2, MCM4 and MCM6, conversely, addition of cyclin E/CDK2 only retarded 
the mobility of the hexamer when probed with MCM4. More investigation is 
required to understand the effect of kinases on the mobility of the hMCM 
hexamer, as hMCM may not be stable under native PAGE conditions.  
5.4.7 Mobility shift of MCM proteins is a reversible phosphorylation 
Increased mobility of MCM2 is not as expected for a phosphorylated protein. 
Lambda phosphatase was used to investigate if the mobility shift noted for 
MCM2 and MCM4 is in fact caused by phosphorylation (Fig. 5.8). Samples were 
incubated with recombinant kinases as before, following which one half of the 
reaction was treated with Lambda phosphatase. These results clearly show the 
effect of cyclin A/CDK2 and DDK on MCM2 is due to phosphorylation and it is 
reversible. The same is also true for MCM4 (Fig. 5.8). Moreover when blotted for 
MCM4 there is an additional species, which runs at approximately 50 KDa. This 
could be degraded MCM4. The antibody used was raised against the N-terminal 
(amino acids 1 – 300), this suggests that the phosphorylation is in the N-terminal 
portion of MCM4 and the structural change produced, inferred from decreased 
mobility, occurs in this small 50 KDa truncated protein. This is consistent with 
studies in S. cerevisiae that have intensely analysed the phosphorylation sites in 
MCM4, demonstrating they are exclusively N-terminal (Masai et al., 2000, 
Devault et al., 2008, Sheu and Stillman, 2010, Sheu and Stillman, 2006, Masai et 
al., 2006).  
5.4.8 Cyclin A/CDK2 is required before DDK to induce increased mobility of 
MCM2 
There has been controversy over the order in which cellular kinases react with 
MCM2-7 (reviewed in Sclafani and Holzen, 2007). Within the cell, kinases are 
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Figure 5.8. MCM2 and MCM4 mobility shift is reversed by dephosphorylation by Lambda 
phosphatase. Recombinant hMCM was incubated with recombinant kinases as 
indicated. Following incubation half the reaction was treated with Lambda phosphatase. 
Samples were analysed by SDS PAGE and western blotted for MCM2 and MCM4. 
Marker is PageRuler Plus Prestained (Thermo Scientific). 
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 differentially expressed and activated to control DNA replication initiation and 
so MCM2-7 is usually exposed to kinases in a specific order and over a gradient 
of concentrations. In mammalian cells, hMCM would be exposed to cyclin 
E/CDK2 in G1 phase followed by cyclin A/CDK and DDK in S phase (Fig. 5.1). 
Therefore, I wanted to investigate if the order in which hMCM is exposed to 
cyclin A/CDK2 and DDK is important in inducing the increased mobility of 
MCM2. This analysis requires inhibitors that are specific to either CDK2 or DDK. 
Roscovitine is a CDK inhibitor that has been extensively used and is specific to 
CDKs (Meijer et al., 1997). Addition of 20 µM roscovitine to hMCM in the 
presence of cyclin A/CDK2 was sufficient to inhibit the phosphorylation of 
MCM4 (Fig. 5.9A, compare lanes 2 and 3). However, in the presence of DDK and 
cyclin A/CDK2, 20 µM roscovitine did not block the shift to increased mobility of 
MCM2 (Fig. 5.9A, compare lanes 4 and 5). This raises the possibility that the 
effect of cyclin A/CDK2 on MCM2 mobility may be kinase independent. To test 
this, the effect of cyclin A and DDK on hMCM was monitored and found not to 
induce the shift of MCM2 (Fig. 5.9B, lane 2). Another possibility is that only a 
small amount of CDK kinase activity is required to increase the mobility of 
MCM2 (less than that required to shift MCM4). Agreeing with this theory, 0.2 
mM roscovitine (10-fold higher than used previously) was sufficient to inhibit the 
MCM2 shift (Fig. 5.9B, lane 1). 
PHA-767491 is a newly identified Cdc7 inhibitor, which has been shown to 
inhibit both DDK activity and CDK2 activity (Montagnoli et al., 2008, Natoni et 
al., 2011). However, in cells, the concentration required to inhibit CDK is 20 fold 
more than DDK activity (Montagnoli et al., 2008). Using 20 µM PHA-767491, the 
MCM2 shift was not inhibited; however, the CDK dependent MCM4 shift was 
inhibited (Fig 5.10A, compare lanes 1 and 2). This implies that, at the 
concentrations used, PHA-767491 is not specific to DDK in this purified system. 
To optimise the use of PHA-767491, the minimum amount of DDK required to 
induce the MCM2 shift was determined (Fig. 5.10B). The data show that 35 nM 
DDK is capable of inducing the MCM2 shift and that this can be inhibited by 20 
µM PHA-767491 (Fig. 5.10B, compare lanes 4 and 5). However, the CDK 
dependent shift of MCM4 is also inhibited, illustrating that CDK activity is also 
affected. Therefore, PHA-767491 was titrated down to identify the minimal 
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Figure 5.9. Effect of the CDK2 inhibitor roscovitine on MCM2 and MCM4 mobility shifts. 
A. Recombinant hMCM was exposed to 0.02 mM roscovitine before and during incubation 
with recombinant kinases as indicated. Samples were analysed by SDS PAGE and 
western blotted for MCM2 and MCM4. 0.02 mM roscovitine inhibits MCM4 shift (compare 
lanes 2 and 3) but is not sufficient to inhibit MCM2 shift (lanes 4 and 5).  B. As in (A) using 
0.2 mM roscovitine, which inhibits both MCM2 and MCM4 shift (Lane 1). Marker is 
PageRuler Plus Prestained (Thermo Scientific).
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Figure 5.10. Effect of DDK inhibitor PHA-767491 on MCM2 mobility shift. A. Recombinant 
hMCM was exposed to PHA-767491 before and during incubation with recombinant 
kinases as indicated. Samples were analysed by SDS PAGE and western blotted for 
MCM2 and MCM4. 20 μM PHA-767491 inhibits MCM4 shift but not MCM2 shift (compare 
lanes 1 and 2). B. As in A. but using reduced concentrations of DDK as indicatited. 35 nM 
DDK is sufficient to induce MCM2 shift and is inhibited by 20 μM PHA-767491 (compare 
lanes 4 and 5). C.  As in B. PHA-767491 inhibits the mobility shift of MCM2 at lanes 
highlighted with arrow.  Marker is PageRuler Plus Prestained (Thermo Scientific).
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 concentration that is able to inhibit the MCM2 mobility shift (Fig. 5.10C). Three 
concentrations were identified (20 µM, 10 µM and 5 µM), 10 µM PHA-767491 (10-
fold lower than used previously) was chosen for future experiments. In these 
experiments the use of an ATP regenerating system means that the ATP 
concentration cannot be determined. As both of these inhibitors are ATP 
competitive this is an important consideration when analysing kinase inhibition. 
To analyse if the order in which hMCM is exposed to cyclin A/CDK2 or DDK 
affected the mobility shift, hMCM was incubated with either cyclin A/CDK2 or 
DDK, which was subsequently inhibited before addition of the second kinase 
(Fig. 5.11A). Using 10 µM PHA-767491 inhibition is specific to DDK as the 
decreased mobility of MCM4 is apparent in both the presence and absence of 
PHA-767491 (Fig. 5.11B, compare lanes 4 and 9). The mobility shift of MCM2 is 
observed when cyclin A/CDK2 is added before DDK (Fig. 5.11B, lane 5), but not 
when added in the reverse order (Fig. 5.11B, lane 6). However, there does appear 
to be a small increase in mobility when DDK is added before CDK, possibly due 
to a conformational change in the denatured MCM2. Also when DDK is added 
before cyclin A/CDK2, MCM4 appears to have a different mobility shift to when 
the kinases are added at the same time (Fig. 5.11B, compare lanes 6 and 7). This 
suggests DDK alters the ability of cyclin A/CDK2 kinase to access potential 
phosphorylation sites on MCM4.  
Thus, the results suggest the following hypothesis; cyclin A/CDK2 activity 
causes a conformational change in the hMCM hexamer, which allows DDK to 
access phosphorylation sites on MCM2 previously concealed (Fig. 5.11C). This 
results in the forms of MCM2 and MCM4 usually seen only in S phase cells 
(Masai et al., 2006, Fujita et al., 1998). Studies analysing a bacterially expressed 
recombinant N-terminal fragment of MCM2, revealed the same DDK 
phosphorylation sites, independent of CDK2 pre-phosphorylation (Montagnoli et 
al., 2006). This suggests that pre-phosphorylation by CDK2 may only be required 
when MCM2 is within the MCM2-7 complex, and may therefore occur to 
subunits other than MCM2 and MCM4. In S. cerevisiae MCM6 has been shown to 
be a target for DDK and so is a possible candidate (Francis et al., 2009).  
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AFigure 5.11. Order of addition experiment which shows that cyclin A/CDK2 must act 
before DDK in order to induce the MCM2 mobility shift. A. Schematic to show order in 
which cyclin A/CDK2 (A) or DDK (D) is incubated with hMCM. The kinase is then 
specifically inhibited using either roscovitine (CDK2 inhibitor - Ai) or PHA-767491 (DDK 
inhibitor – Di) before addition of the second kinase. The effect is monitored by the mobility 
of MCM2 and MCM4 in SDS PAGE. B. Western blot shows that 10 μM PHA-767491 does 
not inhibit MCM4 shift (compare lanes 4 and 9). MCM2 shift is only apparent if hMCM was 
incubated with cyclin A/CDK2 before addition of DDK (compare lane 5 and 6). Marker is 
PageRuler Plus Prestained (Thermo Scientific). C. Interpretation of results, low 
concentrations of cyclin A/CDK2 phosphorylate an unknown MCM subunit. Higher 
concentrations of cyclin A/CDK2 hyperphosphorylates MCM4. Pre incubation with cyclin 
A/CDK2 causes a conformational change in the hexameric complex allowing DDK to 
access additional phosphorylation sites, and cause a conformational change in MCM2.
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In S. cerevisiae the only essential targets for CDK in S phase are Sld2 and Sld3 
(Zegerman and Diffley, 2007, Tanaka et al., 2007). However in G1 phase CDK is 
required for processes other than activation of S phase (Zegerman and Diffley, 
2007). The use of roscovitine (Fig. 5.9) demonstrates that only a low concentration 
of cyclin A/CDK2 is required to prime the MCM2-7 hexamer for DDK activity. 
Consistent with this, when recombinant hMCM is incubated with mid-G1 phase 
nuclei and extract, the mobility of MCM2 is increased with the addition of only 
recombinant DDK (Fig. 5.6B, right). This suggests that in mid-G1 phase, when 
cyclin A/CDK2 levels are low, hMCM is pre-phosphorylated leaving the 
complex susceptible to further phosphorylation by DDK in S phase.  
5.5 Conclusions 
Using a cell free system based on nuclei and extracts from defined points in G1 
phase, recombinant hMCM can be loaded onto chromatin in a manner that is 
promoted by recombinant cyclin E/CDK2 within a narrow concentration range 
(Fig. 5.4B), and down-regulated in extracts from late G1 phase (Fig. 5.2 and 5.3). 
Regulated loading leads to an increase in the number of nuclei able to replicate 
their DNA in vitro (Fig. 5.5B), showing that in vitro loaded recombinant hMCM is 
functional. This system enables evaluation of the process requirements and the 
regulatory sites involved in hMCM loading and activation. 
Using entirely recombinant proteins, I have demonstrated both cyclin A/CDK2 
and DDK are required to shift recombinant MCM2 (in the context of hMCM 
hexamer). Moreover, MCM4 (but not MCM6) is affected under the same 
conditions implying a structural alteration. The phosphorylated forms of MCM2 
and MCM4 are normally exclusively found in S phase. This is the first time 
phosphorylation of naïve MCM2-7 has been studied and the results clearly show 
that to induce the increased mobility form of MCM2, the hMCM hexamer must 
be exposed to cyclin A/CDK2 prior to DDK.   
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 6 Discussion and future work 
The mechanistic biology of the initiation of DNA replication is relevant to ageing 
(Flach et al., 2014, reviewed in Minton, 2014) and cancer (Blow and Gillespie, 
2008). Abnormalities in licensing can lead to re-replication, replication stress and 
genomic instability, which are powerful drivers toward the acquisition of 
mutations. MCM proteins, as well as other components of the pre-RC, are 
elevated in a range of cancer types and have been shown to have diagnostic 
value (Gonzalez et al., 2005, Hook et al., 2007, Williams and Stoeber, 2007, Xouri 
et al., 2004, Lau et al., 2007, Dudderidge et al., 2010, Lau et al., 2010, Neskoromna-
Jedrzejczak et al., 2010, Kelly et al., 2012, Williams and Stoeber, 2012, Coleman 
and Laskey, 2009). The mechanistic implications of elevated expression of MCM 
proteins and potential strategies to intervene, hinge on a detailed knowledge of 
the process as it occurs in mammalian cells. Understanding the regulation of 
MCM2-7 in mammals has potential to generate information that can be translated 
for the benefit of human health, and will yield insight into a fundamental 
biological process.  
To expand on the current knowledge of MCM2-7 loading and activation in 
eukaryotes, mainly generated from studies in S. cerevisiae, my thesis analyses 
MCM2-7 in mammals. I have produced data regarding the production and 
characterisation of recombinant hMCM, the profile of endogenous MCM2-7 
expression and localisation, evidence that probes the functional loading of 
hMCM in isolated nuclei and phosphorylation of naïve hMCM.  
6.1 Recombinant hMCM is active 
We have produced the first recombinant hMCM in E. coli (Chapter 3). To date, 
analysis of MCM2-7 activity has been determined for complexes purified from 
eukaryotic systems or recombinantly expressed in eukaryotic systems (Ilves et 
al., 2010, Moyer et al., 2006, Bochman and Schwacha, 2008). Thus, may not be 
naïve due to phosphorylation by cellular kinases present in the expression 
systems. Phosphorylation may inhibit or activate the MCM2-7 complex. Using 
ATP hydrolysis assays and helicase assays, I have demonstrated that 
149
 recombinant hMCM is active in the absence of any post-translational 
modifications, suggesting ‘activating kinases’ are not required for duplex 
unwinding. In the present work, the DNA template used is a naked forked DNA 
substrate (Appendix B, Fig. B1). The implications of kinases on unwinding DNA 
packaged into chromatin are not clear. Accessory proteins such as Cdc45 and 
GINS in addition to kinase activities may be required for unwinding packaged 
DNA in a nuclear environment.  
6.1.1 hMCM stoichiometry  
An initial human MCM complex purified from HeLa cells was found in a dimer 
of trimers conformation - two of each MCM4, 6 and 7 (Ishimi, 1997). Currently 
the stoichiometry of our recombinant hMCM is unknown. Homohexameric 
MCM complexes and sub-complexes containing MCM4, 6 and 7 have ATP 
hydrolysis activity that is stimulated by DNA (Ishimi et al., 1998, Lee and 
Hurwitz, 2000, Lee and Hurwitz, 2001, You et al., 2003, Liew and Bell, 2011, 
McGeoch et al., 2005, Kasiviswanathan et al., 2004). In contrast, the ATP 
hydrolysis activity of our recombinant hMCM and heterohexameric MCM2-7 
from S. cerevisiae, is not stimulated by DNA (Fig. 3.10B, Schwacha and Bell, 2001, 
Davey et al., 2003, Bochman and Schwacha, 2008). As our hMCM behaves in a 
similar way to S. cerevisiae MCM2-7 this suggests our hMCM is heterohexameric. 
Furthermore, our EM reconstructions show asymmetric symmetry (Fig. 3.14). 
Investigation into the stoichiometry of hMCM would consolidate future analysis. 
Size Exclusion Chromatography - Multi-Angle Laser Light Scattering (SEC-
MALLS) would allow identification of the exact molecular weight of hMCM (567 
KDa if heterohexameric, 580 KDa if a dimer of MCM4, 6, 7). In addition, to 
investigate the homogeneity, SEC-MALLS could be used to compare hMCM 
alone with hMCM bound by an antibody that is specific to MCM2, 3 or 5 as these 
are not found in the MCM4, 6, 7 sub-complex. If the sample is pure 
heterohexameric hMCM, there will be a shift in the size of the total sample. If the 
sample is a mixture of dimer of trimers and heterohexameric hMCM, the output 
will be two peaks.  
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 6.1.2 Essential residues in hMCM 
Recombinant hMCM allows detailed analyses of essential residues. A number of 
conserved residues have been identified in lower organisms such as; the h2i 
mutation which inhibits helicase activity but not ATP hydrolysis (Jenkinson and 
Chong, 2006) and MCM2-G400D in S. cerevisiae, which bypasses a requirement 
for MCM10 in origin firing (Lee et al., 2010). The identification of essential 
residues in hMCM would allow researchers to extend our understanding from 
archaea and S. cerevisiae to mammalian systems. In addition, the production of 
phosphomimetic mutants and insertion of unphosphorylatable residues could be 
used to analyse the MCM2-7 control by kinases (see below for more details). 
6.2 Recombinant hMCM undergoes a conformational change 
when bound to DNA 
Production of asymmetric single particle hMCM reconstructions demonstrated 
that MCM2-7 undergoes a conformational change when bound to DNA (Fig. 3.14 
– 3.16). In the presence of DNA, our structure appears similar to previous EM 
studies of MtMCM and S. cerevisiae MCM2-7 (Yu et al., 2002, Pape et al., 2003, 
Samel et al., 2014). However, EM reconstructions of MCM2-7 purified from 
Drosophila and E. cuniculi demonstrate MCM2-7 is naturally found in a ‘cracked 
ring’ conformation (Fig. 1.3B, Costa et al., 2011, Lyubimov et al., 2012). 
Importantly these studies analyse Drosophila or E. cuniculi MCM2-7 produced in 
Baculovirus and so may not be naïve complexes due to possible phosphorylation 
by host cellular kinases. In addition, E. cuniculi MCM2-7 is a simplified MCM2-7 
model, which lacks the N-terminal domain in each subunit (Lyubimov et al., 
2012). S. cerevisiae and mammalian MCM2 and MCM4 are phosphorylated at 
residues in the N-terminal domain by cellular kinases (Sheu and Stillman, 2006, 
Masai et al., 2006, Masai et al., 2000, Devault et al., 2008, Sheu and Stillman, 2010, 
Montagnoli et al., 2006, Cho et al., 2006, Tsuji et al., 2006, Montagnoli et al., 2008). 
Furthermore, the N-terminal of MCM4 in S. cerevisiae is believed to inhibit DNA 
replication and this inhibition is alleviated by phosphorylation (Sheu and 
Stillman, 2010). Together these data suggest the N-terminal segments of MCM 
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 proteins may be essential for opening the MCM2-7 ring and so may represent an 
important intermediate conformation in MCM2-7 loading. 
6.2.1 Subunit arrangement and orientation 
The crystal structure of archaeal SsoMCM has been fitted into our hMCM EM 
reconstructions (Fig. 3.15 and 3.16, Brewster et al., 2008). However the orientation 
of the complex is not explicit. The crystal structures were fitted into our EM maps 
using Chimera (Goddard et al., 2007). The X-ray crystallography fits contain the 
least amount of error, i.e. with the largest amount of the crystal structure fitted 
within our EM maps (Fig. 3.15 and 3.16). The orientation shown is preferential as 
it gives the lowest amount of error using Chimera (Goddard et al., 2007). To 
identify the correct orientation of our reconstructions, hMCM bound to a gold-
labelled antibody could be analysed by EM. The gold-labelled antibody would be 
detected by EM and allow identification of the hMCM subunit to which it is 
bound. If the antibody is specific for either the N-terminal or C-terminal of an 
hMCM subunit it will allow identification of subunits orientation. 
6.2.2 Which MCM2-7 subunit preferentially binds DNA? 
The hMCM reconstruction in the presence of DNA has a projection on one 
subunit (Fig. 3.14, red circle). This projection could be either bound DNA or the 
purification tags on MCM7 (molecular weight is 15 KDa) that have been 
displaced by the addition of DNA. If the projection was DNA it would be 
interesting to investigate if a particular subunit of hMCM preferentially binds to 
the DNA. Currently there is no literature that shows preferential DNA binding to 
a particular subunit, this could be identified using gold-labelled antibodies as 
described above. 
6.2.3 X-ray crystal structure of hMCM 
I have sent 9 mg of recombinant hMCM to Xiaojiang Chen, a collaborator at the 
University of Southern California, for X-ray crystallography analysis. To date the 
only X-ray crystallography images of MCMs are from homohexameric archaeal 
complexes (Fletcher et al., 2003, Liu et al., 2008, Bae et al., 2009, Brewster et al., 
2008, Miller et al., 2014, Froelich et al., 2014). An X-ray crystallography structure 
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 of the hMCM will allow us to analyse how the subunits interact with each other 
and so will give further insight into the mechanism of functional 
heterohexameric hMCM. One gap in our current knowledge concerning the 
eukaryotic MCM complex relates to the heterohexameric nature of this complex. 
Data from S. cerevisiae show that the subunits are not functionally equivalent 
(Labib et al., 2000, Kang et al., 2014), but how this inequivalence relates to the 
mechanism of unwinding is unclear. Production of an X-ray crystallography 
structure of hMCM is likely to yield useful insights into how ATP hydrolysis, 
DNA translocation and duplex unwinding all occur in concert and the 
mechanisms of control that can be exerted over these processes.  
6.3 MCM2 is transiently associated with the nuclear matrix at 
initiation 
Chapter 4 adds to the growing body of evidence that initiation of DNA 
replication is spatially constrained by immobilisation of DNA replication 
machinery on the nuclear matrix in mammalian cells, and suggests that 
functional assembly of the MCM2-7 complex occurs during a transient presence 
in nuclear matrix-associated loading bays. However it does not explain why 
association is transient, or give clarity to the mechanism of loading or the 
regulation of ring opening. The data identify a specific point in time and location 
at the nuclear matrix, offering a direct route to the identification of the factors 
that spatially constrain the MCM2-7 complex and mediate its transition from one 
state to another at this critical point in the initiation process in mammalian cells.  
6.3.1 Effect of kinase inhibitors on transient nuclear matrix binding of 
MCM2 
The effect of the specific CDK2 and DDK inhibitors roscovitine (Meijer et al., 
1997) and PHA-767491 (Montagnoli et al., 2008) on recruitment or displacement 
of MCM2 from the nuclear matrix could be monitored over the 15-20 hour 
window. Cells could be synchronised in quiescence and released into the cell 
cycle in the presence of either roscovitine or PHA-767491. This would allow us to 
distinguish if CDK2 and/or DDK activity supports MCM2 nuclear matrix 
binding or release of MCM2 from the nuclear matrix. At 19 hours following 
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 release from quiescence, both phosphorylation species of MCM2 are detectable. 
However nuclear matrix bound MCM2 is exclusively the higher molecular 
weight MCM2, i.e. the naïve, unphosphorylated form (Fig. 4.3B). Consequently, I 
predict that CDK2 and/or DDK inhibition at 18 hours will not prevent MCM2 
recruitment to the nuclear matrix at 19 hours, but will restrict its displacement 
from the nuclear matrix and possibly block initiation. Unfortunately due to time 
constraints and the need to complete other aspects of my project I was unable to 
do these experiments. 
6.3.2 Additional proteins bound to nuclear matrix  
The pre-LC assembles away from chromatin and does not appear to be highly 
conserved between S. cerevisiae and metazoans (see section 1.6.2). This suggests a 
different mechanism in metazoans for the formation of the CMG complex, 
compared with S. cerevisiae, which could involve the nuclear matrix. It would be 
interesting to examine if TopBP1, RecQ4, pol ε and GINS (members of the pre-
LC) have a transient association with the nuclear matrix. In T98G glioblastoma 
cells, pol ε has been shown to be associated with the nuclear matrix from the 
G1/S border throughout S phase (Vaara et al., 2012), indicating the pre-LC may 
assemble at the nuclear matrix. However, in asynchronous HeLa and human 
fibroblast cells, RecQ4 has been shown to be not associated with the nuclear 
matrix (Petkovic et al., 2005, Sharma and Brosh, 2007). If the association of RecQ4 
is transient, evidence of its nuclear matrix association in an asynchronous 
population of cells may be difficult (as with MCM2, Chapter 4). Furthermore the 
cell line chosen to analyse nuclear matrix associated proteins is essential as 
tumours, transformed cells in culture, and stem-like cells (Munkley et al., 2011, 
Zink et al., 2004) appear to have a compromised or immature nuclear matrix. To 
date there are no publications which analyse the relationship of TopBP1 or GINS 
with the nuclear matrix. 
Identification of additional proteins bound to the nuclear matrix at the same time 
as MCM2 (such as components of the pre-LC or pre-IC) may allow us to 
understand more about the loading process. Nuclear matrix preparations from 19 
hour nuclei could be evaluated for the presence of proteins involved in MCM2-7 
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 complex loading and function. Analysis over a time course as shown in Fig. 4.4, 
will allow evaluation of whether association is similarly transient, or extends 
through late G1 and S phases. I expect pre-LC components to be detected in the 
nuclear matrix fraction before MCM2 association, possibly for a longer period of 
time. However, I would expect to find a short transient association of pre-IC 
components with the nuclear matrix in a similar way to MCM2.  
6.3.3 Identification of novel proteins involved in DNA replication initiation 
Novel mammalian proteins whose role is to spatially constrain loading by 
anchoring it to the nuclear matrix could be identified by DNase I extraction. To 
do this, standard synchrony experiments could be scaled up to generate DNase I 
nuclear matrix preparations from 19 hour nuclei, after protein-protein cross-
linking with DTSP (Baumert and Fasold, 1989, as described for Fig. 4.5). Partner 
proteins would be isolated by immunopreticipitation (IP) and identified by 
tandem mass spectrometry (MS/MS). This would be a powerful and focused 
way to build a picture of the nuclear matrix-associated MCM ‘loading bay’ and 
could be controlled by comparison to pre or post 19 hour populations. Novel 
proteins identified as nuclear matrix bound at 19 hours could be tested for 
essentiality using short interfering (si) RNA. If proteins are essential, for DNA 
replication initiation, depletion of the newly identified proteins would stall cells 
prior to S phase.  
6.4 Regulated hMCM loading 
Recombinant hMCM can be functionally loaded in isolated mammalian nuclei 
(Chapter 5). Loading of hMCM has, reproducibly, been shown to be a regulated 
event, as a mid-G1 extract (low kinase activity) supports loading more efficiently 
than a late-G1 phase extract (high kinase activity, Fig. 5.2 and 5.3). This is 
consistent with cell free experiments in S. cerevisiae where pre-RC loading has 
been shown to assemble on template DNA only when CDK levels are low 
(reviewed in Sclafani and Holzen, 2007). Addition of low levels of recombinant 
cyclin E/CDK2 to cell free experiments boosts hMCM loading and the ability of 
nuclei to initiate DNA synthesis (Fig. 5.4A and 5.5). This is consistent with 
previous analysis in mammalian cells (Coverley et al., 2002, Geng et al., 2003, 
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 Ohtsubo and Roberts, 1993), where cyclin E was shown to cooperate with Cdc6 
to load endogenous MCM2. Monitoring histone H3 concentration in a 8% gel 
may not be an accurate method for measuring nuclei concentration and so 
although this method has been used widely in the literature (Coverley et al., 
1998, Coverley et al., 2002, Coverley et al., 2005) a more accurate way of 
measuring nuclei content, such as immunofluorescence experiments (as 
described in 2.9.2.2) could be used in future experiments.  
6.4.1 What component of late-G1 phase extract inhibits hMCM loading? 
The component/s in late-G1 phase extract, which restrict hMCM binding, are not 
known. Analysis of the effect of DDK on hMCM loading, suggests low 
concentrations of DDK could be responsible (Fig. 5.6). To test this hypothesis 
specific inhibitors such as roscovitine (Meijer et al., 1997) or PHA-767491 
(Montagnoli et al., 2008) to inhibit CDK2 and DDK respectively could be added 
to the extract to examine if hMCM binding is restored to that of mid-G1 phase 
extract. 
6.4.2 Ability of ATPase deficient mutant hMCM to functionally load onto 
chromatin 
In Xenopus egg extracts, mutation in the Walker A motif of MCM6 and MCM7 to 
inhibit ATP hydrolysis in these subunits, has been shown to have no effect on 
MCM2-7 loading but inhibits DNA replication initiation (Ying and Gautier, 
2005). However, a recent study of S. cerevisiae MCM2-7 suggests ATPase activity 
of all subunit interfaces, other than MCM3/7, are required for loading (Kang et 
al., 2014, Coster et al., 2014). To test if ATP hydrolysis by recombinant hMCM is 
necessary for loading, our ATPase deficient mutant hMCM (Chapter 3) could be 
analysed using cell free loading reactions in the same way as WT hMCM 
(Chapter 5). This would identify if in mammals, the ATPase domains are 
required for loading and/or activation. Further more, individual MCM subunits 
could be mutated (Kang et al., 2014, Coster et al., 2014). Mutants could be tested 
in cell free loading and synthesis experiments (Chapter 5) in order to understand 
the different ATPase domains in mammalian MCM2-7.  
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 6.4.3 Does hMCM bind to the nuclear matrix? 
Functional loading of hMCM has been demonstrated, however the ability of 
hMCM to bind to the nuclear matrix has not been tested. Assembly of hMCM on 
chromatin compared to the nuclear matrix could be assessed using the cell free 
system. Nuclei could be loaded with recombinant hMCM (Chapter 5) and 
subsequently treated with DNase I to reveal proteins that are immobilised by 
attachment to the nuclear matrix (Chapter 4). Recombinant hMCM would be 
detected using specific antibodies (such as His-tag, Trx tag or S tag) to ensure the 
hMCM analysed by immunofluorescence was recombinant hMCM rather than 
endogenous MCM2-7.  
6.4.4 Effect of DDK on in vitro DNA replication initiation 
Low concentrations of DDK inhibited hMCM loading but higher concentrations 
of DDK had little effect on loading (Fig. 5.6). This is an unusual result, which 
should be repeated to confirm. In S. cerevisiae, DDK is believed to be the 
activating kinase involved in transitioning loaded double MCM2-7 hexamers to 
single hexamers that are capable of unwinding DNA (reviewed in Labib, 2010, 
Araki, 2010). However, recent work suggests in S. cerevisiae and Xenopus, DDK 
phosphorylation is not responsible for double MCM2-7 hexamer separation 
(Gambus et al., 2011, On et al., 2014). It would be interesting to assess the 
functionality of loaded hMCM in the presence of DDK by incubating nuclei pre 
loaded with hMCM and DDK (as in Fig. 5.6) followed by incubation in S phase 
extract (as in Fig. 5.5). The work described above would allow us to analyse if 
DDK is the ‘activating kinase’ in a mammalian system.  
6.5 MCM2 undergoes a structural change by the sequential action 
of cyclin A/CDK2 followed by DDK 
I have recapitulated in vitro the mobility shift of MCM2 and MCM4 associated 
with S phase of the cell cycle using entirely recombinant proteins (Fig. 5.7). There 
have been discrepancies in the data that reports on the order of addition in which 
eukaryotic cells require kinases to initiate DNA synthesis (reviewed in Sclafani 
and Holzen, 2007, Labib, 2010). In an S. cerevisiae cell free assay, DDK has been 
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 shown to be required before CDK for initiation (Heller et al., 2011). Conversely 
another study also analysing S. cerevisiae, demonstrated CDK is required before 
DDK (Nougarede et al., 2000). In Xenopus egg extracts, DDK has been shown to 
act before CDK (Jares and Blow, 2000, Walter, 2000). It is suggested that these 
inconsistencies are due to the experimental approaches used (Heller et al., 2011). 
In addition, differences could also be species specific. What theses studies do not 
do is distinguish between the kinase concentrations at each stage. For example it 
is not unreasonable to think that CDK acts before and after DDK, possibly at a 
different concentration. The results presented here, clearly show that naïve 
hMCM must be exposed to CDK activity before DDK activity to induce the form 
of MCM2 associated with S phase.  
6.5.1 Effect of phosphorylation on hMCM hexamer 
When the hMCM hexamer is resolved on native PAGE (Fig. 5.7B), different 
results are obtained when blotted for different subunits. Both MCM2 and MCM4 
run at approximately 480 KDa as expected for the heterohexamer (predicted 
molecular weight = 567 KDa). Whereas MCM6 runs at approximately 700 KDa. 
These results could suggest a mixed population of hMCM sub-complexes within 
the preparation or could simply be artifacts associated with running hMCM on 
native PAGE. To further analyse this, hMCM could be cross-linked with DTSP 
before running on the gel (Baumert and Fasold, 1989) to ensure the complex stays 
together and the complexes analysed are representative of the original 
preparation.  
Another possibility is that the MCM6 band observed is aggregated MCM6 
subunit. MCM6 has been shown to form a homohexamer in Pisum sativum (Tran 
et al., 2010). To investigate if this band is in fact aggregated MCM6 or if other 
MCM proteins are present, this band could be isolated, analysed by SDS PAGE 
and blotted for the remaining MCM subunits. 
6.5.2 Role of phosphorylated MCM2 in DNA replication 
The mobility shifts observed for MCM2 and MCM4 are associated with S phase 
(Masai et al., 2006, Fujita et al., 1998), however the function of these complexes is 
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 not understood. Mutant S. cerevisiae MCM2 expressed at endogenous levels, with 
either one (Ser170) or two (Ser164 and Ser170) unphosphorylatable sites, grow 
normally (Stead et al., 2011). In contrast to this, introduction of one 
unphosphorylatable site in S. cerevisiae MCM2 (Ser170) has been shown to inhibit 
cell growth (Bruck and Kaplan, 2009). Differences between these results are 
thought to be due to expression levels of mutant proteins within the S. cerevisiae 
cell. Phosphomimetic mutant MCM2-7 (Ser164 and Ser170) reduced helicase 
activity by 50% compared to WT MCM2-7 due to increased DNA binding 
capability of the phosphomimetic mutant MCM2-7 (Stead et al., 2011). However 
these sites are not conserved in human MCM2-7. Analysis of human MCM2-7 in 
HeLa cells demonstrates DDK phosphorylation is critical for ATP hydrolysis 
activity (Tsuji et al., 2006). However our naïve recombinant hMCM clearly 
demonstrates ATP hydrolysis activity in the absence of DDK phosphorylation.   
It would be interesting to analyse if recombinant hMCM in relation to the current 
contrasting results regarding MCM2-7 phosphorylation by DDK. The activity of 
in vitro phosphorylated hMCM could be tested using ATP hydrolysis, DNA 
binding, duplex unwinding and processivity assays. In addition, analysis of in 
vitro phosphorylated hMCM in activity assays (as in Fig. 5.5) could be used to 
understand if this form of hMCM is able to initiate DNA synthesis in vitro. 
Ultimately this analysis will allow us to understand if mobility shifted hMCM is 
active or inactive.  
6.5.3 Analysis of phosphorylation sites on hMCM 
To investigate the MCM2 sites that are phosphorylated by sequential addition of 
cyclin A/CDK2 and DDK, in vitro phosphorylated hexamer preparations could 
be evaluated using phospho-site specific antibodies (Montagnoli et al., 2006). 
Strongly implicated sites could be mutated to produce phosphorylation-deficient 
or phosphomimetic hMCM2 and expressed as recombinant hexamer. Purified 
proteins could be subjected to functional analysis using biochemical assays to 
evaluate the effect of mutation on unwinding of naked forked templates, using 
strand displacement assays. Phosphomimetic mutant hMCM complexes could 
also be analysed in cell free activity assays (as in Fig. 5.5), to understand if 
mutants are able to initiate DNA synthesis in vitro.  
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 6.5.4 Is the mobility shift of MCM2 due to a conformational change? 
The impact of phosphorylation on the mobility of MCM2 and the possibility for a 
conformational change, has not been investigated. EM data suggest that the 
MCM2-7 hexamer can adopt different conformations and assembly states during 
the transition from loading to activation (Costa et al., 2014). The phosphorylated 
MCM2-7 complex with the increased mobility form of MCM2 could represent a 
crucial conformational change involved in MCM2-7 function. One possibility is 
that this MCM2-7 complex is open at the 2/5 gate (Fig. 1.2, Costa et al., 2011, 
Lyubimov et al., 2012). Another possibility could involve a conformational 
change resulting in splitting the MCM2-7 double hexamer. Reconstituted pre-RC 
complexes contain double hexamers (Gambus et al., 2011, Evrin et al., 2009, 
Remus et al., 2009), which when treated with DDK, undergoes a small 
conformational change, that can be observed using EM. However, the double 
hexamer does not split (On et al., 2014), suggesting that DDK is not sufficient to 
split the MCM2-7 double hexamer and initiation of DNA replication. In this 
study, researchers did not use both CDK and DDK for phosphorylation and the 
extent of MCM2-7 phosphorylation is not clear leaving the question open.  
In vitro phosphorylated hexamer preparations could be subjected to cryo-EM 
structural analysis to visualise induced alterations in hexamer structure and then 
compared to naïve hMCM structures. It is becoming clear that conformational 
changes to hMCM are key to understanding how it is loaded and activated 
(Costa et al., 2014, Costa et al., 2011) and so it would be interesting to investigate 
if the MCM2-7 species induced by CDK2 and DDK phosphorylation in vitro, is 
active in in vitro biochemical assays and how it behaves in cell free loading and 
replication assays. 
6.6 How does MCM2-7 unwind DNA?  
The open centre of the MCM2-7 hexamer is large enough to accommodate either 
single stranded DNA or double stranded DNA (Evrin et al., 2009, Remus et al., 
2009). Recent studies suggest that when incorporated into the CMG complex, 
MCM2-7 encircles single stranded DNA (Fu et al., 2011, Costa et al., 2014). If 
reconciled with the idea that MCM proteins are located outside of replication 
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 factories during DNA synthesis (Kuipers et al., 2011, Dimitrova et al., 1999, 
Krude et al., 1996, Madine et al., 1995), this implies that template DNA is in 
single stranded form between the site of DNA synthesis and the site of helicase 
action. This is similar to the ‘rotary pump’ mechanism (reviewed in Laskey and 
Madine, 2003). However, this mechanism for unwinding DNA would require 
long lengths of single stranded DNA between the MCM2-7 helicase and the site 
of DNA replication that may be vulnerable to breakages. 
6.7 Conclusions 
In summary, this thesis shows a transient interaction of MCM2-7 with the 
nuclear matrix (Chapter 4) and that naïve hMCM undergoes a conformational 
change when treated with S phase kinases (Chapter 5) that is not associated with 
the nuclear matrix. Previous research on MCM2-7 and the data presented here, 
suggests the following order of events. Naïve MCM2-7 is functionally loaded 
onto chromatin at origins of replication. MCM2-7 is recruited to the nuclear 
matrix where it is activated by S phase kinases, causing dissociation from the 
nuclear matrix but continued association with chromatin. This suggests that 
activated MCM2-7 ‘pumps’ single stranded DNA towards replication factories 
located at the nuclear matrix where DNA is replicated (Fig. 6.1). 
The aims of this thesis were to combine two branches of research, biochemical 
and cell based biology. I have successfully developed both areas and brought the 
two elements together in the cell free assays, a system that allows analysis of the 
functional assembly of the mammalian MCM2-7 complex. Due to the 
discrepancies observed between S. cerevisiae and mammalian systems there is a 
need to move research into mammalian systems so that the details can be used to 
design novel, specific inhibitors that may find application as cancer therapies. 
Production of naïve, recombinant hMCM will allow analysis of the specific 
molecular function of the human DNA replication mechanism. Ultimately these 
insights could be important for our ability to manipulate cell proliferation and 
therefore design useful and specific cancer treatments.  
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Figure 6.1. Model for MCM2-7 unwinding. Naïve MCM2-7 binds to chromatin as a double 
hexamer and is recruited to the nuclear matrix. Sequential phosphorylation of MCM2-7 by 
cyclin A/CDK2 followed by DDK causes a conformational change in MCM2-7. The double 
hexamer splits and dissociates from the nuclear matrix. The single MCM2-7 hexamer is 
now active and pumps single stranded DNA towards replication machinery. Additional 
proteins involved in MCM2-7 loading, such as the pre-IC and pre-LC are omitted for 
simplicity. 
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 Appendix A 
The following work has been accepted for publication in Cold Spring Harbor 
Protocols. It provides an in detail introduction and protocol into the methods 
used in Chapter 4 to extract the nuclear matrix using DNase I.   
163
Chapter 
The nuclear matrix: preparation for microscopy and biochemical analysis 
Topic introduction 
The nuclear matrix: fractionation techniques and analysis  
Short title: Nuclear matrix fractionation 
Wilson, R. H. C.1* Hesketh, E.1 and Coverley, D.1 
1 Department of Biology, University of York, Wentworth Way, York, YO10 5DD, UK 
* Corresponding author: Wilson, R. H. C. rhcw500@york.ac.uk, 01904 328569 
The first descriptions of an insoluble nuclear structure appeared more than 70 years ago, but it is only 
in recent years that a sophisticated picture of its significance has begun to emerge. In this article we 
explain multiple methods for the study of the nuclear matrix. These have led to the understanding that 
the nuclear matrix consists of core components that are consistently present, such as matrins, lamins, 
hnRNPs and other ‘structural’ proteins, and conditional proteins that are recruited into the nuclear 
matrix to facilitate specific processes (Mika and Rost 2005). These include components of the DNA 
replication machinery (reviewed in Wilson & Coverley 2013), transcription machinery (Jackson and 
Cook 1985), DNA repair (Qiao et al. 2001; Boisvert et al. 2005; Campalans et al. 2007), splicing 
(Zeitlin et al. 1987; Jagatheesan et al. 1999) and chromatin remodelling (Reyes et al. 1997) as well as 
a catalogue of proteins identified by proteomic analysis (Albrethsen et al. 2009). In most cases the 
functional significance of their immobilisation remains an area of study, nevertheless, a number of 
nuclear matrix proteins are already gaining credibility as clinically useful biomarkers (Keesee et al. 
1999; Subong et al. 1999; Van Le et al. 2004; Higgins et al. 2012). 
A brief history 
Descriptions of a protein fraction that is resistant to extraction under high salt conditions were first 
made in 1942 (reviewed in Pederson 1998). However, the term ‘nuclear matrix’ was first used in 1974 
to refer to those proteins resistant to extraction with 2.0 M NaCl (Berezney and Coffey 1974). 
‘Nuclear matrix’ has become widely adopted as an overarching term for the proteins that resist 
aggressive methods of extraction, and we use it as such here. The 2.0 M NaCl method has been 
criticised because of its potential to cause aggregation of proteins. This led to the development of 
more refined extraction methods including lithium 3,5-diiodosalicylate (LIS), which was first used by 
Mirkovitch et al. (1984) to reveal a protein fraction termed the nuclear scaffold, and extraction after 
encapsulation in agarose under physiologically relevant salt concentrations (Jackson and Cook 1988) 
to reveal a substructure known as the nuclear skeleton (or nucleoskeleton). Further variations and 
refinement of these techniques have also been used (reviewed in Martelli et al. 2002). A modification 
of the original nuclear matrix method was developed by Capco et al (1982), which reduced the 
potential for aggregation by using more physiologically relevant buffers with lower salt (0.5 M NaCl) 
and used nucleases (DNase I or other enzymes) to digest chromatin into small diffusible fragments. 
This was termed the ‘in situ nuclear matrix’ as the cytoskeleton is also maintained under these 
conditions. Extraction with 2.0 M NaCl has subsequently been termed the ‘core nuclear matrix’. 
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A simple picture? 
Despite the range of approaches used, some controversies have remained and reviews of the evidence 
for and against the nuclear matrix have come to conflicting conclusions (Pederson 1998; Hancock 
2000; Nickerson 2001; Martelli et al. 2002). It has proved difficult to visualise the filamentous 
structure revealed by electron microscopy, using immunofluorescence-light microscopy, which 
typically reveal punctate foci for most of the 100s of nuclear matrix proteins that have been described. 
However it should be bourn in mind that the proteins which fractionate with the nuclear matrix and 
are identified by proteomic analysis may in fact make up highly dynamic ‘local’ matrices rather than 
one large static structure (Martelli et al. 2002). 
One fundamental biological reason for the debate surrounding existence and nature of the nuclear 
matrix may in fact be that it exists in different forms in different cell types and may even be absent in 
some instances. We and others have shown that nuclear matrix composition varies dramatically with 
differentiation and disease status and that some proteins are actively recruited as part of normal 
cellular transitions (Getzenberg 1994; Zink et al. 2004; Munkley et al. 2011; Varma and Mishra 
2011). Thus a lot of work previously undertaken on cancer cell lines, embryonic cells or Xenopus 
eggs must now be interpreted in this light to avoid clouding the picture in normal somatic cells 
(Munkley et al. 2011). There remains a need for a resurgence in nuclear matrix investigation that 
includes comparative analysis, the protocols that we use for this purpose accompany this topic 
introduction (The nuclear matrix: preparation protocol for parallel microscopy and biochemical 
analysis, Wilson et al. 2013).  
Approaches to functional analysis (for schematic see figure 1) 
Electron microscopy 
The resolution of the electron microscope has allowed detailed visualisation of the fibrilar protein 
network within the nucleus of higher eukaryotic cells (Capco et al. 1982; Fey et al. 1986; Jackson and 
Cook 1988). It has been viewed after RNase digestion (Berezney and Coffey 1974), DNase digestion 
(Capco et al. 1982), removal of chromatin by electroelution (Jackson and Cook 1988) and in a range 
of buffer conditions designed to minimise artefacts (Mirkovitch et al. 1984; Jackson and Cook 1988; 
Nickerson et al. 1997; Engelhardt 1999; Wan et al. 1999). The nuclear matrix has also been viewed in 
paraformaldehyde fixed sections of unextracted nuclei, identifying protein rich inter chromosomal 
areas consistent with the description of a NM (Hendzel et al. 1999).  
Proteomic analysis 
Studies to identify the component parts of the nuclear matrix were compiled in a database of Nuclear 
Matrix Proteins, NMPdb (Mika and Rost 2005). Since then, large-scale proteomic screens have been 
undertaken which compare nuclear matrix components enriched in tumour cells and at different 
developmental stages (Albrethsen et al. 2009; Albrethsen et al. 2010; Varma & Mishra 2011 and 
references therein for methods).  
Analysis of attached DNA  
The proteinaceous structure isolated by nuclear matrix extraction protocols is associated with residual 
DNA as well as RNA. Attachment of DNA was first observed by electron microscopy in the 1970s 
(Paulson and Laemmli 1977). Various methods have since been used to study the attached DNA, 
including digestion of chromatin loops with restriction enzymes, DNase I or topoisomerase II to 
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reveal the attachment points (Mirkovitch et al. 1984; Djeliova et al. 2001; Linnemann et al. 2009; 
Rivera-Mulia et al. 2011), followed by isolation and sequencing, labelling by FISH, or by 
incorporation of nucleotide analogues. DNA that remains attached after extraction with high salt are 
termed MARs (matrix attached region), and those remaining following extraction for the scaffold or 
skeleton are known respectively, as SARs (scaffold attached region), or skeleton-attached sequences. 
The possible functional significance of these classes of attachment has been reviewed previously 
(Wilson & Coverley 2013). 
Related protocols (Maximum Fluorescence Halo Radius) that extract histones and loosely attached 
proteins, but which leave chromatin undigested have been used to study the DNA loops that emanate 
from the attachment points on the nuclear matrix (Vogelstein et al. 1980; Gerdes et al. 1994; Lemaitre 
et al. 2005; Guillou et al. 2010). A method combining nuclear matrix extraction with chromosome 
conformation capture (3C) has also recently been developed, termed M3C (Gavrilov et al. 2010).  
Analysis by CSK protocol 
The following method describes the protocol that we prefer to use for the analysis of nuclear matrix 
related functions. This incorporates serial extraction with non-ionic detergent (Triton–X-100) to 
remove membranes and soluble proteins under physiologically relevant salt concentrations, followed 
by 0.5 M NaCl, then DNase I digestion and removal of fragmented DNA. Complimentary analysis by 
immunoblotting and immunofluorescence reveals information on isoforms and on spatial 
organisation. The protocol uses cytoskeletal (CSK) buffer to stabilise the cytoskeleton and nuclear 
matrix in relatively gentle conditions. CSK was first used by Lenk et al. (1977) and later by Capco et 
al. (1982) for electron microscopy. Others have used it for immuno-detection of individual nuclear 
matrix components (Nickerson et al. 1992; Grondin et al. 1996; Huang et al. 2004; Boisvert et al. 
2005; Ainscough et al. 2007; Campalans et al. 2007), identification of protein domains required for 
nuclear matrix binding (Ainscough et al. 2007), analysis of temporally regulated recruitment (Fujita 
1999; Fujita et al. 2002; Miccoli et al. 2003; Samaniego et al. 2006; Sree et al. 2012), and to compare 
recruitment between developmental or differentiation stages and between disease states (Munkley et 
al. 2011). The benefits of this method include the relatively gentle buffer conditions, potential to 
generate robust results by using imaging and biochemical analysis in parallel, and its flexibility to 
incorporate high salt to reveal the core nuclear matrix, or pre-treatment with a protein-protein 
crosslinker to reveal those proteins only weakly associated with the nuclear matrix. It can also be 
combined with other cellular manipulations for specific questions, such as cell synchrony protocols, 
depletion by RNAi and expression of ectopic proteins. Together, these offer the potential to uncover 
the functional relevance of recruitment to the nuclear matrix. 
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Figure legends:  
Figure 1. Schematic to show available methods for analysis of the nuclear matrix and its functional 
significance.  
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Protocol 
The nuclear matrix: preparation protocol for parallel microscopy and 
biochemical analysis 
Short title: Nuclear matrix protocol 
Wilson, R. H. C.1*, Hesketh, E.1 and Coverley, D.1 
1 Department of Biology, University of York, Wentworth Way, York, YO10 5DD, UK 
* Corresponding author: Wilson, R. H. C. rhcw500@york.ac.uk, 01904 328569 
Abstract 
The immobilisation of nuclear proteins is usually investigated using extraction with detergent to 
reveal attachment to insoluble structures. This is often assumed to be chromatin and is described as 
such in many studies. However, the detergent resistant protein fraction consists of both chromatin-
bound and nuclear matrix-bound proteins. To further separate these fractions DNA should be removed 
and the remaining proteins visualised in comparison to those in unextracted cells. We describe two 
related protocols that identify nuclear matrix proteins by immunofluorescence (IF) or immuoblotting 
(IB). IB has the advantage of resolving different forms of a protein of interest and includes analysis of 
soluble fractions excluded by the IF protocol. IF analysis has the advantage of allowing individual 
cells to be monitored rather than homogenised populations and can be performed on very low quantity 
samples. Analysis by IF will also reveal the spatial arrangement of proteins bound to residual nuclear 
structures. These methods have been used by many labs to study nuclear matrix proteins (Nickerson et 
al. 1992; Blencowe et al. 1994; Fujita et al. 1997) and by our laboratory to determine protein domains 
required for nuclear matrix binding (Ainscough et al. 2007), shifts in protein localisation during 
biological transitions (Munkley et al. 2011), and absence from the nuclear matrix fraction in diseased 
states (Munkley et al. 2011). 
Reagents 
Cells grown on coverslips or cytospun onto slides (IF), or one 15 cm plate of adherent cells at > 50% 
confluent density (IB)  
For transfected cells, first evaluate the transfection protocol for destabilizing effects on the nuclear 
matrix. 
Cytoskeletal buffer (CSK) and derivatives. Filter sterilise and store basic buffer in 50 ml aliquots at -
20°C <R> 
DNase I, and buffer recommended by supplier 
Determine optimal concentration, digestion time and temperature using release of DNA (IF) or 
chromatin bound proteins such as histone (IB) as indicator. This will vary with cell type, is unlikely to 
be 100% efficient and will not release MAR DNA. DNase must be RNase free (eg Roche, 
04716728001). Test by incubation with prepared RNA and visualisation of products after 
electrophoresis. 
Hoechst or DAPI DNA counterstain (IF) 
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Use at 0.1 µg/ml and keep constant to allow establishment of imaging conditions. 
Mounting medium (IF) 
Paraformaldehyde (PFA) 4% <R> (IF) 
Phosphate buffered saline (PBS) 
PMSF – 200 mM stock in ethanol, stored at -20°C (IB) 
Primary antibody to protein of interest and secondary antibody for detection.  
Concentration and conditions should be established using cells extracted with detergent. These 
represent a mid-point between unextracted and chromatin-depleted cells with which imaging 
parameters can be determined.  
SDS loading buffer (4x) – standard Laemmli recipe (IB) 
Sodium chloride – 5 M stock 
Triton X-100 – at 1% 
Equipment 
13 mm glass coverslips (IF) 
15 cm culture plates (IB) 
24 well culture plates (IF) 
Cell scraper (IB) 
Fine forceps and hooked needle for moving coverslips (IF) 
Fluorescent microscope with 63 x oil immersion objective and image capture system (IF) 
Gel electrophoresis and Western blotting equipment (IB) 
Glass slides (IF) 
Heat block at 95°C (IB) 
Humidified chamber such as a plastic box with sealable lid (IF) 
Incubator at 37°C 
Parafilm (IF) 
Refridgerated microcentrifuge (IB) 
Vortex (IB) 
Method   
1. Thaw CSK, add supplements as required. See table 1 for volumes <R>. Keep all buffers on ice. 
DNase I should be kept at -20°C until required.  
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A. Immunofluorescence  
2A. Transfer cells on coverslips to PBS in 24 well plates (3-4 per sample).  
Coverslips are processed throughout with cells uppermost. Coverslips can be moved between wells to 
change buffer, or buffers can be gently changed by pipette.  
Coverslips are processed to reveal i) total protein (no extraction), ii) detergent-resistant proteins 
(immobilised by attachment to insoluble structures), iii) high-salt and DNase resistant proteins 
(bound to the nuclear matrix), iv) optional high-salt resistant proteins (tightly bound to chromatin or 
the nuclear matrix). For a summary of the method see figure 1A. 
3A. Transfer coverslip i into 4% PFA (10 minutes, RT). Move to PBS and store at 4°C.  
4A. Move remaining coverslips to CSKb (1 minute, RT). Move ii to PBS and prepare for IF as 3A. 
5A. Move remaining coverslips to CSKc (1 minute, RT).  
6A. Wash coverslips twice in DNase buffer (1 minute, RT). 
Wash step reduces salt concentration in preparation for DNase treatment. 
7A. Place coverslips on parafilm in humidified chamber. For iii add DNase I in DNase buffer, or for 
iv buffer only (20 !l per coverslip). Seal and incubate using optimised time and temperature.  
Humidify chamber to prevent drying out by including a reservoir of sterile water (e.g. damp tissue). 
8A. Move coverslips to CSKc (1 minute, RT), then PBS and prepare for IF as 3A. 
9A. Coverslips should be processed as soon as possible using standard immunofluorescence 
protocols, and imaged using high-resolution fluorescence microscopy and appropriate image capture 
system. 
Blocking agents such as BSA should be of ELISA grade and protease and RNase free (eg. Jackson 
001-000-162). The contrast between treated and untreated samples should be verified by imaging, 
using the minimum effective concentration of DNA counterstain and constant image capture 
parameters (e.g. 10-20 ms). A dramatic reduction in DNA counterstain should be evident for DNase 
treated coverslips, though a small amount of DNA will remain. Immunostaining conditions and 
imaging should be kept constant across a sample set (e.g. 200-400 ms). DNase treated nuclei from 
which the protein of interest is also extracted can be hard to spot. In these cases use an RNA 
counterstain such as propidium iodide or co-stain for a nuclear structure protein, such as lamin B2. 
An example image is shown in figure 1B. 
B. Immunoblotting  
2B. Rinse plate with PBS, then twice with CSKa. Remove and drain plates for 2 mins at 45° on ice. 
Remove excess buffer then scrape harvest cells (recover ~200 µl per 15 cm plate). Measure the 
volume, add 2 mM PMSF and TX100 to 0.1% final concentration. Divide equally between four 500 
!l eppendorfs (i, ii, iii, iv) and record volume (1 x vol).  
Samples will be processed to reveal cell equivalents of ‘T’ total protein, ‘det P’ detergent-resistant 
pellet (proteins immobilised by attachment to insoluble structures), ‘det SN’ detergent-soluble 
supernatant, ‘w’ 0.5 M NaCl-soluble supernatant, ‘DNase P’ DNase-resistant pellet (bound to the 
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nuclear matrix), ‘DNase SN’ DNase-sensitive supernatant  (bound to chromatin), ‘mock P’, high-salt 
resistant pellet (tightly bound to chromatin or the nuclear matrix) and ‘mock SN’ (released during 
control incubation). For a summary of the method see figure 1A. 
3B. To i (T), add 1/3 volume of 4 x SDS loading buffer. Vortex, heat to 95°C for 5 minutes and store 
at -20°C. 
4B. After 2 minutes on ice, centrifuge ii, iii and iv at 6800g (2 minutes, 4 °C). Transfer supernatant 
from ii to a fresh tube (det SN) and resuspend pellet ii in 1 x vol CSKb (det P). Prepare both for SDS-
PAGE as 3B. 
5B. Discard supernatant from iii and iv. Resuspend pellets in 1 x vol CSKc (2 minutes on ice) and 
centrifuge at 6800g (3 minutes, 4 °C). Recover supernatant from iii to a fresh tube (w). Prepare for 
SDS-PAGE as 3B. Discard supernatant from iv.  
6B. Resuspend pellets iii and iv in ~ 100 !l DNase buffer. Centrifuge 9500g, (3 minutes, 4 °C). 
Discard supernatants. 
7B. Resuspend pellets iii and iv in 1 x vol DNase buffer, add DNase I to iii and incubate both tubes 
using optimised amount, time and temperature.  
8B. Add 1/10 volume 5 M NaCl to both tubes and incubate for 5 minutes. Centrifuge 9500g (5 
minutes, 4 °C), transfer supernatants from tubes iii and iv to fresh tubes (DNase SN and mock SN). 
Resuspend pellets in 1 x vol DNase buffer (DNase P and mock P). Prepare these samples for SDS-
PAGE as 3B. 
Pellets iii and iv are very ‘sticky’ and can get stuck in the pipette tip. Resuspend by vortexing. 
9B. Samples can be processed using standard SDS-PAGE and western blotting protocols.  
In addition to the protein of interest, blots should be probed with a control antibody against a 
chromatin bound protein that is released when chromatin is digested (eg. histone H3). If studying a 
protein that is not normally nuclear matrix-bound a second control antibody should be used that 
detects an insoluble component of the nucleus (eg. lamin B2). A successful DNase extraction would be 
expected to release >75% of histone H3 into the DNase supernatant fraction, while retaining all 
histone H3 in the pellet fraction of the mock treated sample. Loss of histone from this fraction 
indicates contamination of buffers, or loss or degradation of residual nuclei. An example image is 
shown in figure 1C. 
Troubleshooting 
Problem: DNA or protein is not released from DNase treated sample 
Solution: Optimise DNase conditions and take care to remove high-salt buffer prior to digestion. For 
IB, mix digestion reaction periodically during incubation to ensure resuspension of pellet, and take 
care to mix after NaCl addition (step 8B).   
Problem: Absence of expected antigen in DNase treated samples. 
Solution: Buffers may be contaminated with proteases or RNases, both of which will degrade (part 
of) the nuclear matrix. Buffers should be remade, possibly with RNase inhibitors and equipment 
cleaned. Check for presence of a protein known to be nuclear matrix bound such as lamin B2. 
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Related Information  
The nuclear matrix can also be revealed by the use of 2.0 M NaCl – the ‘core’ nuclear matrix. The 
protocol can be adapted to use high-salt treatments instead of DNase extraction. Keeping all the cell 
lysate in a single tube, follow Immunoblot protocol to step 2B, then proceed by resuspending pellet in 
CSKb supplemented with increasing NaCl. Repeat with 100mM stepwise increases in NaCl up to 1M, 
collecting each supernatant and the final pellet as separate samples (Ainscough et al. 2007).  
Alternatively, the protocol can be adapted to reveal proteins associated with the nuclear matrix but 
less tightly bound. In this case a protein-protein cross-linker such as DTSP can be used before 
extraction to preserve protein complexes. For method see (Fujita et al. 1999).  
For further information regarding alternative methods for extracting the nuclear matrix, see The 
nuclear matrix: fractionation techniques and analysis (Wilson et al. 2013). 
Recipes: 
<R>  Components Recipe (per 50ml) Vol per 3 sets of 
4 coverslips (IF) 
Vol per 3 
15cm plates 
(IB) 
Cyto-
skeletal 
buffer (CSK) 
a 10mM PIPES/KOH pH 6.8 
100mM NaCl 
300mM Sucrose 
1mM EGTA 
1mM MgCl2 
 
Immediately before use 
add:- 
1mM DTT 
Protease inhibitor cocktail 
(eg Roche, 05 056 489 001) 
0.5ml of 1M  
1ml of 5M  
5.135g  
0.2ml of 250mM  
50!l of 1M  
 
 
 
50ul of 1M  
1 tablet 
50ml 100ml 
CSK 0.1% 
TX100 
b Add  
0.1% Triton X-100 
0.5ml of 10% 
TX100  
 
5ml 1ml 
CSK 0.1% 
TX100 high-
salt 
c Add  
0.1% Triton X-100 
0.5M NaCl 
0.5ml of 10% 
TX100  
4ml of 5M 
2ml 1ml 
PFA  4% paraformaldehyde 
50mM HEPES/KOH 7.8 
 
2g 
2.5ml of 1M stock 
6ml - 
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Appendix B 
Schematics of forked substrates used in Chapter 3.  
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Figure B1. Forked DNA substrate used for ATP hydrolysis and helicase reactions (HS1 
and HS2, Table 2.4).
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Figure B2. Forked DNA substrate bound to hMCM in EM reconstructions (HF150 and 
HR80, Table 2.4).
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 Appendix C 
The following work has been submitted for publication in The Journal of 
Biological Chemistry. It contains much of the work presented here in Chapter 3 
and has additional information provided by other lab members.   
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Background: The human MCM complex 
(hMCM) is an important component of the DNA 
replication apparatus. 
Results: hMCM, after being produced in E. coli, 
has ATPase and DNA helicase activity and 
undergoes a conformational change when bound to 
DNA. 
Conclusion: Recombinant hMCM is functional in 
vitro. 
Significance: hMCM provides an important tool 
for the biochemical reconstitution of the human 
replicative helicase. 
 
ATP-dependent DNA unwinding 
activity has been demonstrated for 
recombinant archaeal homohexameric 
minichromosome maintenance (MCM) 
complexes and their yeast heterohexameric 
counterparts, but in higher eukaryotes such as 
Drosophila, MCM-associated DNA helicase 
activity has only been observed in the context of 
a co-purified Cdc45-MCM-GINS (CMG) 
complex. Here we describe the production of 
recombinant human MCM complex (hMCM) 
in E. coli. This protein displays ATP hydrolysis 
activity and is capable of unwinding duplex 
DNA. Using single particle asymmetric electron 
microscopy reconstruction, we demonstrate 
recombinant hMCM forms a hexamer that 
undergoes a conformational change when 
bound to DNA. Recombinant hMCM produced 
without post-translational modifications is 
functional in vitro and provides an important 
tool for the biochemical reconstitution of the 
human replicative helicase. 
 
DNA replication is fundamental to the 
proliferation of all cells and as such has been the 
subject of intense scrutiny over many years. While 
this work has demonstrated many unifying 
similarities among all eukaryotes with regards to 
DNA replication, it has also become obvious that 
there are a number of differences in the details 
regarding these systems. Significantly, one of the 
main model organisms for eukaryotic DNA 
replication, the yeast Saccharomyces cerevisiae (S. 
cerevisiae), has a closed mitosis that requires 
replication proteins to cross the nuclear envelope 
in a manner not required by other eukaryotes (1). 
The minichromosome maintenance (MCM) 
proteins are a good example of such proteins and 
S. cerevisiae MCMs possess insertions to cater to 
this requirement (Table 1). The models used to 
study replication in Xenopus and Drosophila are 
egg-based and contain unusually high levels of 
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(likely pre-assembled) replication complexes not 
normally seen in post-embryonic systems (2). Data 
from human tissue culture studies are mainly 
based on transformed cells, which probably do not 
accurately reflect the cell cycle controls in primary 
explants (3). Thus, the use of recombinant 
components, which may more accurately 
reconstitute robust DNA helicase activity 
biochemically from recombinant components is of 
significant interest in understanding human DNA 
replication processes. 
The MCM complex is essential for DNA 
replication in eukaryotes and archaea, where it is 
believed to act as the replicative DNA helicase 
(reviewed in (4)). Homohexameric archaeal MCM 
complexes have provided useful models for 
studying DNA helicase activity (5,6). The 
production of a number of crystallographic 
structures has facilitated mapping of key 
enzymatic residues and provided insight into the 
molecular mechanisms utilized in DNA unwinding 
and translocation (7,8). In addition to its essential 
role in DNA replication, the heterohexameric 
eukaryotic Mcm2-7 complex has been implicated 
in DNA damage responses, checkpoint signaling, 
transcription and chromatin remodeling (9-12). 
Isolation of intact, functional MCM 
heterohexamers has proved challenging. 
Functional MCM complex purified from Xenopus 
egg extracts using a “replication licensing factor” 
(RLF) assay demonstrated an additional 
requirement for Cdt1 in MCM chromatin loading 
(13,14). A “CMG” (Cdc45-MCM-GINS) complex 
with DNA helicase activity has been isolated from 
Drosophila egg extracts (15). MCM function is 
post-translationally modulated in vivo by 
phosphorylation, although this is not essential for 
replication elongation (16). The presence of 
inhibitory phosphorylations might explain why 
some purified MCM complexes produced in 
eukaryotic expression systems do not demonstrate 
significant helicase activity. Current methods for 
Mcm2-7 complex analysis rely on purification 
from yeast or insect cells, potentially complicating 
the interpretation of results as the purified Mcm2-
7 complexes may have been post-translationally 
modified prior to purification. 
We report the development of a bacterial 
expression protocol that allows the production of a 
recombinant human Mcm2-7 (hMCM) complex in 
E. coli. Our hMCM complex exhibits DNA 
unwinding and ATP hydrolysis with a different 
salt sensitivity from that reported for the yeast 
complex (17). Structures of the protein obtained 
by electron microscopy (EM) methods show that 
hMCM forms an asymmetric hexameric complex 
that undergoes a conformational change in the 
presence of a forked DNA substrate that it is also 
capable of unwinding. The generation of 
recombinant hMCM represents the development 
of an important tool for understanding the 
mechanisms governing human DNA replication. 
This may ultimately improve our ability to 
manipulate cell proliferation and therefore design 
useful and specific cancer treatments. 
 
EXPERIMENTAL PROCEDURES 
Expression and purification of Mcm2-7 complex- 
PCR amplified Mcm2-7 cDNAs (primers in Table 
2) were cloned into Ek/LIC Duet vectors 
(Novagen). pET32-Mcm2&7, pRSF-Mcm3&5 and 
pCDF-Mcm4&6 were transformed into E. coli 
Rosetta 2 (DE3) (Novagen) and grown in a 75 litre 
fermenter. hMCM complex was bound to His-
Select Cobalt Affinity gel (Sigma), passed over a 
Superdex 200 gel filtration and MonoQ columns. 
Fractions containing MCM2-7 were pooled, 
dialysed against 25 mM Hepes, pH 8.0, 200 mM 
sodium glutamate, 1 mM DTT, 0.5 mM PMSF, 
flash frozen in small aliquots and stored at -80°C. 
Site directed mutagenesis of pET32-Mcm2&7, 
pRSF-Mcm3&5 and pCDF-Mcm4&6 produced 
inactive point mutations in the Walker A motif for 
each hMCM subunit (Mcm2 – K529E, Mcm3 - 
K351E, Mcm4 - K516E, Mcm5 - K387E, Mcm6 - 
K402E and Mcm7 - K387E). ATPase deficient 
mutant protein was produced and purified as wild-
type. 
Western blotting- Individual Mcm subunits were 
confirmed by western blotting the purified protein 
using primary antibodies: Mcm2 (CS732) (18), 
Mcm3 (clone 3A2) Medical and Biological 
Laboratories, Mcm4 (G-7) Santa Cruz 
Biotechnology Inc., Mcm5 (clone 33) BD 
Biosciences., Mcm6 (clone 1/MCM6) BD 
Biosciences and Mcm7 (141.2) Santa Cruz 
Biotechnology Inc. 
ATPase assays- Reactions were modified from (6) 
as follows: reactions contained (30 mM 
K2HPO4/KH2PO4 buffer, pH 8.5, 1 mM DTT, 100 
µg/ml BSA, 2% (v/v) glycerol, 10 mM magnesium 
acetate (MgAc)) and 1.5 nmol cold ATP, 3.08 
pmol of [α-32P] ATP (800 Ci/mmol, (ICN)), 3.5 
nM double stranded circular DNA (pUC119 unless 
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stated otherwise) and 176 nM of protein were 
assembled on ice.  
DNA helicase substrate- Oligonucleotide HS2 
(Table 2) was radiolabelled and annealed to 
oligonucleotide HS1 (Table 2) as described in (6). 
Helicase assays- Helicase reactions (4 nM 32P 
labelled forked substrate, Mcm2-7 as indicated, 30 
mM K2HPO4/KH2PO4 buffer, pH 8.5, 300 mM 
potassium glutamate, 1 mM DTT, 100 µg/ml BSA, 
2% (v/v) glycerol, 10 mM MgAc, 4 mM ATP) 
were incubated (1 hour, 37°C) and stopped using 
¼ volume 80 mM EDTA, 0.8% (w/v) SDS, 40% 
(v/v) glycerol, 0.04% (w/v) xylene cyanol, 0.04% 
(w/v) bromphenol blue. Reaction products were 
separated on 11% (w/v) polyacrylamide TBE gels 
(2 hours, 80 V). Gels were dried, imaged and 
quantified using a Bio-Rad Molecular Imager FX 
and Quantity One software.  
Binding of duplex DNA to hMCM for electron 
microscopy- hMCM was bound to duplex DNA. 
No salt annealing buffer (200 mM HEPES pH 8.0, 
5 mM EDTA) was added to 1 µM (HF150, 150 
bp) and 1 µM (HR80, 80 bp) oligo (Table 2). DNA 
was annealed as follows; 95°C for three minutes, 
cool at 0.02°C/s to 23°C. The temperature was 
kept at 23°C for one minute. 8 µg of hMCM was 
incubated with 60 nM duplex DNA in annealing 
buffer (50 mM HEPES pH7.5, 2 mM DTT, 50 
µg/ml BSA, 10 mM magnesium acetate (MgAc) 
and 4 mM ATP) for 60 minutes at 37°C to bind 
the hMCM and duplex DNA. Samples were snap 
frozen in liquid nitrogen. 
Electron microscopy- hMCM samples were 
applied to continuous carbon grids and stained 
with freshly made methylamine tungstate, pH 7. 
Data were collected on a FEI T12 microscope at 
magnification 67,000 and accelerating voltage 120 
kV, recorded on Kodak SO-163 films and digitised 
using a Zeiss Photoscan densitometer (14µm 
scanning step, corresponding to 2.5 Å/pixel) 
before analysis. 
Image processing- Particle picking was carried out 
automatically using ‘Boxer’ (EMAN suite (19)). 
Analysis of the CTF and correction was completed 
using ‘CTFIT’ (EMAN suite (19)). Image analysis 
was performed using IMAGIC-5 (20): Images 
were normalized to the same standard deviation 
and band-pass filtered; the low-resolution cut-off 
was ~100 Å to remove uneven background in 
particle images and the high-resolution cut-off was 
~7 Å. Images were subjected to an alignment 
procedure followed by statistical analysis. 
Alignment and classification of images was 
performed as previously described (20) and 
yielded classes representing characteristic views of 
the molecule. Primary structural analysis for 
hMCM and hMCM plus DNA complexes was 
performed using an ab initio approach where the 
orientations of the best 10-15 image classes were 
determined by angular reconstitution using C1 
start up. 3D maps were calculated using the exact-
filter back projection algorithm (20). Structural 
analysis was performed using several starting 
models with several different sets of image classes 
for ab initio reconstructions. The first 
reconstructions were used for the following rounds 
of alignment and classification of images.  The 
structures of the complexes were refined by an 
iterative procedure with the number of classes 
gradually increased. The final reconstruction for 
hMCM alone was calculated from the best 100 
classes containing ~11 images each. For hMCM 
plus DNA, the final reconstruction was calculated 
from the best 155 classes containing ~10 images 
each.  Resolution of the map was assessed using 
the 0.5 threshold of Fourier Shell Correlation (21), 
which corresponds to 23 Å. Domain fitting into 
the 3D map of hMCM and hMCM plus DNA 
complexes was performed manually with Chimera 
(22). Illustrations were generated using Chimera. 
Surface representations (unless stated otherwise) 
are displayed at a threshold level of 3σ (standard 
deviation of densities within EM maps) that 
corresponds to ~100% of the expected mass at the 
specific protein density of 0.84 kDa/Å3.  
 
RESULTS 
Production of a soluble hMCM complex  
To avoid potential activity-inhibiting 
phosphorylation by kinases present in eukaryotic 
expression systems, we co-expressed the human 
Mcm2-7 proteins as a stable, soluble complex, in 
E. coli (Fig 1A). The complex was purified 
according to the scheme outlined in Fig 1B. The 
presence of all six hMCM subunits in the purified 
complex was demonstrated by western blotting 
using specific antibodies (Fig 1C). Consistent with 
our western blot results, visualisation of the 
complex using Coomassie stained SDS-PAGE 
revealed the presence of some putative 
degradation products in addition to all six full-
length hMCM subunits (Fig 1D). Typically we 
produce 82.5 µg of hMCM per litre E. coli culture. 
A complex harbouring inactivating point 
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mutations in the Walker A motifs of each hMCM 
subunit (Mcm2 – K529E, Mcm3 - K351E, Mcm4 - 
K516E, Mcm5 - K387E, Mcm6 - K402E and 
Mcm7 - K387E) was produced in the same way.  
ATP hydrolysis activity of hMCM 
Purified wild type (WT) hMCM complex 
and ATPase deficient mutant complexes were 
tested for their ability to hydrolyse ATP in the 
presence and absence of a series of DNA 
substrates (at molar ratios of [hMCM 
hexamer]:[DNA] ranging from [110:1] to [3.8:1], 
Fig 2A). hMCM exhibited ATP hydrolysis that 
was not increased by the addition of DNA. High 
concentrations (46 nM) of double stranded closed 
circular DNA (dsDNA) inhibited ATP hydrolysis 
by ~50% compared to lower concentrations of 
dsDNA, possibly due to a substrate competition 
effect preventing the MCMs from forming a 
productive complex. A similar, but smaller, effect 
was observed for single stranded closed circular 
DNA (ssDNA). A forked DNA substrate had 
negligible effect on hydrolysis activity at the 
concentrations tested. Subsequent ATP hydrolysis 
assays were carried out in the presence of 3.5 nM 
dsDNA. 
Based on previous reports of specific salt 
requirements for yeast MCM activity in vitro (17), 
we examined the ability of hMCM to hydrolyse 
ATP in the presence of sodium chloride, sodium 
glutamate, potassium chloride and potassium 
glutamate (Fig 2B). Increased sodium chloride 
concentrations resulted in a statistically significant 
decrease in ATP hydrolysis.  A similar effect was 
observed for sodium glutamate. The addition of 50 
mM potassium chloride resulted in a pronounced 
inhibition of ATPase activity. Strikingly the 
presence of 300 mM potassium glutamate, twice 
the physiological salt concentration, had no effect 
on ATPase activity (Fig 2B). As expected, 
increasing concentrations of hMCM resulted in 
increased ATP hydrolysis (Fig 2C). Addition of 20 
mM EDTA significantly reduced ATP hydrolysis 
by hMCM, as did replacing the WT protein with 
the ATPase deficient mutant complex (Fig 2C) as 
expected from previous studies in S. cerevisiae 
(5,23).  Using the optimal assay conditions 
identified (3.5 nM dsDNA, 300 mM potassium 
glutamate and 176 nM hMCM) we measured the 
rate of ATP hydrolysis for WT and mutant hMCM 
(Fig 2D). The maximum rate of ATP hydrolysis 
for WT hMCM was 16.7 pmol ADP 
released/min/pmol hMCM compared to 3.9 pmol 
ADP released/min/pmol mutant hMCM. 
 
ATP-dependent DNA unwinding by hMCM 
We tested our purified recombinant 
hMCM complexes for DNA helicase activity using 
a forked DNA substrate in the presence or absence 
of ATP. WT hMCM exhibited a protein 
concentration and ATP-dependent DNA 
unwinding activity (Fig 3). With WT hMCM we 
observed 38% and 50% displacement by 176 nM 
and 352 nM hMcm2-7 respectively (Fig 3), 
broadly comparable to the reported 52% 
displacement by 110 nM yeast Mcm2-7 (17). 
Under conditions where ATP could not be 
hydrolysed – that is, either WT hMCM in the 
absence of ATP, or mutant hMCM in the presence 
of ATP – helicase activity was substantially 
reduced (Fig 3B) consistent with ATP hydrolysis 
being required for helicase activity. 
EM structure of recombinant hMCM. 
The structures of purified hMCM, both 
complex alone and bound to forked DNA, were 
obtained using EM of negatively stained. 
Structures were obtained using single particle 
approach with C1 symmetry (Fig 4). Our results 
revealed that the complex formed ring-shaped 
hexamers with a diameter of 145 Å and a height of 
120 Å (Fig 4A). Our asymmetric reconstructions 
(Fig 4) suggest that the complexes contain six 
different subunits (2-7) as opposed to a dimer of 
Mcm4/6/7 trimers (which would produce C2 
symmetry), or a trimer of Mcm4/7 dimers (C3 
symmetry). When observed in the presence of 
forked DNA (Fig 4A, bottom row), the hMCM 
structure has a different conformation, with a more 
defined two-tiered hexameric shape and a more 
obviously open central cavity. The atomic model 
of the hexamer of Sulfolobus solfataricus 
(Sso)MCM (3F9V) fits into our reconstruction 
(Fig 4B).  
 
DISCUSSION 
ATP hydrolysis has been demonstrated for 
MCM complexes derived from archaea (5) and 
eukaryotes (23,24). We found that the addition of 
DNA did not stimulate ATP hydrolysis by purified 
hMCM. This is consistent with reports of S. 
cerevisiae Mcm2-7 where DNA did not stimulate 
ATP hydrolysis (23,25). It is worth noting that this 
is in contrast to the Mcm4/6/7 sub-complex, which 
is stimulated by DNA (26,27). In agreement with 
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observations from archaeal MCMs (5), high 
concentrations of dsDNA were in fact inhibitory. 
With respect to salt sensitivity, 50 mM potassium 
chloride strongly inhibited the ATPase activity of 
hMCM whereas potassium glutamate, even at a 
concentration of 300 mM, had no such effect. 
These findings are consistent with results reported 
for the DNA helicase activity of the S. cerevisiae 
MCM (17). 
Binding and hydrolysis of ATP by MCM 
purified from S. cerevisiae has recently been 
shown to be required for CDT1 release and double 
hexamer formation (28), with the ATPase sites of 
different MCM subunits implicated in different 
stages of its loading and activation (29). The 
interface between subunits 2 and 5 of the S. 
cerevisiae Mcm2-7 complex is thought to function 
as an ATP-dependant “gate”, the opening of which 
enables the toroidal complex to be loaded onto 
topologically closed DNA (17). The recombinant 
hMCM produced here is an important tool to 
analyse the loading and activation of the human 
complex in light of this finding. 
Robust ATP-dependent DNA helicase 
activities were first demonstrated using archaeal 
homohexamers (5). Limited DNA helicase activity 
was originally demonstrated for a hexameric 
complex purified from HeLa cells that contained 
human Mcm subunits 4, 6 and 7, probably as a 
dimer of trimers (24). This activity was inhibited 
by the addition of mouse Mcm2 (30). Salt-
sensitive DNA helicase activity of a 
heterohexameric Mcm2-7 complex was first 
demonstrated using S. cerevisiae proteins purified 
after Baculovirus expression (17), and DNA 
unwinding activity of higher eukaryotic MCM 
complexes has been observed with  the CMG 
complex from Drosophila (15). Here we describe 
the first demonstration of helicase activity for the 
human Mcm2-7 complex. 
Our results showed that ATP hydrolysis 
was a requirement for DNA helicase activity. The 
negligible unwinding and ATPase activities in the 
mutant hMCM assays suggests that the mutant and 
WT protein preparations were both free from 
contaminating E. coli helicases / ATPases. Under 
ATPase null conditions (either no ATP or mutant 
hMCM) a large proportion of the helicase 
substrate migrated more slowly by native PAGE. 
Similar mobility shift effects have been previously 
observed for the Methanothermobacter 
thermautotrophicus MCM when samples have 
been incubated on ice (6).  This suggests that 
hMCM protein binds to the substrate in the 
absence of ATP (or ATP hydrolysis) but cannot 
unwind it. This is consistent with the idea that 
ATP hydrolysis is not required for DNA-protein 
interactions but is required for DNA unwinding 
(31). 
Overall, these results indicate that the 
recombinant hMCM complex exhibits DNA 
helicase activity and that posttranslational 
modifications to hMCM or accessory proteins 
such as Cdc45 and GINS are not required for the 
unwinding of naked DNA. The requirement for 
Cdc45 and GINS may only be required for 
remodelling or unwinding DNA packaged into 
chromatin. 
The size and shape of our hMCM complex 
is consistent with the organisation of oligomeric 
complexes reported for MCM from other 
eukaryotes (32,33). Analysis of a population of 
Drosophila Mcm2-7 complexes revealed that they 
exist in two different states: a planar, notched ring 
and an open spiral shape (32). Reconstructions of 
Mcm2-7 from Encephalitozoon cuniculi suggest 
that this Mcm2-7 is naturally found in the open 
spiral shape (34). Our reconstruction of the human 
complex is more similar to the notched ring, 
similar to S. cerevisiae (35), but this does not 
preclude the existence of a minority of spiral 
shaped complexes in our sample.  
Interestingly, the conformation taken by 
hMCM in the presence DNA is somewhat similar 
to what has been reported for S. cerevisiae Mcm2-
7 in the absence of DNA (36). One possible reason 
for the differences observed between the yeast and 
human proteins in the absence of DNA could be 
the differences in the primary sequences of the 
yeast and human proteins (outlined in Table 1). 
The prominent projection that appears on the top 
surface of one of the hMCM subunits in the 
presence of DNA (red circle) could be either the 
bound 45 base pair double-stranded portion of the 
DNA substrate, as ssDNA is too small to be 
visualised at this resolution, or a section of protein 
displaced by the presence of the DNA, such as the 
N-terminal S-Trx-His tag on Mcm7 (molecular 
weight is 15 KDa). Further work is required to 
determine which hMCM subunit binds DNA under 
these conditions. 
Human MCM is an important factor in 
cell proliferation and therefore by extension cancer 
development. The ability to produce significant 
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quantities of hMCM for analysis is an important 
step forward. Our biochemical findings show that 
the recombinant complex is active in vitro and our 
structural studies show that its conformation is 
altered when bound to DNA. Our system enables 
the targeted manipulation of individual proteins 
within the hMCM complex, providing the 
potential to address in detail the important 
differences between individual subunits in the 
hMCM heterohexamer. It also provides the 
potential to develop screens for clinically relevant 
hMCM inhibitors. 
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FIGURE LEGENDS 
 
Figure 1. Purification of a bacterially-expressed human MCM complex. A. Schematic of recombinant 
hMCM complex. Predicted arrangement of MCM2-7 subunits indicating which subunits have N-terminal 
affinity tags to aid in protein purification. B. Purification scheme for the recombinant hMCM complex. C. 
Western blot using antibodies specific to individual MCM subunits, showing all six human Mcms in the 
purified complex. D. Purified hMCM complex separated by 10% (w/v) SDS-PAGE gel and visualised by 
Coomassie blue staining. 
  
Figure 2. WT hMCM possesses ATPase activity. A. At 46 nM single stranded closed circular (sscc) 
DNA (a molar ratio of [hMCM hexamer]:[DNA] at [3.8:1]), reduced ATP hydrolysis by one third and 
double stranded closed circular (dscc) DNA reduced ATP hydrolysis by ~50%. Forked DNA had little 
overall effect. Statistics compare labelled bar to 0 nM DNA. *p=0.022 and **p=0.0019. B. Potassium 
Glutamate (KGlut) had no effect on ATPase activity in the presence of 3.5 nM dsDNA. Increasing the 
concentrations of Sodium Chloride (NaCl) and Sodium Glutamate (NaGlut) reduced ATP hydrolysis and 
addition of Potassium Chloride (KCl) greatly reduced ATP hydrolysis. Statistics compare labelled bar to 
0 mM salt. *p=0.018, **p=0.013 and ***p=0.00027. C. ATPase activity increases with protein 
concentration in the presence of 3.5 nM dsDNA, and is inhibited by the addition of 20 mM EDTA to 
chelate the Mg2+. The ATPase deficient mutant hMCM shows 6-fold lower ATP hydrolysis activity than 
WT hMCM. Statistics compare labelled bar to 352 nM hMCM . *p=0.0015 and **p=0.00014. D. The rate 
of ATP hydrolysis by WT hMCM and ATPase deficient mutant hMCM in molecules of ADP released per 
minute with optimized conditions (3.5 nM dsDNA, 300 mM potassium glutamate and 176 nM hMCM). 
The maximum rate of ATP hydrolysis for WT hMCM is 16.7 pmol ADP produced/min/pmol hMCM and 
3.9 pmol ADP produced/min/pmol mutant hMCM in the presence of 3.5 nM dsDNA. (A), (B) and (C) are 
mean values of three replicates, the data in (D) are mean values of two assays; error bars show the 
standard deviation. 
 
Figure 3. Recombinant hMCM displays DNA helicase activity. A. A forked DNA substrate was 
incubated with increasing concentrations of hMCM in the absence or presence of ATP. Heat denatured 
boiled substrate (★) and no protein lanes are included as controls. An arrow indicates the position of 
displaced substrate, an asterisk indicates substrate with unusual mobility, perhaps indicating hMCM that 
is bound to DNA. B. The amount of single stranded substrate in each reaction was quantified as a 
percentage of the boiled substrate control. The data shown are mean values for four independent assays, 
an example of which is shown in (A). Error bars indicate standard error of the mean. Statistics compare 
labelled lane to 352 nM hMCM plus ATP. ***p=0.00013 and **p=0.0014. 
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Figure 4. A. Negative stain, single particle EM 3D asymmetric reconstruction of hMCM to 23 Å 
resolution. Top row: hMCM alone (blue) from three different aspects. The complex undergoes a 
conformational change when the hMCM is bound to forked DNA (middle row, green). Red circle 
highlights protrusion thought to be DNA binding to hMCM. Size indicated in angstroms (Å). Bottom 
row: schematic representation of hMCM subunit configuration. B. The crystal structure of SsoMCM 
fitsinto out reconstructions. hMCM alone (blue) and hMCM bound to forked DNA (green) fitted with 
‘nearly full length’ Sulfolobus solfataricus (Sso) MCM crystal structure (3F9V) (8). The full hMCM 
structure (left) and slice through hMCM (right) show a central cavity in both reconstructions.   
 
 
Table 1. MCM amino acid insertions – comparison of s. cerevisiae and H. Sapiens. 
 
Mcm S. cerevisiae (aa) H. sapiens (aa) aa difference (Sc-
Hs) 
insertion locations 
2 868 904 -36  (-4%) C 
3 971 808 163 (20%) N, C 
4 933 863 70   (8%) N 
5 775 734 41   (6%) N 
6 1017 821 196 (24%) N, (C) 
7 845 719 126 (18%) N 
 
 
Table 2. List of oligonucleotide sequences used in the study. 
Oligo name: Oligo sequence:  
Mcm2 for  gcgggcccggcctccatggcggaatcatcggaatccttcacc  
Mcm2 rev  gaggagaagcccggtcagaactgctgcaggatcattttcc  
Mcm3 for  gcgggcccggccttcatggcgggtaccgtggtgctggac  
Mcm3 rev  gaggagaagcccggtcagatgaggaagatgatgccctcag  
Mcm4 for  gcgggcccggccttcatgtcgtccccggcgtcgacccc  
Mcm4 rev  gaggagaagcccggtcagagcaagcgcacggtcttccc  
Mcm5 for  gacgacgacaagatgtcgggattcgacgatcctggc  
Mcm5 rev  cgcgggcggccgtcacttgaggcggtagagaaccttgc  
Mcm6 for  gacgacgacaagatggacctcgcggcggcagcgg  
Mcm6 rev  cgcgggcggccgtcaatcttcgagcaagtagttaggg  
Mcm7 for  gacgacgacaagatggcactgaaggactacgcgctag  
Mcm7 rev  cgcgggcggccgtcagacaaaagtgatccgtgtccggg  
HF150 cctggcgttacccaacttaatcgccttgcagcacatccccctttctttttttttttttttttttttttttttttttttttttttttt
tttttttttttttttttt 
HR80 tttttttttttttttttttttttttttttttttttgaaagggggatgtgctgcaaggcgattaagttgggtaacgccagg 
HS1   gggacgcgtcggcctggcacgtcggccgctgcggccaggcacccgatggcgtttgtttgtttgtttgtttgt
tt  
HS2  tttgtttgtttgtttgtttgtttgtttgtttgccgacgtgccaggccgacgcgtccc  
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 Appendix D 
The following work has been accepted for publication in Cell Cycle. It contains 
much of the work presented here in Chapter 4 and has additional information 
provided by other lab members.   
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  Abstract  
The minichromosome maintenance complex (MCM2-7) is the putative DNA helicase in 
eukaryotes, and essential for DNA replication. By applying serial extractions to mammalian 
cells synchronized by release from quiescence, we reveal dynamic changes to the sub-nuclear 
compartmentalization of MCM2 as cells pass through late G1 and early S phase, identifying a 
brief window when MCM2 becomes transiently attached to the nuclear-matrix. The data 
distinguish three states that correspond to loose association with chromatin prior to DNA 
replication, transient highly stable binding to the nuclear-matrix coincident with initiation, 
and a post-initiation phase when MCM2 remains tightly associated with chromatin but not the 
nuclear-matrix. The data suggests that functional MCM complex loading takes place at the 
nuclear-matrix. 
 
Keywords: cell cycle / minichromosome maintenance complex/ MCM2-7 / nuclear matrix / 
DNA replication / initiation  
 
Abbreviations: Nuclear matrix (NM), Minichromosome maintenance (MCM), 
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  Introduction    
The nuclear matrix (NM) is a biochemically defined ribonuclear protein framework in higher 
eukaryotic cells that persists when chromatin, soluble proteins and lipids are removed.1 
Chromatin is periodically attached to the NM specifying its characteristic loop organisation in 
interphase nuclei, with functional protein assemblies immobilized at loop bases. Extensive 
evidence places DNA replication in proximity to the NM within DNA replication factories; 
aggregates of replication proteins and multiple co-regulated origins. (2 and reviewed in ref. 3) 
In cycling cells the nucleus is ‘licensed’ for DNA replication in early G1 phase when 
the hetero-hexameric MCM2-7 complex associates with chromatin.4 This is dependent on the 
origin recognition complex (ORC1-6), CDT1 and CDC6. Binding and hydrolysis of ATP by 
MCM2-7 has been shown to be required for CDT1 release and double hexamer formation.5 
CDC45 and GINS bind to chromatin and together with MCM2-7 form the CMG complex, an 
active DNA helicase.6 MCM loading occurs as the cell passes through the G1/S phase 
transition, functionally defined by the commencement of DNA synthesis. In eukaryotes, 
MCM activity is regulated by cyclin-dependent kinases (CDKs) and Dbf4-dependent kinase 
(DDK) (reviewed in ref. 7).  
Recently, full replication of plasmid DNA was achieved, independent of origin 
sequences, using a yeast cell-free system over-expressing multiple initiation proteins.8, 9 Thus, 
initiation has been effectively reconstituted, but the system is not fully defined and the 
mechanism of site selection is not clear. Intrinsic to this is the functional loading of the MCM 
helicase complex, which is believed to involve ring opening between MCM subunits 2 and 
5.10, 11 Exactly how this is achieved on chromatin, and rendered functional by accurate 
interaction with both template and accessory factors, is not fully understood even in yeast. 
In higher eukaryotes where spatial constraints play a role in specifying origins, 
additional considerations come into play, necessitating a description of the relationship 
between the MCM complex and the NM. A number of studies have begun to look at this in 
cell lines engaged in continuous culture, with contradictory results. MCM3 and MCM7 have 
been reported to be resistant to nuclease digestion and therefore characterized as NM 
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  bound.12, 13 However, other studies show MCM2, MCM3, MCM5 and MCM7 to be 
solubilized by nuclease digestion and therefore not NM bound.14-18 None of these studies 
validate the effect of nuclease by demonstrating release of chromatin-associated control 
proteins, so must be interpreted accordingly. Furthermore, transient interaction may be 
masked in asynchronous cells by the bulk fraction of MCM protein, making synchronization 
essential. Here we show fine temporal resolution of the nuclear binding characteristics of 
MCM2 as cells pass through late G1 phase, in order to describe the types of interaction that 
occur during expression, assembly, initiation and beyond. Using murine 3T3 cells that can be 
manipulated to undergo synchronized passage through G1 phase, without the use of chemical 
inhibitors, we demonstrate three distinct binding states of MCM2 in G1 phase following 
quiescence. These are i. chromatin binding prior to initiation of DNA replication, ii. transient 
association with the NM approximately four hours later, which we postulate reflects 
functional loading, and iii. stabilized post-initiation presence on chromatin. 
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  Results  
Murine 3T3 cells can be synchronized in quiescence by contact inhibition and serum 
depletion, then released into cycle as a synchronous wave of cells that pass through G1 
landmarks at defined points (Fig. 1A). Under these conditions serum-independent S phase 
entry is triggered at 15 hours after release from quiescence (restriction point, R) and does not 
vary much between experiments (maximum one hour variance based on appearance of 
cyclins).19 Entry to S phase is first apparent around one hour later, though most cells in the 
population enter S phase after 20 hours, reaching a maximum of 60-70% after 24 hours. 
Cyclin A expression increases steadily over the same period and can be used as a surrogate 
marker of passage through post-restriction point G1.   
Expression of MCM2 in late G1 phase MCM complex proteins are first evident after R, and 
increase through late G1 (Fig. 1B), paralleling the expression of cyclin A. When cells are 
separated into detergent-soluble and insoluble (nuclei) fractions immediately after harvesting 
(Fig. 1B), a notable peak is detected at 19 hours after release from quiescence, and a short 
period of instability both before and after this time. This suggests a mechanism that functions 
to deplete unprotected MCM during this time. Because this temporal profile is not apparent in 
whole cell lysates, this appears not to act on the bulk of the MCM in the cell, having the 
greatest impact when cells are disrupted artificially. Chromatin-bound CDC6 does not appear 
to suffer the same depletion (Fig. 1C), though does peak at the same time as chromatin-bound 
MCM2 (at 18 hours after release from quiescence in this independent experiment). From this 
data we can say that chromatin binding of CDC6 occurs earlier in G1 than NM-binding of 
MCM2.   
Using an immunofluorescence based measure of the proportion of cells with MCM2, 
the data show that populations are relatively uniform with a similar number of positive cells at 
24 hours after release, as at 15 hours (Fig. 1D), in all cases exclusively nuclear. Thus, the 
quantity increase observed by western blot at 19 hours does not reflect expression in a greater 
number of cells. Looking specifically at the detergent-resistant fraction of MCM2, a 
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  significant fall in numbers is seen at 17 hours, consistent with the suggestion that MCM2 may 
be unstable at this time.  
MCM2 is transiently bound to the NM Detergent-resistant proteins are immobilized by 
interaction with cellular components that are themselves not elutable under physiological 
buffer conditions; in the nucleus this means chromatin and/or the NM. By increasing NaCl 
concentration proteins are eluted with different profiles, exemplified here with cyclins A and 
E,20 and histone H3 (Fig. 2A). MCM2 is released gradually from asynchronous cells between 
0.1 and 1 M NaCl, describing a heterogeneous population, of which the bulk of MCM2 is 
unable to resist extraction. However, when applied to synchronized cells, a highly resistant 
sub-population of MCM2 is evident at 19 hours (Fig. 2B), suggesting that MCM2 becomes 
transiently associated with the NM at this time. 
Similar results were obtained using a different NM isolation protocol, in which salt 
concentration does not exceed 0.5 M, but histones and chromatin-associated proteins are 
eluted along with DNA fragments after digestion with DNase1. Under these conditions, 
MCM2 is apparently entirely eluted from asynchronous cells, with none evident in the NM 
fraction (Fig. 3A). However, when this is applied specifically to a 19 hour population a 
resistant fraction is evident, estimated to be 4% of total MCM2 within the cell at this time 
(based on densitometry, Fig. 3A). Similar analysis with an extensive set of antibodies raised 
against other MCM subunits failed to reveal NM-associated populations. This could reflect 
underlying biology, however we cannot draw a strong conclusion because none of these 
antibodies are as sensitive as that used to detect MCM2. 
 NM isolation by DNase1 extraction was recapitulated over a time course (Fig. 3B), 
focusing on the 0.5 M NaCl-resistant fraction (chromatin and/or NM), generating consistent 
results, which show a resistant fraction of MCM2 at 19 hours, partially persisting in this time 
course to 20 hours. At 19 hours, 76% of this immobilized fraction of MCM2 is in fact NM 
bound (resistant to DNase1 extraction), compared to only 5% of histone H3 and 83% of 
Lamin B2 (based on densitometry, Fig 3B). Immunofluorescence analysis of the 0.5 M NaCl-
resistant fraction of MCM2 with (NM) and without (NM and chromatin) digestion with 
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  DNase1, again identified a resistant fraction at 19 hours (Fig. 3C). This shows the number of 
cells with MCM2 in the nucleus regardless of intensity. The data argue that the 0.5 M 
resistant fraction that exists at 19 hours reflects the behavior of the majority of cells. No 
decrease in fluorescence intensity was observed in the chromatin-depleted (NM) population 
compared to the mock treated (NM and chromatin) population (Fig. 3D), showing that all of 
the protein that resists 0.5 M NaCl is in fact attached to the NM. Together the data argue that 
even though only a small fraction of MCM2 is resistant to DNase1 (Fig. 3B), this is the case 
for around half of the cells at 19 hours after release from quiescence (Fig. 3C). Moreover, as 
resistance is a transient state, which may in fact last less than an hour, it is likely that more 
than 50% of the population pass through this state at around this time in late G1 phase. 
MCM2 is tightly associated with chromatin after initiation When cells were treated (prior to 
extraction) with dithiobis succinimidyl propionate (DTSP), a cell-permeable reducing cross-
linker which binds proteins to proteins,21 additional binding characteristics were inferred. 
While the number of nuclei with MCM2, and detergent-resistant MCM2 remained generally 
high across the time course, the 0.5 M NaCl-resistant fraction reports on distinct time-
dependent shifts (Fig. 4A). Again a peak is observed at 19 hours, consistent with transient 
association with the NM, and there was no reduction in fluorescence intensity for MCM2 
after depletion of chromatin at this point (Fig. 4B). However at 24 hours the response to 
digestion with DNase1 distinguishes a fraction of MCM2 that is not bound to the NM but is 
cross-linked to proteins that are themselves tightly-associated with chromatin (possibly 
stabilization of the heterohexameric ring), and which resists 0.5 M NaCl. 
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  Discussion 
Abnormalities in DNA replication are linked to disease (reviewed in ref. 22), and in particular 
to the licensing of DNA for replication (reviewed in ref. 23). Inappropriate licensing can lead 
to re-replication, replication stress and genomic instability,23 which is a powerful driver 
toward acquisition of mutations. MCM proteins, as well as other components of the pre-RC, 
have been shown to be elevated in a range of cancer types,24-33 and MCM complex proteins 
have been shown to have diagnostic value.34 The mechanistic implications of elevated 
expression and potential strategies to intervene, hinge on a detailed knowledge of the process 
as it occurs in mammalian cells. Previous work in yeast,35 Xenopus,4 cancer cells,36, 37 and 
CHO cells,38 all demonstrate stable immobilisation of MCM2 in the nucleus during G1 phase, 
however these analyses do not further define the binding properties over this crucial period or 
distinguish NM-bound MCM from chromatin-bound MCM.  
Using controlled extraction criteria we have shown a transient relationship between 
MCM2 and the NM, immediately before the majority of cells first produce nascent DNA. In 
the cell populations illustrated in Fig. 1A approximately 20% have begun to incorporate 
nascent DNA by 18/19 hours, with the majority delayed by a further 2-3 hours, indicating that 
NM-association is coincident with or precedes DNA synthesis.  
In fact the data show three states of MCM binding (Fig. 4C); i. resistance to detergent 
but extraction with DNase1 or 2 M NaCl identifies a chromatin–associated nuclear fraction 
before 19 hours, ii. resistance to all extraction conditions identifies a transient attachment to 
the NM at 19 hours, iii. cross-linking to DNase1-sensitive protein that is resistant to 0.5 M 
NaCl identifies tight association with chromatin after 19 hours. Based on timing in relation to 
initiation of DNA replication and cyclin A expression (Fig. 1A), we suggest that this 
represents i. pre-initiation chromatin binding, ii. ‘functional loading’ , and, iii. post-initiation 
helicase presence on chromatin. We use the term ‘functional loading’ in order to 
distinguishing what happens at the NM from chromatin binding. It is clear that MCM2 is 
bound to chromatin both before and after its transient association with the NM, so NM-
association is not likely to reflect loading as defined in most other studies (which do not 
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  normally look at the effect of nuclease extraction and so largely report on chromatin binding). 
It is also clear that chromatin binding can be detected before DNA synthesis, so is not on its 
own sufficient to support initiation. Our hypothesis is that chromatin binding is converted to a 
‘functionally loaded’ state at the NM. However, this may not yet be active helicase as the 
MCM complex appears to be located away from the NM (Fig. 4A) and outside of factories 37  
at times when DNA synthesis is detected. Failure of MCM proteins to co-localize with newly 
synthesized DNA 39, 40 unless analyzed in relation to labeled DNA from the previous cell 
cycle 37 suggests that they are recruited to replication factories prior to initiation, but occupy 
remote sites during the synthesis phase. Thus, if helicase and polymerase function at the same 
time they appear not to do it in the same place. It therefore seems unlikely that MCM helicase 
is ‘activated’ during its brief association with the NM. For this reason we use the term 
‘functional loading’ to distinguish this transient and highly extraction-resistant state from the 
more commonly used descriptions of ‘loading’ and ‘activation’.  
The abundance of MCM proteins is far higher than other components of the pre-RC,41  
and in excess of the number of activated origins of replication. Although multiple copies 
appear to be present at each origin, and some are loaded at secondary sites such as those that 
are activated by replication fork arrest,42, 43 only a small fraction of MCM protein appears to 
be functionally assembled. In yeasts, use of degron mutants confirmed that very small 
amounts of MCM are required for initiation, but significantly more for elongation.44 A 
stoichiometric excess of MCM complex may be significant, helping to ensure availability for 
parallel, synchronous and complete loading at all origins at a specific point in G1 phase. Our 
data is consistent with this picture, but could also reflect a very brief association with the NM 
for a far greater proportion of available protein than the 4% detected here (Fig. 3A). In fact 
after the 19 hour loading period MCM2 is in a different state to before 19 hours, and this 
applies to approximately half of the MCM protein in half of the nuclei quantified. Thus, the 
data are also consistent with a loading pipeline in which only ~4% of total MCM2 occupies 
the loading bay at any one time. 
The diffuse nature of replication origins in higher eukaryotic cells (reviewed in ref. 
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  45), argues that structural determinants related to transcription specify their location on the 
template, while association with an active helicase defines their status as a functional site. The 
data presented here suggest that functional loading of the MCM complex is specified by 
activities that are themselves located at the NM, implying that origin selection is governed by 
template recruitment to these sites. MCM2 has been linked with the NM anchoring protein 
AKAP95, and disruption of its interaction is shown to inhibit both initiation and elongation of 
DNA replication, consistent with the idea that NM-association is a requirement for MCM to 
function in the cellular context.46  
In summary, this study adds to the growing evidence that initiation of DNA 
replication is spatially constrained by immobilization on the NM in mammalian cells, and 
suggests that functional assembly of the MCM complex occurs during transient presence in 
NM-associated loading bays. However it does not explain why association is transient, or 
shed light on the mechanism of loading or the regulation of ring opening. Although the open 
center of the MCM2-7 hexamer is large enough to accommodate either single stranded DNA 
or double stranded DNA,47, 48 recent studies suggest that when incorporated into the CMG 
complex it encircles single stranded DNA.49, 50 If reconciled with the idea that MCM proteins 
are located outside of replication factories during DNA synthesis, this implies that template 
DNA is in single stranded form between the site of DNA synthesis and the site of helicase 
action. Consistent with our observations, these data also argue that the MCM2-7 hexamer 
undergoes different conformations and assembly states during the transition from loading to 
activation.50 Our data identify a specific point in time and location at the NM, offering a direct 
route to the identification of the factors that spatially constrain the MCM complex and 
mediate its transition from one state to another at this critical point in the initiation process in 
mammalian cells.   
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  Materials and methods  
Cell culture Murine 3T3 cells were grown in Dulbecco's modified Eagle's medium (DMEM) 
with 10% foetal bovine serum and penicillin/streptomycin/glutamine (10 u/ml, 10 µg/ml, 2.92 
mg/ml respectively) on culture dishes (Nunclon), or on glass coverslips, and synchronized in 
quiescence by contact inhibition and serum depletion as described previously.19 Cells were 
released into cycle by splitting ¼ into fresh media. Click-iT Edu Cell Proliferation Assay kit 
(Life Technologies, Cat: C10337) was used as recommended, to analyse the percentage of 
cells in S phase after a 30 minute labeling period. 
Cellular fractionation Total cell lysates were prepared from adherent cells after rinsing in 
cold PBS and scape harvesting into cold cytoskeletal buffer (CSK; 10 mM Pipes pH 6.8, 300 
mM sucrose, 100 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 1 mM DTT), with protease 
inhibitor cocktail (cOmplete®, EDTA-free; Roche) and 2 mM PMSF, as indicated. For 
separation into detergent-soluble (SN) and detergent-resistant (pellet, P) fractions, lysates 
were supplemented with 0.1% triton X-100, incubated on ice for 2 minutes and separated by 
centrifugation. Serial salt extractions were performed as described previously,51 in cold CSK 
supplemented with protease inhibitors and the indicated concentration of NaCl. Insoluble 
material was removed by centrifugation after 5 minute incubations on ice in each buffer, and 
resuspended in a volume of CSK equal to the starting lysate.  
NM isolation was carried out as described previously.52 Cell lysates were harvested and 
supplemented with 0.1% triton X-100, divided into three aliquots, and separated into pellet 
and supernatant by centrifugation. Pellets were washed by resuspension in CSK plus 0.1% 
triton X-100 and 0.5 M NaCl and salt wash supernatant (W) recovered by centrifugation. 
Pellets were rinsed in DNase1 buffer (400 mM Tris-HCl, 100 mM NaCl, 60 mM MgCl2, 10 
mM CaCl2 pH 7.9), resuspended in the same buffer and incubated at 37°C with DNase1 
(RNase free, Roche), or in buffer alone (Mock). After one-hour samples were supplemented 
with 0.5 M NaCl and separated into SN and P by centrifugation. Cell equivalents were 
analysed by western blot. 
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  Western blot analysis   All fractions were immediately boiled in SDS-PAGE sample buffer 
(240 mM Tris pH 6.8, 8% SDS, 40% glycerol, 0.1% bromophenol blue and 6.8% β 
mecaptoethanol). Samples were separated by 8% SDS-PAGE, transferred to nitrocellulose or 
PVDF, blocked with 1 x TBS, 10% dried milk, 0.1% Tween 20, and probed with anti-MCM2 
at 1/1000 (BM28, BD Transduction Laboratories), anti-cyclin A at 1/1000 (C4710, Sigma), 
anti-lamin B2 at 1/1000 (ab138516, Abcam), anti-histone H3 at 1/10 000 (ab1791, Abcam) 
anti-actin at 1/1000 (AC40, Sigma), anti-cyclin E at 1/500 (ab7959-1, Abcam) or anti-Cdc6 at 
1/250 (sc-9964, Santa Cruz Biotech). Secondary antibodies, anti-mouse HRP (ab6789, 
Abcam) and anti- rabbit HRP (ab6721, Abcam), were used at 1/10 000. Blots were developed 
using enhanced chemiluminescence (ECL) solution (Amersham). Blots were quantified using 
NIH ImageJ. Quantification is comparable within each dataset but not between different 
datasets as all values are relative. 
Immunofluorescence   Cells grown on coverslips were washed in PBS, and either fixed 
immediately in 4% paraformaldehyde (PFA), to visualise ‘total’ protein, or washed with 0.1% 
triton X-100 in CSK, then PBS before fixing in 4% PFA (detergent resistant samples). 
DNase1 and Mock samples were washed first in CSK plus 0.1% triton X-100, then CSK plus 
0.1% triton X-100 and 0.5 M NaCl, and twice in DNase1 incubation buffer before incubation 
with DNase1, (RNase free, Roche) diluted in incubation buffer (DNase) or incubation buffer 
only (Mock), for one hour at 37°C. Cells were further washed in CSK plus 0.1% triton X-100 
and 0.5 M NaCl, followed by PBS before fixing in 4% PFA.52 Coverslips were rinsed in PBS, 
then blocked in 10% BSA, 0.02% SDS, 0.1% triton X-100 in PBS, before incubation with 
anti-MCM2 at 1/50 (BM28, BD Transduction Laboratories), or anti-Lamin B2 1/100 
(ab138516, Abcam). DNA was counterstained with Hoechst 33258. Images were collected 
using a Zeiss Axiovert 200 M and Openlab image acquisition software, using constant image 
acquisition parameters. Three technical replicates were analysed for all samples (n ≥ 99 for 
each).  
Cross-linking Cells growing on 15 cm dishes were washed three times with PBS at room 
temperature, then incubated in 15 ml cross-link buffer (PBS, 1 mM MgCl2, 0.01% triton X-
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  100) with DTSP (Sigma) at 200 µg/ml, on a rotary shaker for 10 minutes.51 Reactions were 
quenched with 10 ml 10 mM Tris-HCl pH 7.6, 1 mM EDTA, before extraction as described. 
Statistics   Analyses were performed using students T-test, with significance indicated by 
stars; *** p<0.001, ** p<0.01, * p<0.05. Error bars are standard error of the mean (SEM) in 
all cases. 
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  Legends  
Fig. 1 Entry to S phase and expression of MCM2 A) Mouse 3T3 cells re-enter the cell 
cycle from quiescence in a temporally well-defined manner, passing out of quiescence (Q) 
and through the restriction point (R) after ~15 hours. They enter S phase (S) as a wave of cells 
from 16 hours onwards, with the majority of the population first incorporating labelled 
nucleotides after 20 hours. The percentage of cells engaged in DNA synthesis (black), and 
relative concentration of cyclin A protein, estimated by densitometry (averaged from three 
biological replicates) and expressed after normalisation to actin (orange), is shown. Inserts 
(top), show example western blots of cyclin A and actin, and (bottom) micrographs showing 
incorporation of Edu into newly synthesized DNA in replicating cells (red). DNA is blue. 
Scale bar is 10 µm.  B) Western blots, and derived quantification, of MCM2 and actin in total 
cell lysates harvested into CSK buffer (upper), and after separation into detergent-soluble 
supernatant, and detergent-resistant pellet (nuclei, lower). C) MCM2, CDC6 and histone H3 
in whole cell lysates and detergent resistant pellet (nuclei). CDC6 chromatin binding precedes 
MCM2 binding. D) The percentage of cells with MCM2 in the nucleus, detected by 
immunofluorescence (IF). All labelled cells were scored regardless of intensity, without prior 
extraction (total MCM2), and after extraction with 0.1% triton X-100 (detergent resistant). 
Error bars show SEM of three replicates (n ≥ 100 for each). Representative images of MCM2 
(green) and DNA (blue) are inset. Scale bar is 10 µm.  
 
Fig. 2 MCM2 is transiently resistant to high-salt extraction. A) Protein fractions from 
asynchronous 3T3 cells derived by sequential NaCl washes showing MCM2, cyclins E, and A 
and histone H3 in the supernatants (SN). 2M pellet (P) represents the resistant fraction that 
includes the nuclear-matrix. B) Protein fractions prepared from synchronized cells in mid G1 
to early S phase, using the indicated sequential NaCl concentrations, showing partitioning of 
MCM2 over time. Total cyclin A and actin are shown for reference. The 19 hour point 
contains a sub-population of MCM2 that is highly resistant to extraction (NM-associated), 
indicated by dotted white lines. Graph shows quantification of MCM2 levels from western 
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  blots by densitometry (arbitrary units). Levels can be compared within each time course but 
not between different fractions. Results are shown relative to the lowest time point in all 
cases, except 2 M pellet fraction which is shown on a different scale to illustrate the peak at 
19 hours. 
 
Fig. 3. MCM2 is transiently resistant to DNase1 extraction. A) Protein fractions prepared 
from asynchronous 3T3 cells, and from G1 phase cells harvested at 19 hours, showing 
MCM2, histone H3 (to reveal efficiency of chromatin digestion) and lamin B2 (to reveal the 
residual nucleus). Detergent-resistant pellet (P), detergent-soluble supernatant (SN), 0.5 M 
NaCl wash (W), DNase1-resistant pellet (P, NM indicated with dotted lines), DNase-soluble 
supernatant (SN, chromatin), mock treatment-resistant pellet (P, NM and chromatin) and 
mock treatment-soluble supernatant (SN). A fraction of the total MCM2 in the cell resists 
extraction at 19 hours, but is not detectable in the asynchronous population. B) Western blots 
of 0.5 M washed pellets after treatment with DNase1 or mock treatment, from an independent 
experiment harvested at 14 hours (pre-R), 17 hours (few cells in S phase), 19 hours (most 
cells initiating) and 20 hours. C) Percentage of cells with MCM2 in the nucleus after DNase1 
(NM) or mock treatment (NM and chromatin), detected by IF (n ≥ 100 for each). Data shown 
for the 19 hour time point are the average of two biological replicates and three technical 
replicates. All other time points show the average of three technical replicates. All error bars 
show SEM. Representative images show MCM2 (green), DNA (blue) and lamin B2 (red). 
Scale bar is 10 µm. D) Mean MCM2 fluorescence intensity (left) of DNase1 (n = 100) and 
mock-extracted (n = 110) 19 hours nuclei, and intensity distribution (right, showing upper bin 
value). 
 
Fig. 4. Post-initiation association with chromatin, revealed by crosslinking with DTSP. 
A) The percentage of nuclei with MCM2, detected by immunofluorescence, in synchronized, 
cross-linked populations showing total protein, detergent-resistant protein, DNase1-resistant, 
and 0.5 M NaCl-resistant protein (mock) (n ≥ 100 for each). Representative images show 
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  MCM2 (green), DNA (blue) and lamin B2 (red). Scale bar is 10 µm. B) Mean MCM2 
fluorescence intensity after DNase1 or mock extraction at 19 hours, (n = 99 and 105 
respectively, left) and at 24 hours (n = 107 and 101 respectively, centre). A comparison of 
DNase1 resistant MCM2 at 19 and 24 hour is also shown (n = 99 and 107 respectively, right). 
C) Schematic showing three states of MCM complex binding in late G1 phase, superimposed 
on the prevailing model of DNA replication in higher eukaryotic nuclei, in which the 
replication machinery is at chromatin loop bases on the nuclear matrix, with newly 
synthesized DNA extruded as nascent daughter loops.2 Our data suggest that i. before 
initiation the MCM complex exists as a chromatin–associated nuclear protein, ii. functional 
loading immediately prior to initiation takes place coincidently with transient attachment to 
the NM, iii. after initiation the MCM complex is functionally bound to chromatin but no 
longer associated with the NM. 
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Abbreviations 
°C  degrees centigrade 
3D  three dimensional 
A  alanine 
aa  amino acids 
ACS  ARS consensus sequence 
AEBSF  4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
APS  ammonium persulphate 
ARS  autonomous replication sequence 
ATP  adenosine 5’triphosphate 
ATPase  ATP hydrolysis 
bp   base pair 
BSA  bovine serum albumin 
Bq  becquerel  
Cdc6   cell division cycle 6 
Cdc7  cell division cycle 7 
Cdc45  cell division cycle 45 
CDK  cyclin dependent kinase 
Cdt1  chromosome licensing and DNA replication factor 1 
Ci  Curie 
CMG  Cdc45-MCM2-7-GINS  
CPK  creatine phosphate kinase 
CSK  cytoskeletal buffer 
CTP  cytidine triphosphate 
CV  column volumes 
D  aspartic acid 
dATP  deoxyadenosine triphosphate 
Dbf4  Dumbbell-forming 4, 
dCTP  deoxycytidine triphosphate 
ddH20  double distilled H20 
DDK  Dbf4-dependent kinase 
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 dGTP  deoxygyanosine triphosphate 
dH20   distilled H20 
DMEM Dulbecco’s modified Eagle’s medium 
DNA  Deoxyribonucleic acid 
Dpb11  DNA polymerase B possible subunit 11 
dPBS  Dulbecco’s phosphate buffered saline 
Drf1  Dbf4 related factor 1 
Drosophila Drosophila melanogaster 
ds  double stranded 
DTSP  dithiobis succinimidyl propionate 
DTT  dithiothreitol 
dTTP  deoxythymidine triphosphate 
DUE-B  DNA unwinding element binding protein 
E  glutamic acid 
EDTA  ethylenediaminetetraacetic acid 
EdU  5-ethynyl-2’-deoxyuridine 
EGTA  ethylene glycol tetraacetic acid 
EM  electron microscopy 
E. cuniculi  Encephalitozoon cuniculi 
G0  quiescence 
G1  growth 1 phase 
G2  growth 2 phase 
GEMC1 geminin coiled coil containing protein 
GINS  Go, Ichi, Nii and San 
GTP  guanosine triphosphate 
HBO1  Histone acetylase binding to Orc1  
HEPES  4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
His-tag histidine tag 
hMCM  human minichromosome maintenance complex 
HOXD13 homobox protein Hox-D13 
HRP  horseradish peroxide 
Hs  human 
h2i  helix 2 insert 
IF  immunofluorescence 
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 IPTG  isopropyl β-D-1-thiogalactopyranoside 
K  lysine 
Kbp  kilo base pairs 
KDa  kilodalton 
Kpsi  kilopound per square inch 
LB  Luria Bertani broth 
M  mitosis 
mA   milliamps 
MAR   matrix attachment region 
MCM  minichromosome maintenance  
min  minutes 
ms  milliseconds 
MSSB  MCM single-stranded binding motif 
Mt  Methanothermobacter thermautotrophicus 
NEB  New England Biolabs 
NES  nuclear export signal 
NLS  nuclear localisation signal 
OD  optical density 
Oligo  oligonucleotide  
ON  overnight 
ORC  origin recognition complex 
Ori  origin of DNA replication 
PAGE  poly acrylamide gel electrophoresis  
PBS  phosphate buffered saline 
PEI  polyethylenimine 
Pf  Pyrococcus furious 
PFA  paraformaldehyde 
PI  protease inhibitor tablet 
PMSF  phenylmethanesulfonylfluride 
PNK  T4 polynucleotide kinase 
pol  polymerase 
Pre-IC  pre initiation complex 
Pre-LC  pre loading complex 
Pre-RC  pre replication complex 
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 Psf  partner of Sld five 
PSG  penicillin streptomycin glutamine 
PVDF  polyvinylidene fluoride 
Q  quiescence 
R  restriction point 
rpm  revolutions per minute 
RT  room temperature 
S  DNA synthesis phase 
S  serine 
SD  standard deviation 
SDS  sodium dodecyl sulphate 
SEM  standard error of the mean 
Ser  serine 
SF6  superfamily 6 
SOB  super optimal broth 
Sld  synthetically lethal with Dpb11 
Sso  Sulfolobus solfataricus 
S. cerevisiae Saccharomyces cerevisiae 
S. pombe Schizosaccharomyces pombe 
T  threonine 
TBE  tris borate EDTA 
TBS  tris buffered saline 
TEMED N,N,N’,N’-tetramethylethylenediamine 
TLC  thin layer chromatography 
TRIS  tris(hydroxymethyl)aminomethane 
Tx100  Triton X-100 
UTP  uridine triphosphate 
vol  volume 
v/v  volume pre volume 
w/v  weight per volume 
WT  wild type 
Xenopus Xenopus laevis 
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